| No relevant target |
LogP |
< |
-3.0 |
|
Partition coefficient (logP) (dodecane) |
CHEMBL1135392 |
| No relevant target |
LogP |
= |
-2.07 |
|
Partition coefficient (logP) |
CHEMBL1135392 |
| No relevant target |
LogP |
= |
-8.1 |
|
Partition coefficient across water-dodecane interface by statistical simulation |
CHEMBL1135392 |
| Human herpesvirus 1 DNA polymerase |
MP |
= |
90.0 |
% |
Percentage of monophosphates (MP) formed in the first step of staggered assay compound was incubated with HSV-1 thymidine kinase for 4 hr |
CHEMBL1124020 |
| Human herpesvirus 1 DNA polymerase |
MP |
= |
3.0 |
% |
Percentage of monophosphates (MP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night |
CHEMBL1124020 |
| Human herpesvirus 1 DNA polymerase |
DP |
= |
10.0 |
% |
Percentage of diphosphates (DP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night |
CHEMBL1124020 |
| Human herpesvirus 1 DNA polymerase |
TP |
= |
84.0 |
% |
Percentage of triphosphates (TP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night |
CHEMBL1124020 |
| Human herpesvirus 1 DNA polymerase |
Inhibition |
= |
60.0 |
% |
Inhibition of DNA polymerase |
CHEMBL1124020 |
| Unchecked |
Inhibition |
= |
22.0 |
% |
Inhibition of DNA polymerase |
CHEMBL1124020 |
| Oryctolagus cuniculus |
ED50 |
= |
3.0 |
ug ml-1 |
Antiviral activity against HSV-1 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures) |
CHEMBL1124020 |
| Oryctolagus cuniculus |
ED50 |
= |
3.0 |
ug ml-1 |
Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures) |
CHEMBL1124020 |
| Human herpesvirus 5 |
EC50 |
= |
1.9 |
ug.mL-1 |
Concentration of compound required to inhibit 50% of HCMV strain AD-169 induced cytopathic effect |
CHEMBL1127976 |
| Human herpesvirus 5 |
EC50 |
= |
0.8 |
ug.mL-1 |
Concentration of compound required to inhibit 50% of HCMV strain Davis induced cytopathic effect |
CHEMBL1127976 |
| HEL 299 |
CC50 |
> |
400.0 |
ug.mL-1 |
Compound was tested for its cytotoxicity against human embryonic lung fibroblast cells (HEL 299) by MTT dye reduction assay |
CHEMBL1127976 |
| ADMET |
Therapeutic index |
> |
200.0 |
|
Therapeutic index measured as ratio of EC50 for AD-169/CC50 for HEL 299 |
CHEMBL1127976 |
| ADMET |
Therapeutic index |
> |
500.0 |
|
Therapeutic index measured as ratio of EC50 for Davis/CC50 for HEL 299 |
CHEMBL1127976 |
| HEL |
IC50 |
= |
1.2 |
ug.mL-1 |
Antiviral activity was measured against cytomegalovirus (CMV) AD-169 strain in human embryonic lung (HEL) cells |
CHEMBL1129905 |
| HEL |
IC50 |
= |
1.3 |
ug.mL-1 |
Antiviral activity was measured against cytomegalovirus (CMV) Davis strain in human embryonic lung (HEL) cells |
CHEMBL1129905 |
| HeLa |
CC50 |
> |
50.0 |
ug.mL-1 |
Cytotoxic activity was measured in human embryonic lung cells (HeLa) |
CHEMBL1129905 |
| E6SM |
CC50 |
> |
100.0 |
ug.mL-1 |
Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells |
CHEMBL1129240 |
| Cytomegalovirus |
MIC |
= |
0.5 |
ug.mL-1 |
Minimum Inhibitory Concentration (MIC) tested for activity against Cytomegalovirus (CMV) using AD169 strain |
CHEMBL1129240 |
| Cytomegalovirus |
MIC |
= |
0.5 |
ug.mL-1 |
Minimum Inhibitory Concentration (MIC) tested for activity against Cytomegalovirus (CMV) using Davis strain |
CHEMBL1129240 |
| Human herpesvirus 5 |
IC50 |
= |
7400.0 |
nM |
Concentration required for 50% inhibition of HCMV replication was measured using a Plaque reduction assay |
CHEMBL1129960 |
| Human herpesvirus 5 |
IC90 |
= |
1600.0 |
nM |
Concentration required for 90% inhibition of HCMV replication was measured using a yield reduction assay |
CHEMBL1129960 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Antiviral activity was measured by plaque assay against HSV-1 virus by ELISA method |
CHEMBL1129960 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration |
CHEMBL1129960 |
| KB |
IC50 |
> |
100000.0 |
nM |
Inhibition of KB cell growth was determined |
CHEMBL1129960 |
| E6SM |
MCC |
> |
100.0 |
ug.mL-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology |
CHEMBL1134545 |
| E6SM |
MIC |
= |
0.004 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-1 KOS (HSV-1) in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
= |
0.004 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-2 G (HSV-2) in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
> |
100.0 |
ug.mL-1 |
Antiviral activity against vesicular simplex virus-1 in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
= |
1.92 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-1 TK-KOS ACV (HSV-1) in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
= |
0.019 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-1 TK-VMW 1837 (HSV-1) in E6SM cell cultures |
CHEMBL1134545 |
| Human herpesvirus 1 |
ID50 |
= |
0.3 |
uM |
In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-1 (F strain) in vero cells tissue culture |
CHEMBL1123033 |
| Human herpesvirus 2 |
ID50 |
= |
1.3 |
uM |
In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-2 (G strain) in vero cells. |
CHEMBL1123033 |
| Human herpesvirus 5 |
ID50 |
= |
6.0 |
uM |
In vitro antiviral and anticellular activity was evaluated against human cytomegalovirus (HCMV AD 169) in (HCMV AD 169) cells. |
CHEMBL1123033 |
| Vero |
ID50 |
= |
500.0 |
uM |
In vitro antiviral and anticellular activity was evaluated against vero cells in tissue culture |
CHEMBL1123033 |
| Mus musculus |
Survivors |
= |
12.0 |
|
Effect of subcutaneous dose at 30 mg/kg on HSV-2 induced mortality in mice; 12/16 |
CHEMBL1123033 |
| Mus musculus |
Survivors |
= |
7.0 |
|
Effect of subcutaneous dose at 10 mg/kg on HSV-2 induced mortality in mice; 7/16 |
CHEMBL1123033 |
| Mus musculus |
Survivors |
= |
4.0 |
|
Effect of subcutaneous dose at 3 mg/kg on HSV-2 induced mortality in mice; 4/16 |
CHEMBL1123033 |
| Mus musculus |
Mean survival time |
= |
13.8 |
day |
Effect of subcutaneous dose at 30 mg/kg on HSV-2 induced mortality in mice(value in parentheses denotes probability |
CHEMBL1123033 |
| Mus musculus |
Mean survival time |
= |
12.4 |
day |
Effect of subcutaneous dose at 10 mg/kg on HSV-2 induced mortality in mice |
CHEMBL1123033 |
| Mus musculus |
Mean survival time |
= |
11.2 |
day |
Effect of subcutaneous dose at 3 mg/kg on HSV-2 induced mortality in mice |
CHEMBL1123033 |
| Mus musculus |
Mean survival time |
< |
0.001 |
|
Mean survival time of HSV-2 induced mortality in mice was determined when the 30 mg/Kg of compound was administered subcutaneously |
CHEMBL1123033 |
| Mus musculus |
Mean survival time |
< |
0.001 |
|
Mean survival time of HSV-2 induced mortality in mice was determined when the 10 mg/Kg of compound was administered subcutaneously |
CHEMBL1123033 |
| Mus musculus |
Mean survival time |
|
|
|
Mean survival time of HSV-2 induced mortality in mice was determined when the 3 mg/Kg of compound was administered subcutaneously; NS means not significant |
CHEMBL1123033 |
| Duck hepatitis B virus |
Inhibition |
|
|
% |
Percent inhibition of viral DNA in the presence of 10 mg/mL compound compared to untreated infected controls in duck hepatocytes; ND means Not determined |
CHEMBL1133838 |
| Nucleic Acid |
EC50 |
= |
1.5 |
ug.mL-1 |
Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls. |
CHEMBL1133838 |
| Vero |
EC50 |
|
|
ug.mL-1 |
Concentration required to inhibit plaque formation by HSV-1 strain KOSSB (TK-) in monolayers of vero cells; ND means Not determined |
CHEMBL1133838 |
| Vero |
EC50 |
|
|
ug.mL-1 |
Concentration required to inhibit plaque formation by HSV-1 strain KOS (TK+) in monolayers of vero cells; ND means Not determined |
CHEMBL1133838 |
| Vero |
EC50 |
|
|
ug.mL-1 |
Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay; ND means Not determined |
CHEMBL1133838 |
| Homo sapiens |
EC50 |
= |
|
ug.mL-1 |
Concentration required to reduce the proliferation of PHA stimulated human peripheral blood T lymphocytes; ND means Not determined |
CHEMBL1133838 |
| Human herpesvirus 1 |
ED50 |
= |
0.016 |
ug ml-1 |
Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells. |
CHEMBL1130421 |
| Human herpesvirus 2 |
ED50 |
= |
0.039 |
ug ml-1 |
Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells. |
CHEMBL1130421 |
| Human herpesvirus 3 |
ED50 |
= |
0.21 |
ug ml-1 |
Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells. |
CHEMBL1130421 |
| Human herpesvirus 5 |
ED50 |
= |
0.21 |
ug ml-1 |
Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells. |
CHEMBL1130421 |
| CCRF-HSB-2 |
IC50 |
= |
17.0 |
ug.mL-1 |
Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells. |
CHEMBL1130421 |
| Human herpesvirus 5 |
IC50 |
= |
3000.0 |
nM |
Inhibitory activity against human cytomegalo virus (HCMV) using standard plaque reduction assay |
CHEMBL1133886 |
| Vero |
CCID50 |
> |
500.0 |
uM |
Compound was evaluated for its cytotoxicity against Vero cell line |
CHEMBL1133886 |
| Protein kinase C (PKC) |
Inhibition |
|
|
% |
Percent inhibition of protein kinase C at 100 uM (not tested) |
CHEMBL1133886 |
| MRC5 |
IC50 |
= |
3000.0 |
nM |
Inhibitory concentration against AD169 strain of HCMV in MRC5 cells |
CHEMBL1133886 |
| MRC5 |
IC50 |
= |
1500.0 |
nM |
Inhibitory concentration against Towne strain of HCMV in MRC5 cells |
CHEMBL1133886 |
| MRC5 |
IC50 |
= |
1400.0 |
nM |
Inhibitory concentration against Davis strain of HCMV in MRC5 cells |
CHEMBL1133886 |
| MRC5 |
IC50 |
> |
10000.0 |
nM |
Inhibitory concentration against Xba F strain of HCMV in MRC5 cells |
CHEMBL1133886 |
| MRC5 |
IC50 |
|
|
nM |
Inhibitory concentration against C8805 strain of HCMV in MRC5 cells; ND means not determined |
CHEMBL1133886 |
| MRC5 |
IC50 |
= |
1600.0 |
nM |
Inhibitory concentration against 2599R strain of HCMV in MRC5 cells |
CHEMBL1133886 |
| Anas sp. |
EC50 |
= |
1.5 |
ug.mL-1 |
Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures |
CHEMBL1135408 |
| Human herpesvirus 5 |
ED50 |
= |
2.7 |
ug ml-1 |
In vitro antiviral activity tested against HCMV, AD169 strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 5 |
ED50 |
= |
3.6 |
ug ml-1 |
In vitro antiviral activity tested against HCMV, Davis strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 5 |
ED50 |
= |
2.8 |
ug ml-1 |
In vitro antiviral activity tested against HCMV, EC strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 5 |
ED50 |
= |
2.4 |
ug ml-1 |
In vitro antiviral activity tested against HCMV, LA strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 5 |
ED50 |
= |
3.1 |
ug ml-1 |
In vitro antiviral activity tested against HCMV, CH strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 5 |
ED50 |
= |
1.0 |
ug ml-1 |
In vitro antiviral activity tested against MCMV Smith strain by plaque reduction assay in mouse embryo fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 5 |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity tested against HCMV, AD169 strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 5 |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity tested against HCMV, Davis strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 5 |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity tested against HCMV, EC strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 5 |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity tested against HCMV, LA strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Human herpesvirus 5 |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity tested against HCMV, CH strain by plaque reduction assay in human foreskin fibroblasts. |
CHEMBL1124752 |
| Murine cytomegalovirus |
ID50 |
> |
100.0 |
ug ml-1 |
In vitro antiviral activity tested against MCMV Smith strain by plaque reduction assay in mouse embryo fibroblasts. |
CHEMBL1124752 |
| Murine cytomegalovirus |
MDD |
= |
7.6 |
|
Tested for mean day to death of nonsurvivors against systemic MCMV infection in mice at 1.9 mg/kg per day |
CHEMBL1124752 |
| Murine cytomegalovirus |
Survivors / treated |
= |
15.0 |
|
Number of survivors per number of systemic MCMV infected mice treated with 33.4 mg/kg per day; 15/15 |
CHEMBL1124752 |
| Murine cytomegalovirus |
Survivors / treated |
= |
15.0 |
|
Number of survivors per number of systemic MCMV infected mice treated with 11.2 mg/kg per day; 15/15 |
CHEMBL1124752 |
| Murine cytomegalovirus |
Survivors / treated |
= |
10.0 |
|
Number of survivors per number of systemic MCMV infected mice treated with 3.8 mg/kg per day; 10/15 |
CHEMBL1124752 |
| Murine cytomegalovirus |
ED50 |
< |
1.9 |
mg kg-1 day-1 |
Tested for the effective dose required to inhibit systemic MCMV in infected mice |
CHEMBL1124752 |
| ADMET |
NT |
|
|
|
Antiviral activity on mock infected cell culture, activity and expressed as EC50/TC50; value given as 8.9/>100 uM |
CHEMBL1150446 |
| Homo sapiens |
Reduction |
= |
97.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 1000 uM |
CHEMBL1123640 |
| Homo sapiens |
Reduction |
= |
97.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 320 uM |
CHEMBL1123640 |
| Homo sapiens |
Reduction |
= |
82.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 100 uM |
CHEMBL1123640 |
| Homo sapiens |
Reduction |
= |
56.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 32 uM |
CHEMBL1123640 |
| Homo sapiens |
Reduction |
= |
35.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 10 uM |
CHEMBL1123640 |
| Homo sapiens |
Reduction |
= |
24.0 |
% |
Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 3.2 uM |
CHEMBL1123640 |
| Homo sapiens |
Reduction |
= |
0.0 |
|
Cytotoxicity was determined at 1000 uM |
CHEMBL1123640 |
| Homo sapiens |
Cytotoxicity |
= |
0.0 |
|
Cytotoxicity was determined at 320 uM |
CHEMBL1123640 |
| Homo sapiens |
Cytotoxicity |
= |
0.0 |
|
Cytotoxicity was determined at 100 uM |
CHEMBL1123640 |
| Homo sapiens |
Cytotoxicity |
= |
0.0 |
|
Cytotoxicity was determined at 32 uM |
CHEMBL1123640 |
| Human herpesvirus 1 |
VR |
= |
1.4 |
|
Antiviral activity against herpes simplex virus type 1 HSV-1 (F) expressed as viral rating (VR) |
CHEMBL1124205 |
| Human herpesvirus 1 |
ED50 |
< |
1.0 |
uM |
Concentration at which 50% of the herpes simplex virus type 1 HSV-1 (F) induced cytopathic effect are inhibited is determined |
CHEMBL1124205 |
| Human herpesvirus 2 |
VR |
= |
1.6 |
|
Antiviral activity against herpes simplex virus type 2 HSV-2 (F) expressed as viral rating (VR) |
CHEMBL1124205 |
| Human herpesvirus 2 |
ED50 |
= |
1.0 |
uM |
Concentration at which 50% of the herpes simplex virus type 2 HSV-1 (F) induced cytopathic effect are inhibited is determined |
CHEMBL1124205 |
| HEp-2 |
Concentration |
> |
3200.0 |
uM |
Cytotoxic concentration against HEP-2 cells |
CHEMBL1124205 |
| NON-PROTEIN TARGET |
MIC |
= |
0.003 |
ug.mL-1 |
The minimum inhibitory concentration was measured against Herpes simplex virus type 1 (KOS strain) on E6SM cells |
CHEMBL1127471 |
| Human herpesvirus 1 |
MIC |
= |
0.004 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (F strain) |
CHEMBL1127471 |
| NON-PROTEIN TARGET |
MIC |
= |
0.004 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (McIntyre strain) |
CHEMBL1127471 |
| NON-PROTEIN TARGET |
MIC |
= |
0.02 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (G strain) |
CHEMBL1127471 |
| NON-PROTEIN TARGET |
MIC |
= |
0.04 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (196 strain) |
CHEMBL1127471 |
| NON-PROTEIN TARGET |
MIC |
= |
0.004 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (Lyons strain) |
CHEMBL1127471 |
| Human herpesvirus 1 |
MIC |
= |
0.08 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against TK+/TK-Herpes simplex virus type 1 (VMW1837 strain) |
CHEMBL1127471 |
| Human herpesvirus 1 |
MIC |
= |
4.5 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against TK-Herpes simplex virus type 1 (B2006 strain) |
CHEMBL1127471 |
| Human herpesvirus 3 |
MIC |
= |
1.4 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells against Varicella zoster virus (YS strain) |
CHEMBL1127471 |
| Human herpesvirus 3 |
MIC |
= |
0.5 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells against Varicella zoster virus (OKA strain) |
CHEMBL1127471 |
| Human herpesvirus 3 |
MIC |
= |
1.4 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells against TK-Varicella zoster virus (YS-R strain) |
CHEMBL1127471 |
| Human herpesvirus 3 |
MIC |
= |
1.5 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells against TK-Varicella zoster virus (07/1 strain) |
CHEMBL1127471 |
| Cytomegalovirus |
MIC |
= |
0.9 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells against Cytomegalovirus virus (Davis strain) |
CHEMBL1127471 |
| Human herpesvirus 5 |
MIC |
= |
1.5 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells against Cytomegalovirus virus (AD-169 strain) |
CHEMBL1127471 |
| Human herpesvirus 3 |
MIC |
> |
120.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Vesicular stomatitis virus |
CHEMBL1127471 |
| Vaccinia virus |
MIC |
> |
80.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Vaccinia virus |
CHEMBL1127471 |
| E6SM |
MIC |
> |
270.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells for morphological alteration |
CHEMBL1127471 |
| HEL |
MIC |
> |
200.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on HEL cells in cell growth |
CHEMBL1127471 |
| Human immunodeficiency virus 1 |
EC50 |
|
|
ug.mL-1 |
Compound was evaluated for the antiviral activity against HIV-1; Not determined |
CHEMBL1130783 |
| Human herpesvirus 1 |
EC50 |
|
|
ug.mL-1 |
Compound was evaluated for the antiviral activity against HSV-1; Not determined |
CHEMBL1130783 |
| Human herpesvirus 2 |
EC50 |
|
|
ug.mL-1 |
Compound was evaluated for the antiviral activity against HSV-2; Not determined |
CHEMBL1130783 |
| Human herpesvirus 5 |
EC50 |
= |
0.74 |
ug.mL-1 |
Compound was evaluated for the antiviral activity against HCMV |
CHEMBL1130783 |
| NON-PROTEIN TARGET |
IC50 |
> |
10.0 |
ug.mL-1 |
Compound was evaluated for its cytotoxicity. |
CHEMBL1130783 |
| Human herpesvirus 2 |
IC50 |
= |
32000.0 |
nM |
Inhibitory activity against herpes simplex virus |
CHEMBL1124871 |
| Human herpesvirus 1 |
ID50 |
= |
0.2 |
ug ml-1 |
Antiviral activity against herpesvirus HSV-1 in BWS strain in tissue culture. |
CHEMBL1125064 |
| Human herpesvirus 2 |
ID50 |
= |
1.6 |
ug ml-1 |
Antiviral activity against herpesvirus HSV-2 in G strain in tissue culture. |
CHEMBL1125064 |
| Human herpesvirus 5 |
ID50 |
= |
5.0 |
ug ml-1 |
Antiviral activity against herpesvirus HCMV in AD-169 strain in tissue culture. |
CHEMBL1125064 |
| Vero |
ID50 |
> |
100.0 |
ug ml-1 |
Antiviral activity against herpesvirus vero cells in tissue culture. |
CHEMBL1125064 |
| NON-PROTEIN TARGET |
ID50 |
> |
100.0 |
ug ml-1 |
Antiviral activity against herpesvirus MRS-5 cells in tissue culture. |
CHEMBL1125064 |
| Human herpesvirus 1 |
MIC |
= |
0.0007 |
ug.mL-1 |
Compound was tested for antiherpes activity against Herpes simplex virus-1(KOS) in E6SM cell cultures |
CHEMBL1129103 |
| Human herpesvirus 2 |
MIC |
= |
0.002 |
ug.mL-1 |
Compound was tested for antiherpes activity against Herpes simplex virus-2(G) in E6SM cell cultures |
CHEMBL1129103 |
| Human herpesvirus 3 |
MIC |
|
|
ug.mL-1 |
Compound was tested for antiherpes activity against Varicella zoster virus(OKA) in HEL cells; Not determined |
CHEMBL1129103 |
| Cytomegalovirus |
MIC |
= |
1.0 |
ug.mL-1 |
Compound was tested for antiherpes activity against Cytomegalovirus virus(AD 169) in HEL cells |
CHEMBL1129103 |
| HFF |
IC50 |
= |
7400.0 |
nM |
Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells |
CHEMBL1133751 |
| HFF |
IC90 |
= |
1600.0 |
nM |
Antiviral activity against towne strain HCMV was determined by yield reduction assay in duplicate wells using HFF cells |
CHEMBL1133751 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells |
CHEMBL1133751 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Visual cytotoxicity against stationary human foreskin fibroblasts (HFF) cells at the time of HCMV plaque enumeration |
CHEMBL1133751 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Compound was tested for the inhibition of KB cell growth in quadruplicate wells |
CHEMBL1133751 |
| HEL |
IC50 |
= |
500.0 |
nM |
Inhibition of human CMV DNA synthesis in CMV-infected HEL cells. |
CHEMBL1128369 |
| HEL |
IC50 |
= |
7000.0 |
nM |
Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR. |
CHEMBL1128369 |
| HEL |
IC90 |
= |
2100.0 |
nM |
Concentration that inhibits HCMV yield by 90% relative to control cultures without drugs |
CHEMBL1128369 |
| Human herpesvirus 1 |
IC50 |
= |
0.001 |
ug.mL-1 |
Tested for antiviral activity against HSV-1 (KOS) |
CHEMBL1134101 |
| Human herpesvirus 1 |
IC50 |
= |
0.48 |
ug.mL-1 |
Tested for antiviral activity against HSV-1 (TK-KOS) |
CHEMBL1134101 |
| Human herpesvirus 2 |
IC50 |
= |
0.002 |
ug.mL-1 |
Tested for antiviral activity against HSV-2 (G) |
CHEMBL1134101 |
| Human herpesvirus 3 |
IC50 |
|
|
ug.mL-1 |
Tested for antiviral activity against VZV (YS); Not determined |
CHEMBL1134101 |
| Human herpesvirus 3 |
IC50 |
|
|
ug.mL-1 |
Tested for antiviral activity against VZV (TK-KOS); Not determined |
CHEMBL1134101 |
| Cytomegalovirus |
IC50 |
= |
0.6 |
ug.mL-1 |
Tested for antiviral activity against HCMV (AD169) |
CHEMBL1134101 |
| Hepatitis B virus |
IC50 |
= |
45.0 |
ug.mL-1 |
Tested for antiviral activity against HBV (Hep AD79) |
CHEMBL1134101 |
| Cytomegalovirus |
EC50 |
= |
0.77 |
ug.mL-1 |
Effective concentration required against HCMV AD169 for antiviral activity |
CHEMBL1134101 |
| Cytomegalovirus |
EC50 |
= |
0.62 |
ug.mL-1 |
Effective concentration required against HCMV strain for antiviral activity |
CHEMBL1134101 |
| Cytomegalovirus |
EC50 |
= |
7.5 |
ug.mL-1 |
Effective concentration required against HCMV strain for antiviral activity |
CHEMBL1134101 |
| Cytomegalovirus |
EC50 |
= |
10.8 |
ug.mL-1 |
Effective concentration required against HCMV strain for antiviral activity |
CHEMBL1134101 |
| MRC5 |
IC50 |
= |
1700.0 |
nM |
In vitro antiviral activity against Human cytomegalovirus (HCMV)strain AD169 in MRC-5 lung fibroblasts using a DNA-hybridization assay |
CHEMBL1127652 |
| CFU-GM |
IC50 |
= |
19000.0 |
nM |
In vitro toxicity against colony forming unit granulocyte macrophage (CFU-GM) |
CHEMBL1127652 |
| ADMET |
IC50 |
= |
29000.0 |
nM |
In vitro toxicity against burst forming unit erythroid (BFU-E) |
CHEMBL1127652 |
| Thymidine kinase, cytosolic |
Activity |
= |
98.0 |
% |
Phosphorylation of compound by purified HSV-1 (F strain) thymidine kinase |
CHEMBL1123332 |
| Vero |
ID50 |
= |
0.2 |
uM |
Antiviral activity determined against herpes simplex type 1 (F strain) by plaque reduction in Vero cells |
CHEMBL1123332 |
| Mus musculus |
Survivors |
= |
10.0 |
|
Effect of subcutaneous treatment with the compound on HSV-2 encephalitis infection in mice at a dose of 20 mg/kg; 10/16 |
CHEMBL1123332 |
| Mus musculus |
MST |
= |
13.5 |
day |
Mean survival time of HSV-2 encephalitis infectuous mice upon subcutaneous treatment with the compound at a dose of 20 mg/kg |
CHEMBL1123332 |
| Cytomegalovirus |
IC50 |
= |
8800.0 |
nM |
Inhibitory activity against human cytomegalovirus determined by plaque reduction assay |
CHEMBL1124273 |
| Human herpesvirus 1 |
IC50 |
= |
3000.0 |
nM |
Antiviral activity against Herpes simplex virus type 1 determined by plaque reduction assay |
CHEMBL1124273 |
| HFF |
IC50 |
> |
100000.0 |
nM |
The compound was tested for cytotoxicity against human foreskin fibroblast cell |
CHEMBL1124273 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
The compound was tested for cytotoxicity against BSC1 cell |
CHEMBL1124273 |
| ADMET |
IC50 |
= |
1000000.0 |
nM |
Average percent inhibition of DNA, RNA, and protein synthesis determined in KB cells |
CHEMBL1124273 |
| Human herpesvirus 1 |
MIC |
= |
0.004 |
ug.mL-1 |
Inhibitory concentration against HSV type 1 strain KOS in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 1 |
MIC |
= |
0.006999999999999999 |
ug.mL-1 |
Inhibitory concentration against HSV type 1 strain F in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 1 |
MIC |
= |
0.001 |
ug.mL-1 |
Inhibitory concentration against HSV type 1 strain Mc Intyre in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 2 |
MIC |
= |
0.004 |
ug.mL-1 |
Inhibitory concentration against HSV type 2 strain G in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 2 |
MIC |
= |
0.02 |
ug.mL-1 |
Inhibitory concentration against HSV type 2 strain 196 in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 2 |
MIC |
= |
0.02 |
ug.mL-1 |
Inhibitory concentration against HSV type 2 strain Lyons in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 1 |
MIC |
= |
2.0 |
ug.mL-1 |
Inhibitory concentration against TK-HSV type 1 strain B2006 in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Human herpesvirus 3 |
MIC |
= |
0.07200000000000001 |
ug.mL-1 |
Inhibitory concentration against VZV strain YS in human embryonic lung (HEL) cell culture |
CHEMBL1126736 |
| Human herpesvirus 3 |
MIC |
= |
0.02 |
ug.mL-1 |
Inhibitory concentration against VZV strain OKA in human embryonic lung (HEL) cell culture |
CHEMBL1126736 |
| Human herpesvirus 3 |
MIC |
= |
0.9 |
ug.mL-1 |
Inhibitory concentration against TK-VZV strain YS-R in human embryonic lung (HEL) cell culture |
CHEMBL1126736 |
| Human herpesvirus 3 |
MIC |
= |
0.1 |
ug.mL-1 |
Inhibitory concentration against TK-VZV strain 07-1 in human embryonic lung (HEL) cell culture |
CHEMBL1126736 |
| Cytomegalovirus |
MIC |
= |
6.2 |
ug.mL-1 |
Inhibitory concentration against CMV strain Davis in human embryonic lung (HEL) cell culture |
CHEMBL1126736 |
| Cytomegalovirus |
MIC |
= |
3.0 |
ug.mL-1 |
Inhibitory concentration against CMV strain AD169 in human embryonic lung (HEL) cell culture |
CHEMBL1126736 |
| Vesicular stomatitis virus |
MIC |
> |
400.0 |
ug.mL-1 |
Inhibitory concentration against VSV in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| Vaccinia virus |
MIC |
= |
70.0 |
ug.mL-1 |
Inhibitory concentration against VV in human embryonic skin muscle (ESM) fibroblast cell culture |
CHEMBL1126736 |
| HEL |
MIC |
= |
85.0 |
ug.mL-1 |
Inhibitory concentration required to inhibit cell growth by 50% in human embryonic lung (HEL) cell culture |
CHEMBL1126736 |
| MRC5 |
IC50 |
= |
6300.0 |
nM |
Inhibitory concentration for anti-HCMV activity against AD-169 strain in MRC-5 cells |
CHEMBL1131418 |
| MRC5 |
CD50 |
> |
125.0 |
uM |
Cytotoxic dose for anti-HCMV activity against AD-169 strain in MRC-5 cells |
CHEMBL1131418 |
| ADMET |
TI |
> |
20.0 |
uM |
Therapeutic index for anti-HCMV activity against AD-169 strain in MRC-5 cells |
CHEMBL1131418 |
| Human herpesvirus 5 |
IC50 |
= |
7400.0 |
nM |
Antiviral activity against human cytomegalovirus (HCMV) in plaque reduction assay |
CHEMBL1129079 |
| Human herpesvirus 5 |
IC90 |
= |
1600.0 |
nM |
Antiviral activity against human cytomegalo virus (HCMV) in yield reduction assay |
CHEMBL1129079 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Antiviral activity against herpes simplex virus type 1 (HSV-1) was performed by HSV-1 ELISA assays. |
CHEMBL1129079 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay. |
CHEMBL1129079 |
| KB |
IC50 |
> |
100000.0 |
nM |
Inhibitory activity against growth of KB cell. |
CHEMBL1129079 |
| HEL |
MIC |
= |
1.5 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of CMV (AD-169) virus plaque formation in HEL cells |
CHEMBL1130007 |
| HEL |
MIC |
= |
0.13 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of CMV (Davis) virus plaque formation in HEL cells |
CHEMBL1130007 |
| HFF |
IC50 |
= |
7400.0 |
nM |
Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay |
CHEMBL1131504 |
| HFF |
IC90 |
= |
1600.0 |
nM |
Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by yield reduction assay |
CHEMBL1131504 |
| HFF |
IC50 |
= |
2600.0 |
nM |
Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay |
CHEMBL1131504 |
| MEF |
IC50 |
= |
3400.0 |
nM |
Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay |
CHEMBL1131504 |
| HFF |
IC50 |
|
|
nM |
Cytotoxicity on stationary HFF cells at time of HCMV plaque enumeration in cells not effected by the virus; Not tested |
CHEMBL1131504 |
| MEF |
IC50 |
|
|
nM |
Cytotoxicity on stationary MEF cells at time of MCMV plaque enumeration in cells not effected by the virus; Not tested |
CHEMBL1131504 |
| KB |
IC50 |
|
|
nM |
Cytotoxicity was evaluated by measuring the inhibition of KB cell growth; Not tested |
CHEMBL1131504 |
| Human herpesvirus 5 |
IC50 |
= |
7400.0 |
nM |
Compound was evaluated for the antiviral activity against HCMV determined by using Plaque assay |
CHEMBL1128463 |
| Human herpesvirus 5 |
IC90 |
= |
1600.0 |
nM |
Compound was evaluated for the antiviral activity against HCMV determined by using Yield reduction assay |
CHEMBL1128463 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Compound was evaluated for the antiviral activity against HSV-1 determined by using ELISA method |
CHEMBL1128463 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Compound was evaluated for the visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration |
CHEMBL1128463 |
| KB |
IC50 |
> |
100000.0 |
nM |
Compound was evaluated for the inhibition of KB cell growth determined in quadruplicate assay |
CHEMBL1128463 |
| Human herpesvirus 5 |
IC50 |
= |
7400.0 |
nM |
Antiviral activity against human cytomegalovirus (HCM virus) in plaque assay |
CHEMBL1129492 |
| Human herpesvirus 5 |
IC90 |
= |
1600.0 |
nM |
Antiviral activity of compound against HCM virus in yield reduction experiments |
CHEMBL1129492 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Antiviral activity against herpes simplex virus type 1 (HSV-1) in an ELISA assay |
CHEMBL1129492 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Visual cytotoxicity of compound on HFF cells at time of HCMV plaque enumeration |
CHEMBL1129492 |
| KB |
IC50 |
> |
100000.0 |
nM |
Inhibitory activity of compound against KB cell growth [>-indicates IC50/IC90 was not reached at the noted (highest) concentration tested] |
CHEMBL1129492 |
| Hepatitis C virus polyprotein |
IC50 |
|
|
nM |
Compound was evaluated for the inhibitory activity against Human Cytomegalovirus (HCMV) polymerase; No data |
CHEMBL1133310 |
| DNA polymerase alpha subunit |
IC50 |
|
|
nM |
Compound was evaluated for the inhibitory activity against Human alpha polymerase; No data |
CHEMBL1133310 |
| HFF |
IC50 |
= |
600.0 |
nM |
Antiviral activity in a cell-based plaque reduction assay, using an HFF cell line and the Davis strain of HCMV |
CHEMBL1133310 |
| Human herpesvirus 1 |
MIC50 |
> |
200.0 |
ug.mL-1 |
Antiviral activity against HSV-1 virus infected HEF cell lines. |
CHEMBL1129609 |
| Human herpesvirus 1 |
MIC50 |
= |
0.02 |
ug.mL-1 |
Antiviral activity against TK-HSV-1 virus infected HEF cell lines. |
CHEMBL1129609 |
| Human herpesvirus 2 |
MIC50 |
= |
0.002 |
ug.mL-1 |
Antiviral activity against HSV-2 virus infected HEF cell lines. |
CHEMBL1129609 |
| Vaccinia virus |
MIC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against vaccinia virus infected HEF cell lines. |
CHEMBL1129609 |
| Vesicular stomatitis virus |
MIC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against vesicular stomatitis virus infected HEF cell lines. |
CHEMBL1129609 |
| HEF |
MIC50 |
> |
100.0 |
ug.mL-1 |
Effects on cell morphology of HEF cell lines. |
CHEMBL1129609 |
| Human herpesvirus 5 |
MIC50 |
= |
0.7 |
ug.mL-1 |
Antiviral activity against HCMV virus infected HEL cell lines. |
CHEMBL1129609 |
| MRC5 |
HCMV yield |
= |
2.4 |
pfu/ml |
Effect of compound treatment on yields of human cytomegalovirus (HCMV) in MRC5 (human diploid embryonic lung cells) monolayer cultures at the concentration of 32 uM |
CHEMBL1125060 |
| MRC5 |
HCMV yield reduction |
= |
3.0 |
pfu/ml |
Effect of compound treatment on yields of human cytomegalovirus (HCMV) in MRC5 (human diploid embryonic lung cells) monolayer cultures at the concentration of 32 uM |
CHEMBL1125060 |
| ADMET |
Permeability coefficient |
= |
4.88 |
|
Permeability coefficient reported (Expressed as Permeability coefficient x 10 e 4 cm/s) |
CHEMBL1129412 |
| HEL |
EC50 |
= |
2700.0 |
nM |
Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection |
CHEMBL1148438 |
| HEL |
EC50 |
= |
3900.0 |
nM |
Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection |
CHEMBL1148438 |
| HEL |
MCC |
> |
150000.0 |
nM |
Minimal cytotoxic concentration required to cause a microscopically visible alteration of HEL cell morphology as measured at day 7 postinfection |
CHEMBL1148438 |
| HEL |
CC50 |
> |
150000.0 |
nM |
Cytostatic concentration required to inhibit HEL cell proliferation measured at day 4 |
CHEMBL1148438 |
| Human herpesvirus 5 |
IC50 |
= |
8700.0 |
nM |
Tested for antiviral activity against human cytomegalovirus (HCMV) by means of plaque reduction assay. |
CHEMBL1124845 |
| Human herpesvirus 1 |
IC50 |
= |
2300.0 |
nM |
Tested for antiviral activity against herpes simplex virus-1(HSV-1) by means of plaque reduction assay. |
CHEMBL1124845 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Tested for cytotoxic activity against human foreskin fibroblasts (HFF) cells. |
CHEMBL1124845 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Tested for cytotoxic activity against monkey kidney cells(BSC-1) cells. |
CHEMBL1124845 |
| ADMET |
IC50 |
= |
1000000.0 |
nM |
Tested for cytotoxic activity against human neoplastic cell line(KB cells). |
CHEMBL1124845 |
| NON-PROTEIN TARGET |
MCC |
> |
100.0 |
ug.mL-1 |
Minimum cytotoxic concentration which causes microscopically detectable alteration of normal cell morphology after 2 days of incubation. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
0.001 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (KOS) strain of HSV-1 virus on human E6SM cells. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
0.002 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (F) strain of HSV-1 virus on human E6SM cells. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
0.003 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Mc Intyre) strain of HSV-1 virus on human E6SM cells. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
0.002 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (G) strain of HSV-2 virus on human E6SM cells. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
0.006 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (196) strain of HSV-2 virus on human E6SM cells. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
0.002 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Lyons) strain of HSV-2 virus on human E6SM cells. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
5.0 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by TK-(B2006) strain of HSV-1 virus on human E6SM cells. |
CHEMBL1130413 |
| Human herpesvirus 1 |
Inhibition |
= |
55.0 |
% |
Evaluated for DNA polymerase inhibition activity against herpes simplex virus-1 (HSV-1) |
CHEMBL1123083 |
| Human herpesvirus 2 |
Inhibition |
= |
13.0 |
% |
Evaluated for DNA polymerase inhibition activity against HeLa cells. |
CHEMBL1123083 |
| Human herpesvirus 1 |
ED50 |
= |
1.0 |
ug ml-1 |
In vitro anti viral activity tested against HSV-1(Schooler) virus on Rabbit kidney cell cultures; 1-3 |
CHEMBL1123083 |
| Human herpesvirus 2 |
ED50 |
= |
3.0 |
ug ml-1 |
In vitro anti viral activity tested against HSV-2(Curtis) virus on Rabbit kidney cell cultures; 3-6 |
CHEMBL1123083 |
| Human herpesvirus 5 |
ED50 |
= |
0.4 |
ug ml-1 |
In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; 0.4-1.6 |
CHEMBL1123083 |
| Human herpesvirus 3 |
ED50 |
= |
1.0 |
ug ml-1 |
In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; 1-2 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Survivors |
= |
7.0 |
|
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously; Tested mice 10 |
CHEMBL1123083 |
| Mus musculus |
Average survival |
= |
14.6 |
day |
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Survivors |
= |
5.0 |
|
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average survival |
= |
12.6 |
day |
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Survivors |
= |
3.0 |
|
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average survival |
= |
9.8 |
day |
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously. |
CHEMBL1123083 |
| Human herpesvirus 5 |
IC50 |
= |
9200.0 |
nM |
Tested in vitro for antiviral activity against human cytomegalovirus (HCMV) in plaque reduction assay. |
CHEMBL1125150 |
| Human herpesvirus 5 |
IC90 |
= |
1.8 |
PuM |
Tested in vitro for antiviral activity against human cytomegalovirus (HCMV) in yield reduction assay. |
CHEMBL1125150 |
| Human herpesvirus 1 |
IC50 |
= |
4500.0 |
nM |
Tested in vitro for antiviral activity against HSV-1 in plaque reduction assay. |
CHEMBL1125150 |
| Human herpesvirus 1 |
IC90 |
= |
1200.0 |
nM |
Tested in vitro for antiviral activity against HSV-1 in yield reduction assay. |
CHEMBL1125150 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells). |
CHEMBL1125150 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells). |
CHEMBL1125150 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells). |
CHEMBL1125150 |
| Human herpesvirus 5 |
IC50 |
= |
7700.0 |
nM |
Compound was evaluated for antiviral activity by their capacity to inhibit replication of HCMV virus |
CHEMBL1131325 |
| Human herpesvirus 1 |
IC50 |
= |
1800.0 |
nM |
Compound was evaluated for the antiviral activity by their capacity to inhibit the replication of HSV-1 virus |
CHEMBL1131325 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity for the compound was determined in uninfected stationary human foreskin fibroblasts (HFF) cells. |
CHEMBL1131325 |
| KB |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity for the compound was determined by the inhibition of the growing KB cells. |
CHEMBL1131325 |
| MRC5 |
EC50 |
= |
9400.0 |
nM |
Inhibitory activity of compound against human cytomegalovirus (HCMV) in MRC-5 cells. |
CHEMBL1144867 |
| Human herpesvirus 5 |
EC50 |
= |
1.09 |
ug.mL-1 |
Antiviral activity was determined against Human cytomegalovirus (HCMV) strain AD-169 using CPE inhibition assay |
CHEMBL1134649 |
| Human herpesvirus 5 |
EC50 |
= |
0.61 |
ug.mL-1 |
Antiviral activity was determined against Human cytomegalovirus (HCMV) strain Davis using CPE inhibition assay |
CHEMBL1134649 |
| HEL 299 |
CC50 |
> |
10.0 |
ug.mL-1 |
Cytotoxic concentration of compound was tested against HEL299(human embryonic lung fibroblast) cells using cytotoxic assay |
CHEMBL1134649 |
| Human herpesvirus 5 |
IC50 |
= |
7900.0 |
nM |
Compound was tested for antiviral activity against human cytomegalovirus (HCMV) plaque reduction assay |
CHEMBL1150438 |
| Human herpesvirus 5 |
IC90 |
= |
2000.0 |
nM |
Compound was tested for antiviral activity against human cytomegalovirus (HCMV) yield reduction assay |
CHEMBL1150438 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Compound was tested for antiviral activity against HSV-1 |
CHEMBL1150438 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against human foreskin fibroblasts (HFF) cells |
CHEMBL1150438 |
| Human herpesvirus 1 |
ID50 |
= |
0.23 |
ug ml-1 |
Antiviral activity of the compound, determined by plaque-reduction assay against Herpes simplex virus (HSV) type 1, BW5 strain in Vero cells |
CHEMBL1124514 |
| Human herpesvirus 1 |
ID50 |
> |
10.0 |
ug ml-1 |
Antiviral activity of the compound, determined by plaque-reduction assay against thymidine kinase deficient Herpes simplex virus type 1, Z826 strain in Vero cells |
CHEMBL1124514 |
| Human herpesvirus 2 |
ID50 |
= |
0.94 |
ug ml-1 |
Antiviral activity determined by plaque-reduction assay against Herpes simplex virus type 2, G strain in Vero cells |
CHEMBL1124514 |
| Human herpesvirus 5 |
ID50 |
= |
1.8 |
ug ml-1 |
Antiviral activity determined by plaque-reduction assay against Human cytomegalovirus, AD-169 strain in MRC-5 cells |
CHEMBL1124514 |
| ADMET |
Solubility |
= |
4300.0 |
ug.mL-1 |
Compound was tested for solubility in water at 25 degree C |
CHEMBL1132422 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
630.0 |
nM |
In vitro antiviral (HCMV-AD169) activity of the compound (Concentration required to reduce 50% of the plaques) determined by plaque reduction assay. |
CHEMBL1132422 |
| HEL 299 |
CC50 |
> |
100000.0 |
nM |
In vitro cytotoxicity of the compound (Concentration required to reduce OD value by 50%) in human embryonic lung fibroblast(HEL 299) cells determined by MTT assay. |
CHEMBL1132422 |
| Rattus norvegicus |
Dose |
= |
3.0 |
% |
Total amount of Ganciclovir recovered in the urine over a 48 hr period after an oral dose of 0.1 mmol/kg to male SD rat |
CHEMBL1132422 |
| Oryctolagus cuniculus |
MCC |
> |
400.0 |
ug.mL-1 |
Evaluated for the minimum cytotoxic concentration (MCC) upon preincubation of rabbit kidney cells in medium containing 10% fetal calf serum at 37 degree Celsius for 24 hr |
CHEMBL1124765 |
| Human herpesvirus 1 |
MIC |
= |
0.2 |
ug.mL-1 |
Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-1 (HSV-1) with strains KOS |
CHEMBL1124765 |
| Human herpesvirus 1 |
MIC |
= |
0.1 |
ug.mL-1 |
Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-1 (HSV-1) with strains F |
CHEMBL1124765 |
| Human herpesvirus 1 |
MIC |
= |
0.2 |
ug.mL-1 |
Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-1 (HSV-1) with strains McIntyre |
CHEMBL1124765 |
| Human herpesvirus 2 |
MIC |
= |
0.02 |
ug.mL-1 |
Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-2 (HSV-2) with strains G |
CHEMBL1124765 |
| Human herpesvirus 2 |
MIC |
= |
0.07 |
ug.mL-1 |
Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-2 (HSV-2) with strains 196 |
CHEMBL1124765 |
| Human herpesvirus 2 |
MIC |
= |
0.1 |
ug.mL-1 |
Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-2 (HSV-2) with strains Lyons |
CHEMBL1124765 |
| Vaccinia virus |
MIC |
= |
150.0 |
ug.mL-1 |
Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against vaccinia virus |
CHEMBL1124765 |
| Vesicular stomatitis virus |
MIC |
> |
400.0 |
ug.mL-1 |
Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against vesicular stomatitis virus |
CHEMBL1124765 |
| Human herpesvirus 1 |
MIC |
= |
20.0 |
ug.mL-1 |
Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against TK- herpes simplex virus type 1 (TK- HSV-1) with strain B2006 |
CHEMBL1124765 |
| Human herpesvirus 1 |
MIC |
= |
10.0 |
ug.mL-1 |
Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against TK- herpes simplex virus type 1 (TK- HSV-1) with strain VMW 1837 |
CHEMBL1124765 |
| Mus musculus |
Mean day appearance of lesions |
= |
29.0 |
|
Topical treatment of intracutaneous TK- herpes simplex virus type 1 of strain VMW 1837 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 3% concentration (v/v in DMSO) |
CHEMBL1124765 |
| Mus musculus |
MTS |
= |
40.4 |
day |
Mean time survival (MTS) of the mice at the end of 28 or 49 days. |
CHEMBL1124765 |
| Mus musculus |
Mean day appearance of lesions |
= |
16.7 |
|
Topical treatment of intracutaneous TK- herpes simplex virus type 1 of strain VMW 1837 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 1% concentration (v/v in DMSO) |
CHEMBL1124765 |
| Mus musculus |
MTS |
= |
35.6 |
day |
Mean time survival (MTS) of the mice at the end of 28 or 49 days. |
CHEMBL1124765 |
| Mus musculus |
Mean day appearance of lesions |
= |
17.0 |
|
Topical treatment of intracutaneous TK- herpes simplex virus type 1 of strain VMW 1837 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 0.3% concentration (v/v in DMSO) |
CHEMBL1124765 |
| Mus musculus |
MTS |
= |
43.4 |
day |
Mean time survival (MTS) of the mice at the end of 28 or 49 days. |
CHEMBL1124765 |
| Mus musculus |
Mean day appearance of lesions |
= |
12.0 |
|
Topical treatment of intracutaneous HSV-1 (KOS) herpes simplex virus type 1 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 3% concentration (v/v in DMSO) |
CHEMBL1124765 |
| Mus musculus |
MTS |
= |
23.2 |
day |
Mean time survival (MTS) of the mice at the end of 28 or 49 days. |
CHEMBL1124765 |
| Mus musculus |
Mean day appearance of lesions |
= |
14.2 |
|
Topical treatment of intracutaneous HSV-1 (KOS) herpes simplex virus type 1 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 1% concentration (v/v in DMSO) |
CHEMBL1124765 |
| Mus musculus |
MTS |
= |
22.2 |
day |
Mean time survival (MTS) of the mice at the end of 28 or 49 days. |
CHEMBL1124765 |
| Mus musculus |
Mean day appearance of lesions |
= |
8.2 |
|
Topical treatment of intracutaneous HSV-1 (KOS) herpes simplex virus type 1 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 0.3% concentration (v/v in DMSO) |
CHEMBL1124765 |
| Mus musculus |
MTS |
= |
11.6 |
day |
Mean time survival (MTS) of the mice at the end of 28 or 49 days. |
CHEMBL1124765 |
| Human herpesvirus 5 |
EC50 |
= |
4100.0 |
nM |
In vitro effective concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line |
CHEMBL1137080 |
| Human herpesvirus 5 |
CC50 |
> |
100000.0 |
nM |
In vitro cytotoxic concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line |
CHEMBL1137080 |
| Human herpesvirus 5 |
EC50 |
= |
2300.0 |
nM |
In vitro effective concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line |
CHEMBL1137080 |
| HFF |
CC50 |
> |
392000.0 |
nM |
In vitro cytotoxic concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line |
CHEMBL1137080 |
| MEF |
EC50 |
= |
5000.0 |
nM |
In vitro effective concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line |
CHEMBL1137080 |
| Murine cytomegalovirus |
CC50 |
> |
35000.0 |
nM |
In vitro cytotoxic concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line |
CHEMBL1137080 |
| E6SM |
MIC |
> |
1600000.0 |
nM |
Minimum inhibitory concentration required to elicit microscopically visible cell morphology in E6SM cell lines |
CHEMBL1134563 |
| E6SM |
EC50 |
= |
1.2 |
nM |
Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines |
CHEMBL1134563 |
| E6SM |
EC50 |
= |
1.2 |
nM |
Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines |
CHEMBL1134563 |
| E6SM |
EC50 |
> |
100000.0 |
nM |
Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines |
CHEMBL1134563 |
| HeLa |
EC50 |
> |
100000.0 |
nM |
Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines |
CHEMBL1134563 |
| HEL |
EC50 |
= |
7800.0 |
nM |
Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in AD-169 strain HEL cell lines |
CHEMBL1134563 |
| HEL |
EC50 |
= |
11800.0 |
nM |
Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in Davis-169 strain HEL cell lines |
CHEMBL1134563 |
| HEL |
MIC |
> |
150000.0 |
nM |
Minimum inhibitory concentration required to elicit microscopically visible cell morphology in HEL cell lines |
CHEMBL1134563 |
| Human herpesvirus 5 |
IC50 |
= |
0.3 |
ug.mL-1 |
Antiviral activity determined against human cytomegalovirus (HCMV) in Hs 68 cell line by plaque reduction assay |
CHEMBL1133219 |
| Hs68 |
CC50 |
= |
12.5 |
ug.mL-1 |
Cytotoxic activity in Hs 68 cell line by inhibition of cell proliferation |
CHEMBL1133219 |
| ESM |
MIC |
= |
0.004 |
ug.mL-1 |
Concentration required to inhibit HSV-1 (KOS) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
0.004 |
ug.mL-1 |
Concentration required to inhibit HSV-1 (F) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
0.004 |
ug.mL-1 |
Concentration required to inhibit HSV-1 (McIntyre) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
0.004 |
ug.mL-1 |
Concentration required to inhibit HSV-2(G) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
0.004 |
ug.mL-1 |
Concentration required to inhibit HSV-2(lyons) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
0.004 |
ug.mL-1 |
Concentration required to inhibit HSV-2(196) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
20.0 |
ug.mL-1 |
Concentration required to inhibit VV induced cytopathogenicity in ESM cells by 50%. |
CHEMBL1125932 |
| ESM |
MIC |
= |
7.0 |
ug.mL-1 |
Concentration required to inhibit TK-HSV-1 (B2006) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
= |
1.0 |
ug.mL-1 |
Concentration required to inhibit TK-HSV-1 (VMW2837) induced cytopathogenicity in ESM cells by 50% |
CHEMBL1125932 |
| HEL |
MIC |
|
|
ug.mL-1 |
Concentration required to inhibit VZV (YS) induced cytopathogenicity in HEL cells by 50% |
CHEMBL1125932 |
| HEL |
MIC |
|
|
ug.mL-1 |
Concentration required to inhibit VZV (oka) induced cytopathogenicity in HEL cells by 50% |
CHEMBL1125932 |
| HEL |
MIC |
|
|
ug.mL-1 |
Concentration required to inhibit TK-VZV (YSR) induced cytopathogenicity in HEL cells by 50% |
CHEMBL1125932 |
| HEL |
MIC |
|
|
ug.mL-1 |
Concentration required to inhibit TK-VZV (07-1) induced cytopathogenicity in HEL cells by 50% |
CHEMBL1125932 |
| HEL |
MIC |
= |
1.0 |
ug.mL-1 |
Concentration required to inhibit CMV (Davis) induced cytopathogenicity in HEL cells by 50% |
CHEMBL1125932 |
| HEL |
MIC |
= |
1.0 |
ug.mL-1 |
Concentration required to inhibit CMV (AD-169) induced cytopathogenicity in HEL cells by 50% |
CHEMBL1125932 |
| ESM |
MIC |
> |
400.0 |
ug.mL-1 |
Concentration required to cause a microscopically detectable alteration of normal cell morphology in ESM cells |
CHEMBL1125932 |
| ESM |
MIC |
> |
200.0 |
ug.mL-1 |
Concentration required to cause 50% reduction in cellular DNA synthesis in ESM cells |
CHEMBL1125932 |
| HEL |
MIC |
= |
90.0 |
ug.mL-1 |
Concentration required to cause 50% reduction in HEL cell growth. |
CHEMBL1125932 |
| HFF |
IC50 |
= |
7400.0 |
nM |
Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells |
CHEMBL1133755 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Compound was tested for antiviral activity against herpes simplex virus type 1 (HSV-1) |
CHEMBL1133755 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells |
CHEMBL1133755 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay. |
CHEMBL1133755 |
| HFF |
IC90 |
= |
1600.0 |
nM |
Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by yield reduction assay using HFF cells |
CHEMBL1133755 |
| MRC5 |
IC50 |
= |
4000.0 |
nM |
In vitro antiherpesvirus activity against MRC-5 cells infected with HCMV (AD-169 strain) |
CHEMBL1125512 |
| HFF |
IC50 |
= |
7400.0 |
nM |
Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells |
CHEMBL1133754 |
| HFF |
IC90 |
= |
1600.0 |
nM |
Compound was tested for antiviral activity against Towne strain of HCMV in a yield reduction assay using HFF cells |
CHEMBL1133754 |
| Human herpesvirus 5 |
IC50 |
= |
2000.0 |
nM |
Compound was tested for antiviral activity against HCMV in viral cytopathic effect(CPE) assay |
CHEMBL1133754 |
| Human herpesvirus 5 |
IC50 |
= |
880.0 |
nM |
Compound was tested for antiviral activity against HCMV in DNA hybridization assay |
CHEMBL1133754 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Compound was tested for antiviral activity against HSV-1 assayed by ELISA in quadruplicate wells |
CHEMBL1133754 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration |
CHEMBL1133754 |
| KB |
IC50 |
> |
100000.0 |
nM |
Compound was tested for inhibition of KB cell growth in quadruplicate assay |
CHEMBL1133754 |
| HFF |
IC50 |
= |
4500.0 |
nM |
Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells |
CHEMBL1133754 |
| HFF |
IC50 |
= |
4100.0 |
nM |
Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells |
CHEMBL1133754 |
| HFF |
IC90 |
= |
3300.0 |
nM |
Compound was tested for antiviral activity against wild-type AD169 strain of HCMV in yield reduction assay using HFF cells |
CHEMBL1133754 |
| HFF |
IC90 |
= |
3600.0 |
nM |
Compound was tested for antiviral activity against 2916 AD169 strain of HCMV in yield reduction assay using HFF cells |
CHEMBL1133754 |
| Human herpesvirus 1 |
EC50 |
|
|
nM |
In vitro antiviral activity against Herpes simplex virus (HSV-1) was determined; ND= Not determined |
CHEMBL1135020 |
| Human herpesvirus 2 |
EC50 |
|
|
nM |
In vitro antiviral activity against Herpes simplex virus (HSV-2) was determined; ND= Not determined |
CHEMBL1135020 |
| Human herpesvirus 5 |
EC50 |
= |
780.0 |
nM |
In vitro antiviral activity against Human cytomegalovirus (HCMV) was determined |
CHEMBL1135020 |
| Human herpesvirus 4 |
EC50 |
|
|
nM |
In vitro antiviral activity against Epstein Barr virus (EBV) was determined; ND= Not determined |
CHEMBL1135020 |
| Human herpesvirus 3 |
EC50 |
|
|
nM |
In vitro antiviral activity against Varicella zoster virus (VZV) was determined; ND= Not determined |
CHEMBL1135020 |
| CCRF-CEM |
IC50 |
> |
390000.0 |
nM |
In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity |
CHEMBL1135020 |
| CCRF-CEM |
IC50 |
|
|
nM |
Inhibitory concentration for spectrum antiviral activity against herpes viruses; ND= Not determined |
CHEMBL1135020 |
| Human herpesvirus 5 |
IC50 |
= |
8700.0 |
nM |
Inhibition of human cytomegalovirus (HCMV) in plaque reduction assay |
CHEMBL1124846 |
| Human herpesvirus 5 |
IC50 |
= |
1800.0 |
nM |
Inhibition of human cytomegalovirus (HCMV) in plaque reduction assay |
CHEMBL1124846 |
| Human herpesvirus 1 |
IC50 |
= |
4500.0 |
nM |
Inhibition of herpes simplex virus (HSV-1) in plaque reduction assay |
CHEMBL1124846 |
| Human herpesvirus 1 |
IC50 |
= |
1200.0 |
nM |
Inhibition of herpes simplex virus (HSV-1) in yield reduction assay |
CHEMBL1124846 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Compound was evaluated for cytotoxic activity against HFF cells |
CHEMBL1124846 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Compound was evaluated for cytotoxic activity against BSC cells |
CHEMBL1124846 |
| Neoplastic cell line |
IC50 |
> |
100000.0 |
nM |
Compound was evaluated for cytotoxic activity against KB cells |
CHEMBL1124846 |
| Mus musculus |
Mortality |
= |
27.0 |
% |
Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 16.7 mg/kg at 6 h |
CHEMBL1124846 |
| Mus musculus |
Mortality |
= |
47.0 |
% |
Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 16.7 mg/kg at 24 h |
CHEMBL1124846 |
| Mus musculus |
Mortality |
= |
53.0 |
% |
Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 16.7 mg/kg at 48 h |
CHEMBL1124846 |
| Mus musculus |
Mortality |
= |
33.0 |
% |
Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 5.6 mg/kg at 6 h |
CHEMBL1124846 |
| Mus musculus |
Mortality |
= |
47.0 |
% |
Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 5.6 mg/kg at 24 h |
CHEMBL1124846 |
| Mus musculus |
Mortality |
= |
67.0 |
% |
Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 5.6 mg/kg at 48 h |
CHEMBL1124846 |
| Mus musculus |
Mortality |
= |
33.0 |
% |
Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 1.9 mg/kg at 6 h |
CHEMBL1124846 |
| Mus musculus |
Mortality |
= |
80.0 |
% |
Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 1.9 mg/kg at 24 h |
CHEMBL1124846 |
| Mus musculus |
Mortality |
= |
73.0 |
% |
Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 1.9 mg/kg at 48 h |
CHEMBL1124846 |
| Mus musculus |
Mortality |
= |
93.0 |
% |
Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 0.6 mg/kg at 6 h |
CHEMBL1124846 |
| Mus musculus |
Mortality |
= |
80.0 |
% |
Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 0.6 mg/kg at 24 h |
CHEMBL1124846 |
| Mus musculus |
Mortality |
= |
93.0 |
% |
Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 0.6 mg/kg at 48 h |
CHEMBL1124846 |
| Mus musculus |
MDD |
= |
4.6 |
|
Compound was evaluated for mean day of death at 0.6 mg/kg at 6 h |
CHEMBL1124846 |
| Mus musculus |
MDD |
= |
5.4 |
|
Compound was evaluated for mean day of death at 0.6 mg/kg at 24 h |
CHEMBL1124846 |
| Mus musculus |
MDD |
= |
5.3 |
|
Compound was evaluated for mean day of death at 0.6 mg/kg at 48 h |
CHEMBL1124846 |
| Mus musculus |
MDD |
= |
3.8 |
|
Compound was evaluated for mean day of death at 16.7 mg/kg at 6 h |
CHEMBL1124846 |
| Mus musculus |
MDD |
= |
5.3 |
|
Compound was evaluated for mean day of death at 16.7 mg/kg at 24 h |
CHEMBL1124846 |
| Mus musculus |
MDD |
= |
5.5 |
|
Compound was evaluated for mean day of death at 16.7 mg/kg at 48 h |
CHEMBL1124846 |
| Mus musculus |
MDD |
= |
4.2 |
|
Compound was evaluated for mean day of death at 5.6 mg/kg at 6 h |
CHEMBL1124846 |
| Mus musculus |
MDD |
= |
5.3 |
|
Compound was evaluated for mean day of death at 5.6 mg/kg at 24 h |
CHEMBL1124846 |
| Mus musculus |
MDD |
= |
5.5 |
|
Compound was evaluated for mean day of death at 5.6 mg/kg at 48 h |
CHEMBL1124846 |
| Mus musculus |
MDD |
= |
5.4 |
|
Compound was evaluated for mean day of death at 1.9 mg/kg at 6 h |
CHEMBL1124846 |
| Mus musculus |
MDD |
= |
4.9 |
|
Compound was evaluated for mean day of death at 1.9 mg/kg at 24 h |
CHEMBL1124846 |
| Mus musculus |
MDD |
= |
4.9 |
|
Compound was evaluated for mean day of death at 1.9 mg/kg at 48 h |
CHEMBL1124846 |
| Mus musculus |
Activity |
= |
14.0 |
|
Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 0.6 mg/kg at 6 hr followed (MCMV) virus inoculation |
CHEMBL1124846 |
| Mus musculus |
Activity |
= |
12.0 |
|
Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 0.6 mg/kg at 24 h followed (MCMV) virus inoculation |
CHEMBL1124846 |
| Mus musculus |
Activity |
= |
14.0 |
|
Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 0.6 mg/kg at 48 h followed (MCMV) virus inoculation |
CHEMBL1124846 |
| Mus musculus |
Activity |
= |
4.0 |
|
Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 16.7 mg/kg at 6 hr followed (MCMV) virus inoculation |
CHEMBL1124846 |
| Mus musculus |
Activity |
= |
7.0 |
|
Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 16.7 mg/kg at 24 hr followed (MCMV) virus inoculation |
CHEMBL1124846 |
| Mus musculus |
Activity |
= |
8.0 |
|
Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 16.7 mg/kg at 48 hr followed (MCMV) virus inoculation |
CHEMBL1124846 |
| Mus musculus |
Activity |
= |
5.0 |
|
Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 5.6 mg/kg at 6 hr followed (MCMV) virus inoculation |
CHEMBL1124846 |
| Mus musculus |
Activity |
= |
7.0 |
|
Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 5.6 mg/kg at 24 hr followed (MCMV) virus inoculation |
CHEMBL1124846 |
| Mus musculus |
Activity |
= |
10.0 |
|
Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 5.6 mg/kg at 48 hr followed (MCMV) virus inoculation |
CHEMBL1124846 |
| Mus musculus |
Activity |
= |
5.0 |
|
Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 1.9 mg/kg at 6 hr followed (MCMV) virus inoculation |
CHEMBL1124846 |
| Mus musculus |
Activity |
= |
12.0 |
|
Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 1.9 mg/kg at 24 hr followed (MCMV) virus inoculation |
CHEMBL1124846 |
| Mus musculus |
Activity |
= |
11.0 |
|
Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 1.9 mg/kg at 48 hr followed (MCMV) virus inoculation |
CHEMBL1124846 |
| Human herpesvirus 5 |
EC50 |
= |
0.1 |
ug.mL-1 |
The compound was tested for the cytomegalovirus; Effective concentration required to inhibit 50% virus proliferation |
CHEMBL1130360 |
| Human herpesvirus 5 |
IC50 |
= |
1.2 |
ug.mL-1 |
The concentration required to reduce virus plaque formation by 50% was measured on AD-169 strains of human cytomegalovirus |
CHEMBL1132117 |
| Human herpesvirus 5 |
IC50 |
= |
1.9 |
ug.mL-1 |
The concentration required to reduce virus plaque formation by 50% was measured on Davis strains of human cytomegalovirus |
CHEMBL1132117 |
| HEL |
CC50 |
> |
50.0 |
ug.mL-1 |
The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells |
CHEMBL1132117 |
| HEL |
MCC |
> |
50.0 |
ug.mL-1 |
The minimum cytotoxic concentration was measured on Human Embryonic Lung (HEL) cells |
CHEMBL1132117 |
| Vero |
IC50 |
|
|
ug.mL-1 |
Inhibitory activity against Herpes Simplex virus type 1 (KOS strain) in a Plaque reduction Assay in vero cells;Not determined |
CHEMBL1151552 |
| Vero |
IC50 |
|
|
ug.mL-1 |
Inhibitory activity against Herpes Simplex virus type 1 (186 strain) in a Plaque reduction Assay in vero cells;Not determined |
CHEMBL1151552 |
| Vero |
IC50 |
|
|
ug.mL-1 |
Cytotoxicity in Vero cell line;Not determined |
CHEMBL1151552 |
| F2002 cell line |
IC50 |
= |
0.1 |
ug.mL-1 |
Inhibitory activity against human cytomegalo virus (WFI strain) in a plaque reduction assay in flow 2002 human fibroblast cells |
CHEMBL1151552 |
| ADMET |
CC50 |
> |
100.0 |
ug.mL-1 |
Cytotoxicity in Flow 2002 cell line |
CHEMBL1151552 |
| E6SM |
MCC |
> |
100.0 |
ug.mL-1 |
Inhibition of virus-induced cytopathicity in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| ADMET |
EC50 |
= |
0.019 |
ug.mL-1 |
Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Human herpesvirus 1 |
EC50 |
= |
0.019 |
ug.mL-1 |
Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Human herpesvirus 1 |
EC50 |
= |
0.019 |
ug.mL-1 |
Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| ADMET |
EC50 |
= |
0.019 |
ug.mL-1 |
Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Unchecked |
EC50 |
= |
0.032 |
ug.mL-1 |
Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Unchecked |
EC50 |
= |
0.019 |
ug.mL-1 |
Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Vaccinia virus |
EC50 |
> |
100.0 |
ug.mL-1 |
Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Vesicular stomatitis virus |
EC50 |
> |
100.0 |
ug.mL-1 |
Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| ADMET |
EC50 |
= |
2.4 |
ug.mL-1 |
Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| NON-PROTEIN TARGET |
MCC |
= |
392000.0 |
nM |
Minimum cytotoxic concentration in E6SM fibroblast cells |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
30.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-1(KOS) |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
45.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-1(F) |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
40.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-1 (McIntyre) |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
60.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-2(G) |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
100.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-2(196) |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
45.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-2(Lyons) |
CHEMBL1135643 |
| NON-PROTEIN TARGET |
MIC |
= |
7500.0 |
nM |
Minimum inhibitory concentration against Herpes simplex Virus-1 (KOS) (ACV) |
CHEMBL1135643 |
| E6SM |
MIC |
= |
0.0064 |
ug.mL-1 |
Tested for antiviral activity against herpes simplex virus type 1(KOS) in E6SM cell line(human embryonic skin-muscle fibroblasts) |
CHEMBL1135216 |
| E6SM |
MIC |
= |
9.6 |
ug.mL-1 |
The compound was tested for antiviral activity against thymidine kinase-deficient (TK-HSV-1)virus in E6SM cell line(human embryonic skin-muscle fibroblasts) |
CHEMBL1135216 |
| E6SM |
MIC |
= |
0.019 |
ug.mL-1 |
Tested for antiviral activity against thymidine kinase-deficient (TK-HSV-2G) virus in E6SM cell line(human embryonic skin-muscle fibroblasts) |
CHEMBL1135216 |
| HEL |
MIC |
= |
2.0 |
ug.mL-1 |
Tested for antiviral activity against human cytomegalovirus (AD-169) in human embryonic lung fibroblasts |
CHEMBL1135216 |
| E6SM |
MIC |
> |
100.0 |
ug.mL-1 |
Tested for antiviral activity against vaccinia virus in human embryonic skin muscle fibroblast |
CHEMBL1135216 |
| E6SM |
MIC |
= |
9.6 |
ug.mL-1 |
Tested for antiviral activity against VSV-virus in human embryonic skin muscle fibroblasts |
CHEMBL1135216 |
| E6SM |
MCC |
> |
100.0 |
ug.mL-1 |
Tested for cytotoxic activity in human embryonic skin muscle fibroblast (E6SM) |
CHEMBL1135216 |
| HEL |
MCC |
> |
50.0 |
ug.mL-1 |
Tested for cytotoxic activity in human embryonic lung fibroblast (HEL) |
CHEMBL1135216 |
| Human herpesvirus 5 |
IC50 |
= |
7700.0 |
nM |
Tested for antiviral activity against human cytomegalovirus by plaque assay |
CHEMBL1127034 |
| Human herpesvirus 5 |
IC90 |
= |
1800.0 |
nM |
Tested for antiviral activity against human cytomegalovirus by yield reduction assay |
CHEMBL1127034 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Tested for antiviral activity against Herpes simplex virus type-1 using plaque assay |
CHEMBL1127034 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Tested for cytotoxicity in human foreskin fibroblasts at time of HCMV plaque enumeration |
CHEMBL1127034 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Tested for the inhibition of KB cell growth |
CHEMBL1127034 |
| HEL |
MCC |
> |
150000.0 |
nM |
Minimal cytotoxic concentration required to cause a morphological alteration of human embryonic lung fibroblast(HEL) cell cultures |
CHEMBL1136504 |
| HEL |
CC50 |
> |
150000.0 |
nM |
Concentration required against HEL cell proliferation |
CHEMBL1136504 |
| Human herpesvirus 5 |
EC50 |
= |
4000.0 |
nM |
Antiviral activity evaluated against human cytomegalovirus (HCMV) AD169 |
CHEMBL1136504 |
| Human herpesvirus 5 |
EC50 |
= |
5700.0 |
nM |
Antiviral activity evaluated against human cytomegalovirus (HCMV) Davis |
CHEMBL1136504 |
| Human herpesvirus 5 |
IC50 |
= |
0.5 |
ug.mL-1 |
Anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells |
CHEMBL1131427 |
| Cytomegalovirus |
IC50 |
= |
0.5 |
ug.mL-1 |
Anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells |
CHEMBL1131427 |
| HEL |
IC50 |
|
|
ug.mL-1 |
Compound was tested for Anti-VZV activity against OKA strain TK+ in HEL cells;d ='not determined' |
CHEMBL1131427 |
| HEL |
IC50 |
|
|
ug.mL-1 |
Compound was tested for Anti-VZV activity against YS TK+ in HEL cells;d ='not determined' |
CHEMBL1131427 |
| HEL |
IC50 |
|
|
ug.mL-1 |
Compound was tested for Anti-VZV activity against 07/1 TK- in HEL cells;d ='not determined' |
CHEMBL1131427 |
| HEL |
IC50 |
|
|
ug.mL-1 |
Compound was tested for Anti-VZV activity against YS/R TK- in HEL cells;d ='not determined' |
CHEMBL1131427 |
| HEL |
CC |
> |
100.0 |
ug ml-1 |
Inhibition of cell proliferation expressed as CC50 |
CHEMBL1131427 |
| NON-PROTEIN TARGET |
Selectivity index |
> |
200.0 |
|
Ratio of Cytotoxicity concentration to that of virus-inhibitory concentration. |
CHEMBL1131427 |
| Rattus norvegicus |
AUC |
= |
209.7 |
|
Area under curve (Pharmacokinetic property) was determined |
CHEMBL1151543 |
| Rattus norvegicus |
F |
= |
3.6 |
% |
Oral bioavailability in rat |
CHEMBL1151543 |
| Human immunodeficiency virus 1 |
|
|
|
|
Antiviral activity against HIV-1 was determined; No inhibition |
CHEMBL1124905 |
| Human herpesvirus 5 |
|
|
|
|
Antiviral activity against HCMV was determined; No inhibition |
CHEMBL1124905 |
| HFF |
IC50 |
= |
7700.0 |
nM |
Antiviral activity was determined by the HCMV plaque assay using HFF cells |
CHEMBL1129959 |
| HFF |
IC90 |
= |
1800.0 |
nM |
Antiviral activity was estimated by the HCMV yield reduction experiments |
CHEMBL1129959 |
| KB |
IC50 |
= |
3500.0 |
nM |
Antiviral activity was estimated by HSV-1 ELISA method (data of single experiment) |
CHEMBL1129959 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity in HFF cells was estimated by the visual scoring of cells affected by virus infection in the plaque reduction assay (data of single experiment) |
CHEMBL1129959 |
| KB |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity in KB cells. |
CHEMBL1129959 |
| Human herpesvirus 5 |
IC50 |
= |
8800.0 |
nM |
Inhibitory concentration against human cytomegalovirus (HCMV) in plaque reduction assay |
CHEMBL1123999 |
| Human herpesvirus 1 |
IC50 |
= |
3000.0 |
nM |
Inhibitory concentration against HCMV in plaque reduction assay |
CHEMBL1123999 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against uninfected human foreskin fibroblast(HFF cells) |
CHEMBL1123999 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against uninfected monkey kidney cells (BSC-1) |
CHEMBL1123999 |
| ADMET |
Inhibition |
= |
1000.0 |
% |
Cytotoxicity against human neoplastic cell line(KB cells) |
CHEMBL1123999 |
| Human herpesvirus 5 |
IC50 |
= |
7400.0 |
nM |
antiviral activity in Human cytomegalovirus by plaque assay (HCMV) |
CHEMBL1128464 |
| Human herpesvirus 5 |
IC90 |
= |
1600.0 |
nM |
antiviral activity in Human cytomegalovirus by plaque assay given as yield |
CHEMBL1128464 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Antiviral activity in Herpes simplex virus-1 assayed by ELISA in quadruplicate wells |
CHEMBL1128464 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration |
CHEMBL1128464 |
| KB |
IC50 |
> |
100000.0 |
nM |
cell growth inhibition was determined in KB cells in quadruplicate assays |
CHEMBL1128464 |
| Human herpesvirus 5 |
IC50 |
= |
720.0 |
nM |
Concentration required to inhibit human cytomegalovirus HCMV-AD169 in antiviralplaque reduction assay |
CHEMBL1136799 |
| Vero |
CCID50 |
> |
500.0 |
uM |
Growth inhibition of cytomegalovirus in Vero cells |
CHEMBL1136799 |
| Human herpesvirus 5 |
IC50 |
= |
7900.0 |
nM |
Antiviral activity against Human cytomegalovirus in a plaque-reduction assay |
CHEMBL1124509 |
| Human herpesvirus 1 |
IC50 |
= |
2300.0 |
nM |
Antiviral activity was determined against Herpes simplex virus type 1 by Plaque-reduction assay |
CHEMBL1124509 |
| Homo sapiens |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against Normal human diploid cells (human foreskin fibroblasts cells) |
CHEMBL1124509 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against Monkey kidney cells(BSC-1 cells) |
CHEMBL1124509 |
| ADMET |
IC50 |
= |
1000000.0 |
nM |
Cytotoxicity against human neoplastic cell line (KB) |
CHEMBL1124509 |
| HEL |
MIC |
= |
0.8 |
ug.mL-1 |
Concentration required to reduce CMV(Davis) plaque formation by 50% at 20 plaque forming units(PFU) in human embryonic lung (HEL) cell cultures. |
CHEMBL1126074 |
| HEL |
MIC |
= |
0.3 |
ug.mL-1 |
Concentration required to reduce CMV (Davis) plaque formation by 50% at 100 plaque forming units(PFU) in human embryonic lung (HEL) cell cultures. |
CHEMBL1126074 |
| HEL |
MIC |
= |
3.0 |
ug.mL-1 |
Concentration required to reduce varicella zoster virus(VZV)OKA plaque formation by 50% at 20 plaque forming units(PFU) in human embryonic lung (HEL) cell cultures. |
CHEMBL1126074 |
| HEL |
MCC |
= |
89.0 |
ug.mL-1 |
Concentration required to reduce human embryonic lung (HEL) cell growth by 50%. |
CHEMBL1126074 |
| Unchecked |
CC50 |
= |
75000.0 |
nM |
Inhibitory activity against HSV-1-TK transfected osteosarcoma cells |
CHEMBL1144911 |
| Thymidine kinase, cytosolic |
k cat |
= |
0.1 |
s-1 |
Catalytic turnover constant of compound against HSV-1 thymidine kinase |
CHEMBL1144911 |
| NON-PROTEIN TARGET |
CC50 |
= |
75000.0 |
nM |
Cytotoxic concentration against HSV-1 TK-transfected osteosarcoma cells |
CHEMBL1144911 |
| NON-PROTEIN TARGET |
CC50 |
= |
300000.0 |
nM |
Cytotoxic concentration against non transfected osteosarcoma cells non transfected (MG-63-hTK1) |
CHEMBL1144911 |
| NON-PROTEIN TARGET |
CC50 |
= |
200000.0 |
nM |
Cytotoxic concentration against HSV-1 TK- transfected osteosarcoma cells |
CHEMBL1144911 |
| Human herpesvirus 4 |
EC50 |
= |
50000.0 |
nM |
Effective concentration of compound against Epstein Barr virus was determined |
CHEMBL1132243 |
| ADMET |
ID50 |
= |
75.0 |
uM |
Cytotoxicity on human P3HR1 derived H1 cells |
CHEMBL1132243 |
| Unchecked |
Inhibition |
|
|
% |
Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process |
CHEMBL1130487 |
| NON-PROTEIN TARGET |
Activity |
|
|
|
Anti proliferation activity determined; Weak effect |
CHEMBL1130487 |
| Vero |
ID50 |
= |
0.2 |
uM |
In vitro antiviral activity was measured against HSV-1(F) in Vero cells |
CHEMBL1123173 |
| Vero |
ID50 |
= |
1.6 |
uM |
In vitro antiviral activity was measured against HSV-2(G) in Vero cells |
CHEMBL1123173 |
| MRC5 |
ID50 |
= |
5.0 |
uM |
In vitro antiviral activity was measured against HCMV(AD-169) in MRC5 cells |
CHEMBL1123173 |
| Vero |
ID50 |
= |
10.0 |
uM |
In vitro antiviral activity was measured against HSV-1 (F delta 305) in Vero cells |
CHEMBL1123173 |
| Vero |
ID50 |
= |
125.0 |
uM |
In vitro antiviral activity was measured against HSV-1 (MP-PAA/DHPG) in Vero cells |
CHEMBL1123173 |
| Vero |
ID50 |
= |
450.0 |
uM |
In vitro anticellular activity was measured against vero cells |
CHEMBL1123173 |
| Mus musculus |
Survivors |
= |
11.0 |
|
Effect of oral treatment with compound on HSV-2 induced mortality in mice at 20 mg/kg dose; 11/20 |
CHEMBL1123173 |
| Mus musculus |
Survivor increase |
= |
0.005 |
|
Effect of oral treatment with compound on HSV-2 induced mortality in mice at 20 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
MST |
= |
11.9 |
day |
Effect of on mean survival time upon oral treatment on HSV-2 induced mortality in mice at 20 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
MST increase |
< |
0.01 |
|
Effect of oral treatment with compound on HSV-2 induced mortality in mice at 20 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
Survivors |
= |
6.0 |
|
Effect of oral treatment with compound on HSV-2 induced mortality in mice at 10 mg/kg dose; 6/20 |
CHEMBL1123173 |
| Mus musculus |
Survivor increase |
|
|
|
Effect of oral treatment with compound on HSV-2 induced mortality in mice at 10 mg/kg dose; NS=Not significant |
CHEMBL1123173 |
| Mus musculus |
MST |
= |
10.9 |
day |
Effect of on mean survival time upon oral treatment on HSV-2 induced mortality in mice at 10 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
MST increase |
< |
0.025 |
|
Effect of oral treatment with compound on HSV-2 induced mortality in mice at 10 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
Survivors |
= |
0.0 |
|
Effect of oral treatment with compound on HSV-2 induced mortality in mice at 5 mg/kg dose; 0/19 |
CHEMBL1123173 |
| Mus musculus |
Survivor increase |
|
|
|
Effect of oral treatment with compound on HSV-2 induced mortality in mice at 5 mg/kg dose; NS=Not significant |
CHEMBL1123173 |
| Mus musculus |
MST |
= |
11.3 |
day |
Effect of on mean survival time upon oral treatment on HSV-2 induced mortality in mice at 5 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
MST increase |
< |
0.01 |
|
Effect of oral treatment with compound on HSV-2 induced mortality in mice at 5 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
Survivors |
= |
15.0 |
|
Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 15 mg/kg dose; 15/15 |
CHEMBL1123173 |
| Mus musculus |
Survivor increase |
< |
0.001 |
|
Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 15 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
MST |
> |
21.0 |
day |
Effect of on mean survival time upon oral treatment on HSV-2 induced mortality in mice at 15 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
MST increase |
< |
0.001 |
|
Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 15 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
Survivors |
= |
10.0 |
|
Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 5 mg/kg dose; 10/15 |
CHEMBL1123173 |
| Mus musculus |
Survivor increase |
< |
0.001 |
|
Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 5 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
MST |
= |
13.8 |
day |
Effect of on mean survival time upon oral treatment on HSV-2 induced mortality in mice at 5 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
MST increase |
< |
0.001 |
|
Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 5 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
Survivors |
= |
8.0 |
|
Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 1.5 mg/kg dose; 8/15 |
CHEMBL1123173 |
| Mus musculus |
Survivor increase |
= |
0.01 |
|
Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 1.5 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
MST |
= |
12.4 |
day |
Effect of on mean survival time upon oral treatment on HSV-2 induced mortality in mice at 1.5 mg/kg dose |
CHEMBL1123173 |
| Mus musculus |
MST increase |
< |
0.001 |
|
Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 1.5 mg/kg dose |
CHEMBL1123173 |
| Human herpesvirus 5 |
IC50 |
= |
8800.0 |
nM |
Antiviral activity of the compound was evaluated against the Human cytomegalo virus (HCMV) |
CHEMBL1124393 |
| ADMET |
IC50 |
= |
3000.0 |
nM |
Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells |
CHEMBL1124393 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity was evaluated against the Human diploid cells (HFF) |
CHEMBL1124393 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity was evaluated against the Monkey kidney cells (BSC) |
CHEMBL1124393 |
| ADMET |
IC50 |
= |
1000000.0 |
nM |
Cytotoxicity was evaluated in Human neoplastic cell line (KB) |
CHEMBL1124393 |
| HFF |
IC50 |
= |
7400.0 |
nM |
Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells |
CHEMBL1133752 |
| HFF |
IC90 |
= |
1600.0 |
nM |
Antiviral activity against HCMV was determined by yield reduction assay using HFF cells |
CHEMBL1133752 |
| ADMET |
IC50 |
= |
3500.0 |
nM |
ELISA assay was performed using BSC-1 cells to determine activity against HSV-1 |
CHEMBL1133752 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration |
CHEMBL1133752 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Inhibition of KB cell growth was determined. |
CHEMBL1133752 |
| HEL |
CC50 |
> |
200.0 |
ug.mL-1 |
Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells. |
CHEMBL1128256 |
| HEL |
IC50 |
= |
0.02 |
ug.mL-1 |
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%. |
CHEMBL1128256 |
| HEL |
IC50 |
= |
0.07200000000000001 |
ug.mL-1 |
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50% |
CHEMBL1128256 |
| HEL |
IC50 |
= |
0.1 |
ug.mL-1 |
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%. |
CHEMBL1128256 |
| HEL |
IC50 |
= |
0.9 |
ug.mL-1 |
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%. |
CHEMBL1128256 |
| HEL |
IC50 |
= |
2.9 |
ug.mL-1 |
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%. |
CHEMBL1128256 |
| HEL |
IC50 |
= |
6.2 |
ug.mL-1 |
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%. |
CHEMBL1128256 |
| Human herpesvirus 5 |
IC50 |
= |
0.3 |
ug.mL-1 |
Anti-HCMV activity in the human fibroblast Hs 68 cell line |
CHEMBL1132334 |
| Hs68 |
CC50 |
= |
12.5 |
ug.mL-1 |
Cytotoxicity in the Hs 68 cell line |
CHEMBL1132334 |
| Human herpesvirus 5 |
IC50 |
= |
8700.0 |
nM |
Antiviral activity against human cytomegalovirus by plaque reduction assay |
CHEMBL1129622 |
| Human herpesvirus 5 |
IC50 |
= |
2200.0 |
nM |
Antiviral activity against human cytomegalo virus using ELISA |
CHEMBL1129622 |
| Human herpesvirus 1 |
IC50 |
= |
3000.0 |
nM |
Antiviral activity against herpes simplex virus using ELISA |
CHEMBL1129622 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection. |
CHEMBL1129622 |
| KB |
IC50 |
> |
320000.0 |
nM |
Cytotoxicity (growth inhibition) against human epidermoid oral carcinoma KB cell line. |
CHEMBL1129622 |
| Human herpesvirus 5 |
IC50 |
= |
7400.0 |
nM |
In vitro antiviral activity against HCMV (Towne strain) in HFF (human fibroblast) cells. |
CHEMBL1129958 |
| Human herpesvirus 5 |
IC90 |
= |
1600.0 |
nM |
In vitro reduction in yield of Towne strain of HCMV in HFF (human fibroblast) cells. |
CHEMBL1129958 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
In vitro antiviral activity against HSV-1 virus in BSC-1 (monkey kidney) cells. |
CHEMBL1129958 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Visual cytotoxicity was scored on Human foreskin fibroblasts (HFF cells) at the time of plaque enumeration. |
CHEMBL1129958 |
| KB |
IC50 |
> |
100000.0 |
nM |
In vitro inhibition of KB (human carcinoma) cell growth. |
CHEMBL1129958 |
| HEL |
EC50 |
= |
900.0 |
nM |
Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures |
CHEMBL1137972 |
| HEL |
EC50 |
= |
800.0 |
nM |
Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures |
CHEMBL1137972 |
| HEL |
CC50 |
> |
150000.0 |
nM |
Cytotoxic concentration required to reduce HEL cell growth by 50% |
CHEMBL1137972 |
| Homo sapiens |
IC50 |
> |
390000.0 |
nM |
Concentration of the drug required to reduce the uptake of neural red stain by uninfected cell monolayers (HFF) |
CHEMBL1126774 |
| Homo sapiens |
EC50 |
|
|
nM |
Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells; ND is Not Determined |
CHEMBL1126774 |
| Homo sapiens |
EC50 |
|
|
nM |
Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells; ND is Not Determined |
CHEMBL1126774 |
| Homo sapiens |
EC50 |
|
|
nM |
Inhibitory concentration of the drug against the cytopathic effect for ellen strain of varicella zoster virus-2 (VZV-2) in human HFF cells; ND is Not Determined |
CHEMBL1126774 |
| Raji |
EC50 |
|
|
nM |
Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells; ND is Not Determined |
CHEMBL1126774 |
| Homo sapiens |
EC50 |
= |
500.0 |
nM |
Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells |
CHEMBL1126774 |
| Homo sapiens |
IC50 |
= |
168000.0 |
nM |
Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells |
CHEMBL1126774 |
| Human herpesvirus 1 |
MIC |
= |
0.006 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against KOS strain of human Herpes Simplex Virus -1 |
CHEMBL1134637 |
| Human herpesvirus 1 |
MIC |
= |
0.004 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against F strain of human Herpes Simplex Virus-1 (HSV-1) |
CHEMBL1134637 |
| Human herpesvirus 1 |
MIC |
= |
0.006 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against McIntyre strain of human Herpes Simplex Virus-1 |
CHEMBL1134637 |
| Human herpesvirus 2 |
MIC |
= |
0.01 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against G strain of human Herpes Simplex Virus-2 |
CHEMBL1134637 |
| Human herpesvirus 2 |
MIC |
= |
0.02 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against 196 strain of human Herpes Simplex Virus-2 |
CHEMBL1134637 |
| Human herpesvirus 2 |
MIC |
= |
0.04 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against Lyons strain of human Herpes Simplex Virus-2 |
CHEMBL1134637 |
| Vaccinia virus |
MIC |
> |
100.0 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against VV |
CHEMBL1134637 |
| Vesicular stomatitis virus |
MIC |
> |
100.0 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against VSV |
CHEMBL1134637 |
| Human herpesvirus 1 |
MIC |
= |
0.48 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against Thymidine kinase deficient(TK-) HSV-1 of Acyclovir |
CHEMBL1134637 |
| Human herpesvirus 1 |
MIC |
= |
0.07 |
ug.mL-1 |
Minimal inhibitory concentration to reduce virus-induced cytopathicity against TK-/TK+ HSV-1 of VMW 837 |
CHEMBL1134637 |
| NON-PROTEIN TARGET |
MCC |
> |
100.0 |
ug.mL-1 |
Minimal cytotoxic concentration (MCC) to cause a microscopically detectable change in normal cell morphology |
CHEMBL1134637 |
| Human herpesvirus 5 |
IC50 |
= |
7400.0 |
nM |
Activity against human cytomegalovirus (HCMV) using plaque reduction assay |
CHEMBL1127453 |
| Human herpesvirus 5 |
IC90 |
= |
1600.0 |
nM |
Tested for the activity against human cytomegalovirus (HCMV) using yield reduction assay |
CHEMBL1127453 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Tested for anti-viral activity against Herpes simplex virus type-1 using ELISA. |
CHEMBL1127453 |
| Human herpesvirus 5 |
IC50 |
> |
100000.0 |
nM |
Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration |
CHEMBL1127453 |
| Human herpesvirus 5 |
IC50 |
= |
8400.0 |
nM |
Concentration required to decrease the growth rate to 50% of control was evaluated against HCMV by using plaque reduction assay. |
CHEMBL1126319 |
| Human herpesvirus 5 |
IC90 |
= |
1800.0 |
nM |
Concentration required to decrease the growth rate to 50% of control was evaluated against HCMV by using yield reduction assay. |
CHEMBL1126319 |
| Human herpesvirus 1 |
IC50 |
= |
4500.0 |
nM |
Concentration required to decrease the growth rate to 50% of control was evaluated against HSV-1 by using plaque reduction assay. |
CHEMBL1126319 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity of compound was determined visually in human diploid fibroblasts (HFF). |
CHEMBL1126319 |
| KB |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB). |
CHEMBL1126319 |
| Human herpesvirus 5 |
IC50 |
= |
5900.0 |
nM |
Antiviral activity against Human cytomegalovirus (AD169) strain(HCMV) |
CHEMBL1131869 |
| Human herpesvirus 5 |
CC50 |
> |
98000.0 |
nM |
Cytotoxicity against Human cytomegalovirus (AD169) strain(HCMV) |
CHEMBL1131869 |
| Human herpesvirus 5 |
IC50 |
= |
5900.0 |
nM |
Antiviral activity against clinical isolates of human origin CMV-strainA |
CHEMBL1131869 |
| Human herpesvirus 5 |
IC50 |
= |
3900.0 |
nM |
Antiviral activity against clinical isolates of human origin CMV-strain B |
CHEMBL1131869 |
| Human herpesvirus 5 |
IC50 |
= |
3900.0 |
nM |
Antiviral activity against clinical isolates of human origin CMV-strainC |
CHEMBL1131869 |
| Human herpesvirus 5 |
IC50 |
= |
7700.0 |
nM |
In vitro antiviral activity against human cytomegalovirus by plaque method. |
CHEMBL1128465 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Antiviral activity against herpes simplex virus type 1(HSV-1) ELISA method |
CHEMBL1128465 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Visual cytotoxicity scored on HFF cells at the time of HCMV plaque enumeration. |
CHEMBL1128465 |
| KB |
IC50 |
> |
100000.0 |
nM |
In vitro inhibition of KB cell proliferation. |
CHEMBL1128465 |
| Human herpesvirus 5 |
IC90 |
= |
1800.0 |
nM |
In vitro antiviral activity against human cytomegalovirus by yield reduction assay. |
CHEMBL1128465 |
| Human herpesvirus 1 |
IC50 |
= |
100.0 |
nM |
Inhibition of growth of herpes simplex virus (HSV-1) by plaque reduction assay in vero cell line |
CHEMBL1123942 |
| Human herpesvirus 2 |
IC50 |
= |
100.0 |
nM |
Inhibition of growth of herpes simplex virus (HSV-2) by plaque reduction assay in vero cell line |
CHEMBL1123942 |
| Human herpesvirus 3 |
IC50 |
= |
2800.0 |
nM |
Inhibition of growth of varicella zoster virus(VZV) by plaque reduction assay in vero cell line |
CHEMBL1123942 |
| Cytomegalovirus |
IC50 |
= |
3400.0 |
nM |
Inhibition of growth of human cytomegalovirus (HCMV) was determined by plaque reduction assay in human lung fibroblast cell line |
CHEMBL1123942 |
| Human herpesvirus 4 |
IC50 |
= |
50.0 |
nM |
Inhibition of growth of Epstein Barr virus(EBV) in human lung fibroblast cell line |
CHEMBL1123942 |
| Human herpesvirus 4 |
Activity |
= |
|
|
Inhibition of epstein barr virus(EBV) by nucleic acid hybridization assay in human lung fibroblast cell line; 30/380 |
CHEMBL1123942 |
| Hepatitis B virus |
EC50 |
= |
4000.0 |
nM |
In vitro antiviral activity against duck hepatitis B virus (DHBV) |
CHEMBL1134840 |
| ADMET |
IC50 |
= |
156000.0 |
nM |
Inhibitory activity against human foreskin fibroblast cell proliferation |
CHEMBL1134840 |
| Human herpesvirus 5 |
EC50 |
= |
230.0 |
nM |
Antiviral activity against human cytomegalovirus |
CHEMBL1134840 |
| HEL |
IC50 |
|
|
nM |
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain; Not determined |
CHEMBL1132303 |
| HEL |
IC50 |
|
|
nM |
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain; Not determined |
CHEMBL1132303 |
| HEL |
IC50 |
|
|
nM |
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) 07/1 strain; Not determined |
CHEMBL1132303 |
| HEL |
IC50 |
|
|
nM |
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) YS/R strain; Not determined |
CHEMBL1132303 |
| HEL |
IC50 |
= |
1000.0 |
nM |
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain |
CHEMBL1132303 |
| HEL |
IC50 |
= |
5000.0 |
nM |
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain |
CHEMBL1132303 |
| HEL |
IC50 |
> |
50000.0 |
nM |
Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells |
CHEMBL1132303 |
| HEL |
IC50 |
> |
50000.0 |
nM |
The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50% |
CHEMBL1132303 |
| MRC5 |
IC50 |
= |
3.2 |
ug.mL-1 |
Anti HCMV (human cytomegalovirus) activity in MRC-5 cells infected with AD619 strain of HCMV (plaque reduction assay). |
CHEMBL1128451 |
| MRC5 |
TC50 |
> |
1000.0 |
ug ml-1 |
Visual cytotoxicity of stationary MRC-5 cells, median toxic concentration is evaluated by anti HCMV plaque reduction assay performed in MRC-5 cells using the AD169 strain of HCMV |
CHEMBL1128451 |
| HFF |
IC50 |
= |
4.4 |
ug.mL-1 |
Anti HCMV(human cytomegalovirus) activity in HFF cell line Hs 68 infected with AD619 strain of HCMV(plaque reduction assay). |
CHEMBL1128451 |
| HFF |
TC50 |
> |
1000.0 |
ug ml-1 |
Visual cytotoxicity of stationary HFF Cell line Hs68, median toxic concentration is evaluated by anti HCMV plaque reduction assay performed in HFF Cell line Hs 68 |
CHEMBL1128451 |
| HFF |
IC50 |
= |
52.0 |
ug.mL-1 |
Anti HCMV(human cytomegalovirus) activity in MRC-5 cells infected with DHPG-resistant D16 strain of HCMV(plaque reduction assay). |
CHEMBL1128451 |
| HFF |
TC50 |
> |
1000.0 |
ug ml-1 |
Visual cytotoxicity of stationary MRC-5 cells, median toxic concentration is evaluated by anti HCMV plaque reduction assay performed in HFF Cell line Hs 68 |
CHEMBL1128451 |
| Vero |
TC50 |
= |
270.0 |
ug ml-1 |
Anti viral activity against vero cells (concentration required to reduce the log phase cell growth by 50%). |
CHEMBL1128451 |
| MRC5 |
TC50 |
> |
500.0 |
ug ml-1 |
Anti viral activity against MRC-5 cells (concentration required to reduce the log phase cell growth by 50%). |
CHEMBL1128451 |
| Human herpesvirus 5 |
EC50 |
= |
0.98 |
ug.mL-1 |
Tested for antiviral activity against HCMV in AD169 cell line |
CHEMBL1134207 |
| Human herpesvirus 5 |
EC50 |
= |
4.07 |
ug.mL-1 |
Tested for antiviral activity against HCMV in Davis cell line |
CHEMBL1134207 |
| CCRF-CEM |
EC50 |
> |
200000.0 |
nM |
Compound was tested for anti-viral activity against HIV-1 in CEM cells |
CHEMBL1136483 |
| CCRF-CEM |
EC50 |
> |
200000.0 |
nM |
Compound was tested for anti-viral activity against HIV-2 in CEM cells |
CHEMBL1136483 |
| CCRF-CEM |
CC50 |
> |
200000.0 |
nM |
Compound concentration required to reduce viability of CEM cells |
CHEMBL1136483 |
| HEL |
EC50 |
|
|
nM |
Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells; ND=Not determined |
CHEMBL1136483 |
| HEL |
EC50 |
= |
60.0 |
nM |
Compound was tested for anti-viral activity against HSV-1(G) in HEL cells |
CHEMBL1136483 |
| HEL |
EC50 |
|
|
nM |
Compound was tested for anti-viral activity against HSV-1TK neg in HEL cells; ND=Not determined |
CHEMBL1136483 |
| HEL |
CC50 |
> |
400000.0 |
nM |
Compound concentration required to reduce viability of HEL cells |
CHEMBL1136483 |
| Human herpesvirus 2 |
EC50 |
= |
230.0 |
nM |
Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50% |
CHEMBL1134633 |
| MRC5 |
IC50 |
= |
2.1 |
ug.mL-1 |
Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation. |
CHEMBL1130711 |
| MRC5 |
CC50 |
> |
100.0 |
ug.mL-1 |
Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation. |
CHEMBL1130711 |
| Human herpesvirus 1 |
ID50 |
= |
0.04 |
uM |
compound was tested for antiherpes activity against HSV-1(Schooler) in tissue culture by plaque reduction assay |
CHEMBL1125671 |
| Human herpesvirus 2 |
ID50 |
= |
0.04 |
uM |
compound was tested for antiherpes activity against HSV-2(186) in tissue culture by plaque reduction assay |
CHEMBL1125671 |
| Human herpesvirus 3 |
ID50 |
= |
2.0 |
uM |
compound was tested for antiherpes activity against VZV(Ellen) in tissue culture by plaque reduction assay |
CHEMBL1125671 |
| Human herpesvirus 5 |
ID50 |
= |
2.0 |
uM |
compound was tested for antiherpes activity against HCMV(AD 169) in tissue culture by plaque reduction assay |
CHEMBL1125671 |
| Murine cytomegalovirus |
ID50 |
= |
4.0 |
uM |
compound was tested for antiherpes activity against MCMV(Smith) in tissue culture by plaque reduction assay |
CHEMBL1125671 |
| Mus musculus |
Survivors alive/total |
= |
10.0 |
|
Subcutaneous efficacy in a mouse cytomegalovirus infection at 100 mg/kg/day dose; Value expressed as survivors/total tested = 10/10 |
CHEMBL1125671 |
| Mus musculus |
Survivors alive/total |
= |
10.0 |
|
Subcutaneous efficacy in a mouse cytomegalovirus infection at 50 mg/kg/day dose; Value expressed as survivors/total tested = 10/10 |
CHEMBL1125671 |
| Mus musculus |
Survivors alive/total |
= |
10.0 |
|
Subcutaneous efficacy in a mouse cytomegalovirus infection at 25 mg/kg/day dose; Value expressed as survivors/total tested = 10/10 |
CHEMBL1125671 |
| Mus musculus |
Survivors alive/total |
= |
7.0 |
|
Subcutaneous efficacy in a mouse cytomegalovirus infection at 12.5 mg/kg/day dose; Value expressed as survivors/total tested = 7/10 |
CHEMBL1125671 |
| Mus musculus |
PD50 |
< |
12.5 |
mg kg-1 day-1 |
subcutaneous efficacy of compound in a lethal MCMV infection on mouse |
CHEMBL1125671 |
| Mus musculus |
Mean day of death for total dead |
= |
5.7 |
|
Mean day of death for total no. of dead mouse at 12.5 mg/kg/day dosep<0.05 |
CHEMBL1125671 |
| Mus musculus |
Survivors alive/total |
= |
5.0 |
|
oral efficacy in a mouse cytomegalovirus infection at 50 mg/kg/day dose; Value expressed as survivors/total tested = 5/10 |
CHEMBL1125671 |
| Mus musculus |
Survivors alive/total |
= |
1.0 |
|
oral efficacy in a mouse cytomegalovirus infection at 25 mg/kg/day dose; Value expressed as survivors/total tested = 1/10 |
CHEMBL1125671 |
| Mus musculus |
Survivors alive/total |
= |
1.0 |
|
oral efficacy in a mouse cytomegalovirus infection at 12.5 mg/kg/day dose; Value expressed as survivors/total tested = 1/10 |
CHEMBL1125671 |
| Mus musculus |
PD50 |
= |
57.0 |
mg kg-1 day-1 |
subcutaneous efficacy of compound in a lethal MCMV infection on mouse |
CHEMBL1125671 |
| Mus musculus |
Mean day of death for total dead |
= |
4.4 |
|
Mean day of death for total no. of dead mouse at 50 mg/kg/day dose |
CHEMBL1125671 |
| Mus musculus |
Mean day of death for total dead |
= |
4.8 |
|
Mean day of death for total no. of dead mouse at 25 mg/kg/day dosep<0.05 |
CHEMBL1125671 |
| Mus musculus |
Mean day of death for total dead |
= |
3.6 |
|
Mean day of death for total no. of dead mouse at 12.5 mg/kg/day dose |
CHEMBL1125671 |
| Human herpesvirus 1 |
Inhibition |
= |
60.0 |
% |
Compound was tested for the inhibition of HSV-1 polymerase |
CHEMBL1123186 |
| DNA polymerase alpha subunit |
Inhibition |
= |
17.0 |
% |
Compound was tested for the inhibition of HeLa DNA polymerase |
CHEMBL1123186 |
| F2002 cell line |
PD50 |
= |
0.1 |
ug ml-1 |
The compound was tested for inhibitory activity against human cytomegalovirus (HCMV) (WFl strain) in plaque reduction assay in flow 2002 cells |
CHEMBL1130439 |
| F2002 cell line |
CD50 |
> |
100.0 |
ug ml-1 |
The compound was tested for inhibitory activity against human cytomegalovirus (HCMV) in flow 2002 cells |
CHEMBL1130439 |
| HFF |
IC50 |
= |
8400.0 |
nM |
In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay. |
CHEMBL1126393 |
| ADMET |
Cytotoxicity |
> |
100.0 |
uM |
Cytotoxicity of compound in uninfected cells determined by examining the effect on growth of KBcells |
CHEMBL1126393 |
| Human herpesvirus 5 |
IC50 |
= |
7400.0 |
nM |
Concentration required for 50% inhibition of HCMV replication was measured using a Plaque reduction assay |
CHEMBL1129961 |
| Human herpesvirus 5 |
IC90 |
= |
1600.0 |
nM |
Concentration required for 90% inhibition of HCMV replication was measured using a yield reduction assay |
CHEMBL1129961 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Antiviral activity was measured by plaque assay against HSV-1 virus by ELISA method |
CHEMBL1129961 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration |
CHEMBL1129961 |
| KB |
IC50 |
> |
100000.0 |
nM |
Inhibition of KB cell growth was determined |
CHEMBL1129961 |
| Human herpesvirus 5 |
IC50 |
= |
7400.0 |
nM |
Antiviral activity assayed by ability to inhibit Towne strain of HCMV virus |
CHEMBL1131342 |
| Human herpesvirus 5 |
IC90 |
= |
1600.0 |
nM |
Compound was evaluated for the Yield reduction assays on HCMV virus, |
CHEMBL1131342 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Antiviral activity evaluated by their ability to inhibit the KOS strain of herpes simplex virus type-1 (HSV-1).plaque assay was used |
CHEMBL1131342 |
| Homo sapiens |
IC50 |
> |
100000.0 |
nM |
Compound was evaluated for the cytotoxicity scored on HFF cells at time of HCMV plaque enumeration. |
CHEMBL1131342 |
| KB |
IC50 |
> |
100000.0 |
nM |
Compound was evaluated for the cytotoxicity by the inhibition of KB cell growth. |
CHEMBL1131342 |
| HEL |
IC50 |
= |
2.0 |
ug.mL-1 |
Antiviral activity against Cytomegalovirus (AD-169 strain) to reduce plaque formation in human embryonic lung (HEL) cells |
CHEMBL1153258 |
| HEL |
IC50 |
= |
1.5 |
ug.mL-1 |
Antiviral activity against Cytomegalovirus (Davis strain) to reduce plaque formation in human embryonic lung (HEL) cells |
CHEMBL1153258 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity (to alter cell morphology) against Cytomegalovirus in human embryonic lung (HEL) cells |
CHEMBL1153258 |
| HEL |
CC50 |
= |
200.0 |
ug.mL-1 |
Cytotoxicity (to reduce cell growth) against Cytomegalovirus in human embryonic lung (HEL) cells |
CHEMBL1153258 |
| Human herpesvirus 5 |
IC50 |
= |
0.3 |
ug.mL-1 |
Antiviral activity was tested against human cytomegalovirus AD-169 which reduces virus plaque formation by 50% |
CHEMBL1135344 |
| Human herpesvirus 5 |
IC50 |
= |
0.4 |
ug.mL-1 |
Antiviral activity was tested against human cytomegalovirus Davis which reduces virus plaque formation by 50% |
CHEMBL1135344 |
| Human herpesvirus 3 |
IC50 |
|
|
ug.mL-1 |
Antiviral activity against TK+ Varicella-Zoster virus YS which reduces virus plaque formation by 50%; ND denotes no data |
CHEMBL1135344 |
| Human herpesvirus 3 |
IC50 |
|
|
ug.mL-1 |
Antiviral activity against TK+ Varicella-Zoster virus OKA which reduces virus plaque formation by 50%; ND denotes no data |
CHEMBL1135344 |
| Human herpesvirus 3 |
IC50 |
|
|
ug.mL-1 |
Antiviral activity against TK- Varicella-Zoster virus 07/1 which reduces virus plaque formation by 50%; ND denotes no data |
CHEMBL1135344 |
| Human herpesvirus 3 |
IC50 |
|
|
ug.mL-1 |
Antiviral activity against TK- Varicella-Zoster virus YS/R which reduces virus plaque formation by 50%; ND denotes no data |
CHEMBL1135344 |
| HEL |
MCC |
> |
50.0 |
ug.mL-1 |
Minimum cytotoxic concentration against HEL cell morphology. |
CHEMBL1135344 |
| HEL |
MCC |
|
|
ug.mL-1 |
Minimum cytotoxic concentration against HEL cell morphology; ND denotes no data |
CHEMBL1135344 |
| HEL |
CC50 |
> |
50.0 |
ug.mL-1 |
Cytotoxic concentration reducing HEL cell growth by 50%. |
CHEMBL1135344 |
| HEL |
CC50 |
|
|
ug.mL-1 |
Cytotoxic concentration to reduce HEL cell growth by 50%; ND denotes no data |
CHEMBL1135344 |
| Human herpesvirus 5 |
IC50 |
= |
5900.0 |
nM |
Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells |
CHEMBL1133624 |
| MRC5 |
CC50 |
= |
98000.0 |
nM |
Concentration required to reduce MRC-5 cell growth by 50% |
CHEMBL1133624 |
| Human herpesvirus 5 |
IC50 |
= |
3700.0 |
nM |
In vitro inhibition of HCMV (AD-169) plaque formation. |
CHEMBL1133628 |
| Human herpesvirus 5 |
IC50 |
= |
5900.0 |
nM |
In vitro inhibition of HCMV (Davis) plaque formation. |
CHEMBL1133628 |
| HEL |
EC50 |
|
|
|
concentration required to reduce virus Thymidine Kinase-Varicella-Zoster Virus(OKA)plaque formation by 50%; ND=No Data |
CHEMBL1133628 |
| HEL |
EC50 |
|
|
|
concentration required to reduce virus Thymidine Kinase-Varicella Zoster Virus(YS)plaque formation by 50%; ND=No Data |
CHEMBL1133628 |
| HEL |
EC50 |
|
|
|
Concentration required to reduce Thymidine Kinase deficient Varicella Zoster Virus (07/1) plaque formation by 50%; ND=No Data |
CHEMBL1133628 |
| HEL |
EC50 |
|
|
|
Concentration required to reduce Thymidine Kinase deficient Varicella Zoster Virus (YS/R) plaque formation by 50%; ND=No Data |
CHEMBL1133628 |
| HEL |
CC50 |
= |
394000.0 |
nM |
Inhibition of cell growth in HEL cells. |
CHEMBL1133628 |
| HEL |
MCC |
> |
150000.0 |
nM |
In vitro alteration in cell morphology in HEL cells. |
CHEMBL1133628 |
| Human herpesvirus 5 |
IC50 |
= |
6200.0 |
nM |
concentration required to reduce virus HCMV (A)plaque formation by 50% |
CHEMBL1133628 |
| Human herpesvirus 5 |
IC50 |
= |
6200.0 |
nM |
concentration required to reduce virus HCMV (B)plaque formation by 50% |
CHEMBL1133628 |
| Human herpesvirus 5 |
IC50 |
= |
6200.0 |
nM |
concentration required to reduce virus HCMV (C)plaque formation by 50% |
CHEMBL1133628 |
| Human herpesvirus 5 |
IC50 |
= |
4100.0 |
nM |
concentration required to reduce virus HCMV (D)plaque formation by 50% |
CHEMBL1133628 |
| Human herpesvirus 5 |
IC50 |
= |
4100.0 |
nM |
concentration required to reduce virus HCMV (E)plaque formation by 50% |
CHEMBL1133628 |
| Human herpesvirus 5 |
IC50 |
= |
6200.0 |
nM |
concentration required to reduce virus HCMV (F)plaque formation by 50% |
CHEMBL1133628 |
| Human herpesvirus 5 |
IC50 |
= |
8200.0 |
nM |
concentration required to reduce virus HCMV (G)plaque formation by 50% |
CHEMBL1133628 |
| Vero |
ID50 |
= |
0.2 |
uM |
Antiviral activity was determined in plaque reduction assay in vero cells against HSV-1 F strain |
CHEMBL1122960 |
| Mus musculus |
Survival |
= |
8.0 |
|
Effect of oral treatment on HSV-2 encephalitis infection in mice and survivors/total was reported at a dose 20 mg/kg; 8/20 |
CHEMBL1122960 |
| Mus musculus |
Survival |
= |
5.0 |
|
Effect of oral treatment on HSV-2 encephalitis infection in mice and survivors/total was reported at a dose 10 mg/kg; 5/20 |
CHEMBL1122960 |
| Mus musculus |
Survival |
= |
8.0 |
|
Effect of oral treatment on HSV-2 encephalitis infection in mice and survivors/total was reported at a dose 5 mg/kg; 8/20 |
CHEMBL1122960 |
| Mus musculus |
Survival time |
= |
13.8 |
day |
Effect of oral treatment on HSV-2 encephalitis infection in mice and mean survival time was reported at a dose 20 mg/kg |
CHEMBL1122960 |
| Mus musculus |
Survival time |
= |
10.9 |
day |
Effect of oral treatment on HSV-2 encephalitis infection in mice and mean survival time was reported at a dose 10 mg/kg |
CHEMBL1122960 |
| Mus musculus |
Survival time |
= |
9.9 |
day |
Effect of oral treatment on HSV-2 encephalitis infection in mice and mean survival time was reported at a dose 5 mg/kg |
CHEMBL1122960 |
| Human herpesvirus 5 |
IC50 |
= |
0.1 |
ug.mL-1 |
Compound was tested in vitro for inhibitory activity against HCMV (Human cytomegalovirus) |
CHEMBL1130572 |
| Human herpesvirus 5 |
CC50 |
> |
100.0 |
ug.mL-1 |
Compound was tested in vitro for cytotoxic activity against HCMV (Human cytomegalovirus) |
CHEMBL1130572 |
| F2002 cell line |
IC50 |
= |
0.1 |
ug.mL-1 |
Compound was tested for Anti-HCMV activity against F2002 cell line(exp 1) |
CHEMBL1130710 |
| F2002 cell line |
IC50 |
= |
0.2 |
ug.mL-1 |
Compound was tested for Anti-HCMV activity against F2002 cell line(exp 2) |
CHEMBL1130710 |
| F2002 cell line |
CD50 |
> |
100.0 |
ug ml-1 |
Anti-HCMV activity against F2002 cell line |
CHEMBL1130710 |
| ADMET |
MIC |
= |
0.001 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-1 (KOS) in E6SM cell culture |
CHEMBL1133586 |
| Human herpesvirus 1 |
MIC |
= |
0.001 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-1 (F) in E6SM cell culture |
CHEMBL1133586 |
| ADMET |
MIC |
= |
0.001 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-1 (McIntyre) in E6SM cell culture |
CHEMBL1133586 |
| Human herpesvirus 1 |
MIC |
= |
0.002 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-1 (G) in E6SM cell culture |
CHEMBL1133586 |
| ADMET |
MIC |
= |
0.001 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-2 (196) in E6SM cell culture |
CHEMBL1133586 |
| NON-PROTEIN TARGET |
MIC |
= |
0.001 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-2 (Lyons) in E6SM cell culture |
CHEMBL1133586 |
| NON-PROTEIN TARGET |
MIC |
= |
0.48 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-1 (TK-KOS ACV) in E6SM cell culture |
CHEMBL1133586 |
| Human herpesvirus 3 |
MIC |
= |
0.01 |
ug.mL-1 |
Minimum inhibitory concentration was determined against HSV-1 (TK-/TK+VMW1837) in E6SM cell culture |
CHEMBL1133586 |
| Cytomegalovirus |
MIC |
= |
0.6 |
ug.mL-1 |
Minimum inhibitory concentration was determined against CMV(AD169) in E6SM cell culture |
CHEMBL1133586 |
| Cytomegalovirus |
MIC |
= |
0.8 |
ug.mL-1 |
Minimum inhibitory concentration was determined against CMV(Davis) in E6SM cell culture |
CHEMBL1133586 |
| Vero |
Cytotoxicity |
> |
100.0 |
|
Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in Vero |
CHEMBL1133586 |
| E6SM |
Cytotoxicity |
> |
50.0 |
|
Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in E6SM |
CHEMBL1133586 |
| HEL |
Cytotoxicity |
> |
50.0 |
|
Cytotoxicity concentration required to microscopically detectable alteration of cell morphology HEL |
CHEMBL1133586 |
| ADMET |
Papp |
= |
0.23 |
cm/s * 10E6 |
Permeability Coefficient in Caco-2 cell culture model |
CHEMBL1145178 |
| ADMET |
Papp |
= |
8.7 |
cm/s * 10E6 |
Permeability Coefficient in 2/4/A1 cell model |
CHEMBL1145178 |
| Unchecked |
Papp |
= |
6.7 |
cm/s * 10E6 |
Permeability Coefficient in hexadecane membranes model |
CHEMBL1145178 |
| ADMET |
Papp |
= |
97.0 |
cm/s * 10E6 |
Percentage of mass balance in hexadecane membranes model |
CHEMBL1145178 |
| ADMET |
FA |
= |
5.0 |
% |
Fraction absorbed in human intestine after oral administration compound was measured |
CHEMBL1145178 |
| Molecular identity unknown |
EC50 |
= |
0.24 |
ug.mL-1 |
Effective concentration required to reduce plaque formation by AD-169 strain of CMV virus in Human embryonic lung cells |
CHEMBL1141177 |
| Human herpesvirus 3 |
EC50 |
|
|
ug.mL-1 |
Effective concentration to reduce plaque formation of thymidine kinase deficient Varicella zoster virus TK- VZV 07/1 strain in human embryonic lung cell cultures; ND=Not determined |
CHEMBL1141177 |
| HEL |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration of compound that causes alteration of cell morphology in human embryonic lung cells |
CHEMBL1141177 |
| HEL |
CC50 |
= |
65.4 |
ug.mL-1 |
Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells |
CHEMBL1141177 |
| Molecular identity unknown |
EC50 |
= |
0.34 |
ug.mL-1 |
Effective concentration required to reduce plaque formation by Davis strain of CMV virus in Human embryonic lung cells |
CHEMBL1141177 |
| Human herpesvirus 3 |
EC50 |
|
|
ug.mL-1 |
Effective concentration of compound required to reduce plaque formation by OKA strain of thymidine kinase positive VZ virus TK+ in human embryonic lung cells; ND=Not determined |
CHEMBL1141177 |
| Human herpesvirus 3 |
EC50 |
|
|
ug.mL-1 |
Effective concentration of compound required to reduce plaque formation by VZV07/1 strain of thymidine kinase(TK-) deficient VZ virus in human embryonic lung cells; ND=Not determined |
CHEMBL1141177 |
| HEL |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration of compound that causes alteration of cell morphology in human embryonic lung cells |
CHEMBL1141177 |
| HEL |
CC50 |
= |
65.4 |
ug.mL-1 |
Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells |
CHEMBL1141177 |
| Cytomegalovirus |
EC50 |
= |
0.24 |
ug.mL-1 |
Effective concentration to reduce plaque formation of Cytomegalovirus AD-169 strain in human embryonic lung cell cultures |
CHEMBL1141177 |
| Cytomegalovirus |
EC50 |
= |
0.34 |
ug.mL-1 |
Effective concentration of the compound to reduce plaque-formation of Cytomegalovirus davis strain in human embryonic lungcell cultures |
CHEMBL1141177 |
| Human herpesvirus 3 |
EC50 |
|
|
ug.mL-1 |
Effective concentration to reduce plaque formation of thymidine kinase positive Varicella zoster virus TK+ VZ OKA strain in human embryonic lung cell cultures; ND=Not determined |
CHEMBL1141177 |
| Cytomegalovirus |
EC50 |
= |
0.37 |
ug.mL-1 |
Effective concentration against AD-169 strain of CMV virus expressed in HEL cells |
CHEMBL1145184 |
| Cytomegalovirus |
EC50 |
= |
0.37 |
ug.mL-1 |
Effective concentration against Davis strain of CMV virus expressed in HEL cells |
CHEMBL1145184 |
| Cell line |
MCC |
>= |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology |
CHEMBL1145184 |
| Cell line |
CC50 |
|
|
ug.mL-1 |
Cytotoxic concentration required to reduce cell growth by 50%; nd=not determined |
CHEMBL1145184 |
| HEL |
IC50 |
= |
2.7 |
ug.mL-1 |
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Davis using HEL cell line |
CHEMBL1142046 |
| MRC5 |
IC50 |
= |
2.2 |
ug.mL-1 |
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Ad169 using MRC-5 cell line |
CHEMBL1142046 |
| MRC5 |
IC50 |
= |
1.2 |
ug.mL-1 |
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains P8 using MRC-5 cell line |
CHEMBL1142046 |
| MRC5 |
IC50 |
= |
8.7 |
ug.mL-1 |
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains C8704(UL97 mutation) using MRC-5 cell line |
CHEMBL1142046 |
| MRC5 |
IC50 |
= |
7.8 |
ug.mL-1 |
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains D16(UL54 mutation) using MRC-5 cell line |
CHEMBL1142046 |
| MRC5 |
CC50% |
> |
1000.0 |
ug ml-1 |
Cytotoxic compound concentration to reduce neutral red uptake by 50% using MRC-5 cell line |
CHEMBL1142046 |
| Vero |
IC50 |
= |
1.274 |
ug.mL-1 |
Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line |
CHEMBL1142046 |
| Vero |
IC50 |
= |
1.22 |
ug.mL-1 |
Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line |
CHEMBL1142046 |
| Vero |
CC50% |
> |
100.0 |
ug ml-1 |
Minimum cytotoxic compound concentration to induce microscopically detectable alteration of cell morphology, using Vero cell line |
CHEMBL1142046 |
| HEL |
EC50 |
= |
500.0 |
nM |
Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture |
CHEMBL1138797 |
| HEL |
EC50 |
= |
1500.0 |
nM |
Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture |
CHEMBL1138797 |
| ADMET |
MCC |
> |
150000.0 |
nM |
Minimum cytotoxic concentration that causes microscopically detectable alteration of cell morphology in HEL cell culture |
CHEMBL1138797 |
| ADMET |
CC50 |
> |
150000.0 |
nM |
Cytotoxic concentration required to reduce HEL cell growth by 50% |
CHEMBL1138797 |
| E6SM |
EC50 |
= |
0.004 |
ug.mL-1 |
Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture |
CHEMBL1138797 |
| E6SM |
EC50 |
= |
0.003 |
ug.mL-1 |
Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture |
CHEMBL1138797 |
| E6SM |
EC50 |
= |
2.4 |
ug.mL-1 |
Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture |
CHEMBL1138797 |
| E6SM |
EC50 |
> |
100.0 |
ug.mL-1 |
Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture |
CHEMBL1138797 |
| E6SM |
MCC |
> |
100.0 |
ug.mL-1 |
Minimum cytotoxic concentration that caused a microscopically detectable alteration of cell morphology in E6SM Cell Culture |
CHEMBL1138797 |
| Human herpesvirus 5 |
IC50 |
= |
7400.0 |
nM |
Concentration required to inhibit plaque formation in human cytomegalovirus cultures was determined |
CHEMBL1138812 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Inhibitory activity against herpes simplex virus type-1 cultures was determined by ELISA assay |
CHEMBL1138812 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination |
CHEMBL1138812 |
| KB |
IC50 |
> |
100000.0 |
nM |
Concentration required to inhibit KB cell line growth was determined by crystal violet staining method |
CHEMBL1138812 |
| HFF |
IC50 |
= |
7400.0 |
nM |
Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay |
CHEMBL1138813 |
| ADMET |
IC50 |
= |
3500.0 |
nM |
Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay |
CHEMBL1138813 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells |
CHEMBL1138813 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells |
CHEMBL1138813 |
| HFF |
IC50 |
= |
7400.0 |
nM |
Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay |
CHEMBL1138814 |
| ADMET |
IC50 |
= |
3500.0 |
nM |
Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay |
CHEMBL1138814 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells |
CHEMBL1138814 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells |
CHEMBL1138814 |
| HFF |
IC50 |
= |
1200.0 |
nM |
Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay |
CHEMBL1138814 |
| HFF |
IC50 |
= |
1200.0 |
nM |
Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay |
CHEMBL1138814 |
| HFF |
IC50 |
= |
1200.0 |
nM |
Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay |
CHEMBL1138814 |
| HFF |
IC50 |
= |
2500.0 |
nM |
Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay |
CHEMBL1138814 |
| Human herpesvirus 5 |
IC50 |
= |
7400.0 |
nM |
Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay |
CHEMBL1137100 |
| Human herpesvirus 1 |
IC50 |
= |
3500.0 |
nM |
Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay |
CHEMBL1137100 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells |
CHEMBL1137100 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells |
CHEMBL1137100 |
| HEL |
EC50 |
= |
1500.0 |
nM |
Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection |
CHEMBL1143578 |
| HEL |
EC50 |
= |
1500.0 |
nM |
Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection |
CHEMBL1143578 |
| HEL |
MCC |
> |
1500000.0 |
nM |
Minimum cytotoxic concentration required to cause a microscopically visible alteration of HEL fibroblast cell morphology |
CHEMBL1143578 |
| HEL |
CC50 |
> |
150000.0 |
nM |
Cytotoxic concentration required to reduce HEL cell growth |
CHEMBL1143578 |
| Human herpesvirus 5 |
EC50 |
= |
2100.0 |
nM |
Effective concentration for antiviral activity against towne strain of human cytomegalovirus in plaque reduction assay |
CHEMBL1139499 |
| Human herpesvirus 5 |
EC50 |
= |
1600.0 |
nM |
Effective concentration for antiviral activity against AD169 strain of human cytomegalovirus in plaque reduction assay |
CHEMBL1139499 |
| NON-PROTEIN TARGET |
EC50 |
= |
2100.0 |
nM |
Effective concentration for antiviral activity against AD169 strain of murine cytomegalovirus in plaque reduction assay |
CHEMBL1139499 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxic concentration against town strain of human cytomegalovirus infected HFF cells of human (visual cytotoxicity) |
CHEMBL1139499 |
| HFF |
CC50 |
> |
392000.0 |
nM |
Cytotoxic concentration against AD169 strain of human cytomegalovirus infected HFF cells of human (by neutral red uptake) |
CHEMBL1139499 |
| MEF |
CC50 |
> |
392000.0 |
nM |
Cytotoxic concentration against murine cytomegalovirus infected MEF cells |
CHEMBL1139499 |
| Human herpesvirus 4 |
EC50 |
= |
5000.0 |
nM |
Effective concentration required to inhibit Epstein-barr virus replication in H-1 cells in DNA hybridization assay |
CHEMBL1139499 |
| Coxsackievirus |
EC50 |
|
|
nM |
Effective concentration required to inhibit Coxsackie B3 virus induced cytopathicity in vero cells; not determined |
CHEMBL1141175 |
| Human herpesvirus 1 |
EC50 |
= |
60.0 |
nM |
Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells |
CHEMBL1141175 |
| HFF |
IC50 |
= |
1300.0 |
nM |
Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO |
CHEMBL1141075 |
| HFF |
IC50 |
|
|
nM |
Antiviral activity against Varicella-Zoster virus (Webster strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed; [nd = not determined] |
CHEMBL1141075 |
| Vero |
IC50 |
|
|
nM |
Antiviral activity against herpes simplex virus type 1 (KOS strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed; [nd = not determined] |
CHEMBL1141075 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Toxicity on uninfected human foreskin fibroblast cells determined in microscopic evaluation and quantitative neutral red dye uptake assay |
CHEMBL1141075 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Toxicity on uninfected African green monkey kidney cells determined in microscopic evaluation and quantitative neutral red dye uptake assay |
CHEMBL1141075 |
| HFF |
IC50 |
= |
800.0 |
nM |
Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO |
CHEMBL1141075 |
| HFF |
IC50 |
= |
800.0 |
nM |
Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO |
CHEMBL1141075 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against Varicella-Zoster virus 07/1 strain |
CHEMBL1148578 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against Varicella-Zoster virus YS strain |
CHEMBL1148578 |
| Human herpesvirus 1 |
EC50 |
= |
60.0 |
nM |
Antiviral activity against HSV1 KOS in HEL cells |
CHEMBL1148592 |
| Human herpesvirus 2 |
EC50 |
= |
60.0 |
nM |
Antiviral activity against HSV2 G in HEL cells |
CHEMBL1148592 |
| Human immunodeficiency virus 1 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against HIV1 IIIB in CEM cells |
CHEMBL1148592 |
| Human immunodeficiency virus 2 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against HIV2 ROD in CEM cells |
CHEMBL1148592 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against Varicella-Zoster virus YS/R strain |
CHEMBL1148578 |
| Human herpesvirus 5 |
EC50 |
= |
5100.0 |
nM |
Antiviral activity against human cytomegalovirus AD169 strain |
CHEMBL1148578 |
| Human herpesvirus 5 |
EC50 |
= |
8700.0 |
nM |
Antiviral activity against human cytomegalovirus Davis strain |
CHEMBL1148578 |
| HEL |
CC50 |
> |
197000.0 |
nM |
Cytotoxic activity against cultured human embryonic lung (HEL) cells |
CHEMBL1148578 |
| HEL |
MCC |
> |
197000.0 |
nM |
Cytotoxic activity against cultured human embryonic lung (HEL) cells |
CHEMBL1148578 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Antiviral activity against HEL cells |
CHEMBL1147740 |
| Vero |
MCC |
|
|
|
Antiviral activity against vero cells |
CHEMBL1147740 |
| HeLa |
MCC |
|
|
|
Antiviral activity against HeLa cells |
CHEMBL1147740 |
| Human herpesvirus 1 |
MIC50 |
= |
0.096 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 1 KOS strain in HEL cells |
CHEMBL1147740 |
| Human herpesvirus 2 |
MIC50 |
= |
0.032 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 2 G strain in HEL cells |
CHEMBL1147740 |
| Vaccinia virus |
MIC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in HEL cells |
CHEMBL1147740 |
| Vesicular stomatitis virus |
MIC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus in HEL cells |
CHEMBL1147740 |
| Human herpesvirus 1 |
MIC50 |
= |
0.48 |
ug.mL-1 |
Antiviral activity against herpes simplex virus 1 TK- KOS ACVr strain in HEL cells |
CHEMBL1147740 |
| Human parainfluenza virus 3 |
MIC50 |
|
|
|
Antiviral activity against Parainfluenza-3 virus in vero cells |
CHEMBL1147740 |
| Mammalian orthoreovirus 1 |
MIC50 |
|
|
|
Antiviral activity against Reovirus 1 in vero cells |
CHEMBL1147740 |
| Sindbis virus |
MIC50 |
|
|
|
Antiviral activity against Sindbis virus in vero cells |
CHEMBL1147740 |
| Human coxsackievirus B4 |
MIC50 |
|
|
|
Antiviral activity against Coxsackie virus B4 in vero cells |
CHEMBL1147740 |
| Punta Toro virus |
MIC50 |
|
|
|
Antiviral activity against Punta Toro virus in vero cells |
CHEMBL1147740 |
| Respiratory syncytial virus |
MIC50 |
|
|
|
Antiviral activity against Respiratory syncytial virus in HeLa cells |
CHEMBL1147740 |
| Human coxsackievirus B4 |
MIC50 |
|
|
|
Antiviral activity against Coxsackie virus B4 in HeLa cells |
CHEMBL1147740 |
| Vesicular stomatitis virus |
MIC50 |
|
|
|
Antiviral activity against Vesicular stomatitis virus in HeLa cells |
CHEMBL1147740 |
| Cytomegalovirus |
EC50 |
= |
3.2 |
ug.mL-1 |
Antiviral activity against Cytomegalovirus AD169 in human embryonic lung cells |
CHEMBL1149435 |
| Cytomegalovirus |
EC50 |
= |
3.2 |
ug.mL-1 |
Antiviral activity against Cytomegalovirus Davis in human embryonic lung cells |
CHEMBL1149435 |
| HEL |
MCC |
>= |
400.0 |
ug.mL-1 |
Cytotoxicity as determined by alteration in the cell morphology of HEL cells |
CHEMBL1149435 |
| HEL |
CC50 |
= |
34.0 |
ug.mL-1 |
Cytotoxicity against HEL cells |
CHEMBL1149435 |
| Hepatitis B virus |
Inhibition |
|
|
% |
Antiviral activity against HBV M204I mutant transfected in B1 cell line at 10 ug/mL |
CHEMBL1148649 |
| Hepatitis B virus |
Inhibition |
|
|
% |
Antiviral activity against HBV L180M/M204V mutant transfected in D88 cell line at 10 ug/mL |
CHEMBL1148649 |
| HepG2 |
CC50 |
|
|
|
Cytotoxicity against human HepG2 cell line |
CHEMBL1148649 |
| Vero |
CC50 |
|
|
|
Cytotoxicity against Vero cell line |
CHEMBL1148649 |
| Human herpesvirus 5 |
IC100 |
= |
5.0 |
uM |
Inhibition of human CMV growth by viral yield assay |
CHEMBL1149480 |
| Human herpesvirus 5 |
IC100 |
= |
10.0 |
uM |
Inhibition of human CMV growth by plaque reduction assay |
CHEMBL1149480 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells |
CHEMBL1149480 |
| Jurkat |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against human Jurkat cells |
CHEMBL1149480 |
| Osteoclast-like |
IC50 |
= |
30000.0 |
nM |
Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage |
CHEMBL1149480 |
| Human herpesvirus 5 |
EC50 |
= |
1800.0 |
nM |
Inhibition of HCMV towne replication in HFF cells by plaque reduction assay |
CHEMBL1137379 |
| Human herpesvirus 5 |
EC50 |
= |
150.0 |
nM |
Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay |
CHEMBL1137379 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cell by neutral red uptake assay |
CHEMBL1137379 |
| Human herpesvirus 4 |
EC50 |
= |
5000.0 |
nM |
Inhibition of EBV replication in H1 cells by DNA hybridization assay |
CHEMBL1137379 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
19.0 |
nM |
Antiviral activity against HSV1 KOS in HEL cells |
CHEMBL1138863 |
| ADMET |
IC50 |
= |
1.9 |
nM |
Cytotoxicity against human OST TK- cells expressing HSV1 TK |
CHEMBL1138227 |
| ADMET |
IC50 |
= |
41.0 |
nM |
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine |
CHEMBL1138227 |
| ADMET |
IC50 |
= |
33.0 |
nM |
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine |
CHEMBL1138227 |
| ADMET |
IC50 |
= |
18.0 |
nM |
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine |
CHEMBL1138227 |
| ADMET |
IC50 |
= |
110.0 |
nM |
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine |
CHEMBL1138227 |
| ADMET |
IC50 |
= |
81.0 |
nM |
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine |
CHEMBL1138227 |
| ADMET |
IC50 |
= |
50.0 |
nM |
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine |
CHEMBL1138227 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
480.0 |
nM |
Antiviral activity against HSV1 KOS in HEL cells |
CHEMBL1138863 |
| Human herpesvirus 2 |
EC50 |
= |
32.0 |
nM |
Antiviral activity against HSV2 in HEL cells |
CHEMBL1138863 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against vaccinia virus in HEL cells |
CHEMBL1138863 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against vesicular somatitis virus in HEL cells |
CHEMBL1138863 |
| HEL |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HEL cells |
CHEMBL1138863 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
0.00038 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
0.91 |
ug.mL-1 |
Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Human herpesvirus 2 |
EC50 |
= |
0.0014 |
ug.mL-1 |
Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Human herpesvirus 2 |
EC50 |
= |
0.0096 |
ug.mL-1 |
Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Human herpesvirus 5 |
EC50 |
= |
1.5 |
ug.mL-1 |
Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Human herpesvirus 5 |
EC50 |
= |
1.5 |
ug.mL-1 |
Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| HEL |
Activity |
> |
100.0 |
ug ml-1 |
Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days |
CHEMBL1142867 |
| HEL |
Activity |
= |
83.6 |
ug ml-1 |
Cytotoxicity against HEL cells assessed as inhibition of cell growth after 3 days |
CHEMBL1142867 |
| Human herpesvirus 5 |
IC50 |
= |
1300.0 |
nM |
Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay |
CHEMBL1142135 |
| Human herpesvirus 5 |
IC50 |
= |
1400.0 |
nM |
Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay |
CHEMBL1142135 |
| Human herpesvirus 5 |
IC50 |
= |
1400.0 |
nM |
Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay |
CHEMBL1142135 |
| Human herpesvirus 5 |
IC50 |
= |
5600.0 |
nM |
Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay |
CHEMBL1142135 |
| Human herpesvirus 5 |
IC50 |
= |
7100.0 |
nM |
Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay |
CHEMBL1142135 |
| Human herpesvirus 5 |
IC50 |
= |
30200.0 |
nM |
Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay |
CHEMBL1142135 |
| Human herpesvirus 5 |
IC50 |
= |
1900.0 |
nM |
Antiviral activity against Human CMV AD169 in HFF cells by PRA |
CHEMBL1142135 |
| Human herpesvirus 5 |
IC50 |
= |
10000.0 |
nM |
Antiviral activity against Human CMV T2293 in HFF cells by PRA |
CHEMBL1142135 |
| Human herpesvirus 5 |
IC50 |
= |
4100.0 |
nM |
Antiviral activity against Human CMV T2291 in HFF cells by PRA |
CHEMBL1142135 |
| Human herpesvirus 5 |
IC50 |
= |
12400.0 |
nM |
Antiviral activity against Human CMV T2311 in HFF cells by PRA |
CHEMBL1142135 |
| Human herpesvirus 5 |
IC50 |
= |
4900.0 |
nM |
Antiviral activity against Human CMV Towne in MRC5 cells by PRA |
CHEMBL1142135 |
| Human herpesvirus 5 |
IC50 |
= |
5400.0 |
nM |
Antiviral activity against Human CMV T2296 in MRC5 cells by PRA |
CHEMBL1142135 |
| Human herpesvirus 5 |
IC50 |
= |
30100.0 |
nM |
Antiviral activity against Human CMV T2287 in MRC5 cells by PRA |
CHEMBL1142135 |
| Human herpesvirus 4 |
EC50 |
= |
5000.0 |
nM |
Inhibition of EBV replication in H1 cells by DNA hybridization assay |
CHEMBL1149318 |
| CCRF-CEM |
CC50 |
= |
5000.0 |
nM |
Cytotoxicity against CEM cells |
CHEMBL1149318 |
| Human herpesvirus 5 |
EC50 |
= |
2100.0 |
nM |
Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay |
CHEMBL1149318 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells by visual cytotoxicity |
CHEMBL1149318 |
| Human herpesvirus 5 |
EC50 |
= |
2200.0 |
nM |
Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay |
CHEMBL1149318 |
| HFF |
CC50 |
> |
392000.0 |
nM |
Cytotoxicity against HFF cells by neutral red uptake assay |
CHEMBL1149318 |
| Human herpesvirus 2 |
EC50 |
> |
50000.0 |
nM |
Inhibition of HSV1 in Vero cells by plaque reduction assay |
CHEMBL1149318 |
| Vero |
EC50 |
> |
50000.0 |
nM |
Inhibition of HSV2 in Vero cells by plaque reduction assay |
CHEMBL1149318 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
96.0 |
nM |
Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| Human herpesvirus 2 |
MIC |
= |
96.0 |
nM |
Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| Vaccinia virus |
MIC |
= |
60000.0 |
nM |
Antiviral activity against Vaccinia virus-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| Vesicular stomatitis virus |
MIC |
> |
100000.0 |
nM |
Antiviral activity against in Vesicular stomatitis virus-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
800.0 |
nM |
Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| E6SM |
MIC |
> |
100000.0 |
nM |
Cytotoxicity against E6SM cells |
CHEMBL1144557 |
| Human herpesvirus 8 |
IC50 |
= |
70000.0 |
nM |
Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay |
CHEMBL1147135 |
| Human herpesvirus 8 |
IC50 |
= |
81000.0 |
nM |
Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC2 cells after 120 hrs by MTT assay |
CHEMBL1147135 |
| ADMET |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against DG75 cells after 120 hrs by MTT assay |
CHEMBL1147135 |
| E6SM |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against E6SM cells assessed as alteration in cell morphology |
CHEMBL1143708 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
0.002 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Human herpesvirus 2 |
EC50 |
= |
0.006999999999999999 |
ug.mL-1 |
Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Vaccinia virus |
EC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Human herpesvirus 1 |
EC50 |
= |
0.7 |
ug.mL-1 |
Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Human herpesvirus 1 |
EC50 |
= |
0.02 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
6300.0 |
nM |
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation |
CHEMBL1143708 |
| Human herpesvirus 5 |
EC50 |
= |
2750.0 |
nM |
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation |
CHEMBL1143708 |
| HEL |
MCC |
> |
200000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration in cell morphology |
CHEMBL1143708 |
| Human immunodeficiency virus 1 |
EC50 |
|
|
|
Antiviral activity against HIV1 in MT4 cells |
CHEMBL1144587 |
| Human herpesvirus 1 |
EC50 |
= |
1500.0 |
nM |
Antiviral activity against HSV1 in CCL81 cells |
CHEMBL1144587 |
| Human herpesvirus 2 |
EC50 |
= |
1500.0 |
nM |
Antiviral activity against HSV2 in CCL81 cells |
CHEMBL1144587 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1010.0 |
nM |
Antiviral activity against HCMV AD169 |
CHEMBL1144587 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
4800.0 |
nM |
Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days |
CHEMBL1145384 |
| Human herpesvirus 5 |
EC50 |
= |
1300.0 |
nM |
Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days |
CHEMBL1145384 |
| HEL |
MCC |
> |
1575000.0 |
nM |
Cytotoxicity against HEL cells assessed as cell morphology after 7 days |
CHEMBL1145384 |
| HEL |
CC50 |
= |
172000.0 |
nM |
Cytotoxicity against HEL cells assessed as cell growth after 7 days |
CHEMBL1145384 |
| Human herpesvirus 3 |
EC50 |
= |
2300.0 |
nM |
Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days |
CHEMBL1148703 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days |
CHEMBL1148703 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days |
CHEMBL1148703 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days |
CHEMBL1148703 |
| Human herpesvirus 5 |
EC50 |
= |
5100.0 |
nM |
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days |
CHEMBL1148703 |
| Human herpesvirus 5 |
EC50 |
= |
8700.0 |
nM |
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days |
CHEMBL1148703 |
| HEL |
MCC |
> |
200000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days |
CHEMBL1148703 |
| HEL |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against HEL cells after 3 days |
CHEMBL1148703 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
6500.0 |
nM |
Antiviral activity against CMV AD169 in human HEL cells after 7 days |
CHEMBL1148744 |
| Human herpesvirus 5 |
EC50 |
= |
2600.0 |
nM |
Antiviral activity against CMV Davis in human HEL cells after 7 days |
CHEMBL1148744 |
| HEL |
MCC |
>= |
1575000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration in cell morphology |
CHEMBL1148744 |
| HEL |
CC50 |
= |
262000.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduction of cell growth |
CHEMBL1148744 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
32.0 |
nM |
Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Human herpesvirus 2 |
MIC |
= |
6.4 |
nM |
Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Vaccinia virus |
MIC |
= |
100000.0 |
nM |
Antiviral activity against Vaccinia virus in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Human herpesvirus 5 |
IC50 |
= |
3000.0 |
nM |
Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay |
CHEMBL1146335 |
| MRC5 |
IC50 |
= |
970000.0 |
nM |
Cytotoxicity against MRC5 cells |
CHEMBL1146376 |
| Human herpesvirus 5 |
IC50 |
= |
910.0 |
nM |
Antiviral activity against HCMV in MRC5 cells by plaque reduction assay |
CHEMBL1146376 |
| Unchecked |
Ratio CC50/IC50 |
= |
1100.0 |
|
Selectivity index, ratio of CC50 for MRC5 cells to IC50 for HCMV |
CHEMBL1146376 |
| Human herpesvirus 5 |
IC50 |
= |
1000.0 |
nM |
Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay |
CHEMBL1147861 |
| Human herpesvirus 5 |
EC99.9 |
= |
5.0 |
uM |
Antiviral activity against HCMV infected HFF cells after 5 to 7 days by viral yield assay |
CHEMBL1147861 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells by alamar blue assay |
CHEMBL1147861 |
| Jurkat |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human Jurkat cells by alamar blue assay |
CHEMBL1147861 |
| ADMET |
CC50 |
= |
30000.0 |
nM |
Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days |
CHEMBL1147861 |
| Human herpesvirus 5 |
IC50 |
= |
1300.0 |
nM |
Antiviral activity against HCMV in human foreskin fibroblast assessed as inhibition of virus plaque formation |
CHEMBL1149529 |
| Human herpesvirus 1 |
IC50 |
|
|
|
Antiviral activity against HSV1 in human foreskin fibroblast assessed as inhibition of virus plaque formation |
CHEMBL1149529 |
| Human herpesvirus 3 |
IC50 |
|
|
|
Antiviral activity against VZV in human foreskin fibroblast assessed as inhibition of virus plaque formation |
CHEMBL1149529 |
| HEL |
EC50 |
= |
0.00056 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| HEL |
EC50 |
= |
0.9 |
ug.mL-1 |
Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Human herpesvirus 2 |
EC50 |
= |
0.0014 |
ug.mL-1 |
Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Human herpesvirus 2 |
EC50 |
= |
0.0036 |
ug.mL-1 |
Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Human herpesvirus 5 |
EC50 |
= |
1.68 |
ug.mL-1 |
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Human herpesvirus 5 |
EC50 |
= |
1.29 |
ug.mL-1 |
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as alteration in morphology after 3 days |
CHEMBL1138246 |
| HEL |
CC50 |
= |
122.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as cell growth after 3 days |
CHEMBL1138246 |
| ADMET |
IC50 |
= |
270000.0 |
nM |
Cytotoxicity against MCA cells |
CHEMBL1138268 |
| ADMET |
IC50 |
= |
150.0 |
nM |
Cytotoxicity against MCA-TK cells |
CHEMBL1138268 |
| Human herpesvirus 5 |
IC50 |
= |
1300.0 |
nM |
Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay |
CHEMBL1139940 |
| Human herpesvirus 1 |
IC50 |
|
|
|
Antiviral activity against HSV1 KOS in Vero cells by plaque reduction assay |
CHEMBL1139940 |
| Human herpesvirus 3 |
IC50 |
|
|
|
Antiviral activity against VZV Webster in HFF cells by plaque reduction assay |
CHEMBL1139940 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells after 3 days |
CHEMBL1139940 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation |
CHEMBL1140488 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against TK- VZV 07/1 in HEL cells assessed as reduction of virus plaque formation |
CHEMBL1140488 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
0.51 |
ug.mL-1 |
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days |
CHEMBL1140488 |
| Human herpesvirus 5 |
EC50 |
= |
0.8 |
ug.mL-1 |
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days |
CHEMBL1140488 |
| HEL |
MCC |
= |
100.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days |
CHEMBL1140488 |
| HEL |
CC50 |
= |
146.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days |
CHEMBL1140488 |
| Thymidine kinase |
IC50 |
= |
800000.0 |
nM |
Inhibition of Herpes B virus recombinant thymidine kinase-mediated [3H]TdR phosphorylation |
CHEMBL1145504 |
| Thymidine kinase |
Activity |
|
|
|
Activity of Herpes B virus recombinant thymidine kinase at 100 uM |
CHEMBL1145504 |
| Thymidine kinase |
Activity |
|
|
|
Activity of Herpes B virus recombinant thymidine kinase at 1 mM |
CHEMBL1145504 |
| Macacine herpesvirus 1 |
EC50 |
= |
14500.0 |
nM |
Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs |
CHEMBL1145504 |
| Macacine herpesvirus 1 |
EC50 |
= |
23500.0 |
nM |
Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs |
CHEMBL1145504 |
| Macacine herpesvirus 1 |
EC50 |
= |
19200.0 |
nM |
Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs |
CHEMBL1145504 |
| Human herpesvirus 1 |
EC50 |
= |
700.0 |
nM |
Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs |
CHEMBL1145504 |
| Vero |
CC50 |
= |
666000.0 |
nM |
Cytotoxicity against african green monkey Vero cells after 2 days |
CHEMBL1145504 |
| Human herpesvirus 5 |
EC50 |
= |
2500.0 |
nM |
Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay |
CHEMBL1144038 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells |
CHEMBL1144038 |
| E6SM |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against human E6SM cells |
CHEMBL1149790 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against human HEL cells assessed as alteration of cell morphology |
CHEMBL1149790 |
| Human herpesvirus 1 |
MIC |
= |
0.032 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 1 |
MIC |
= |
0.032 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 2 |
MIC |
= |
0.032 |
ug.mL-1 |
Antiviral activity against HSV2 G in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 2 |
MIC |
= |
0.032 |
ug.mL-1 |
Antiviral activity against HSV2 G in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vaccinia virus |
MIC |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vaccinia virus |
MIC |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vesicular stomatitis virus |
MIC |
> |
100.0 |
ug.mL-1 |
Antiviral activity against in Vesicular stomatitis virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vesicular stomatitis virus |
MIC |
> |
100.0 |
ug.mL-1 |
Antiviral activity against in Vesicular stomatitis virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 1 |
MIC |
= |
2.4 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 1 |
MIC |
= |
2.4 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
0.64 |
ug.mL-1 |
Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation |
CHEMBL1149790 |
| Human herpesvirus 5 |
EC50 |
= |
1.9 |
ug.mL-1 |
Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation |
CHEMBL1149790 |
| HEL |
CC50 |
= |
87.0 |
ug.mL-1 |
Cytotoxicity against human HEL cells assessed as reduction of cell growth |
CHEMBL1149790 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
4800.0 |
nM |
Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days |
CHEMBL1156695 |
| Human herpesvirus 5 |
EC50 |
= |
1300.0 |
nM |
Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days |
CHEMBL1156695 |
| HEL |
MCC |
> |
1575000.0 |
nM |
Cytotoxicity against HEL cells assessed as change in cell morphology |
CHEMBL1156695 |
| HEL |
CC50 |
= |
172000.0 |
nM |
Cytotoxicity against HEL cells assessed as reduction in cell growth |
CHEMBL1156695 |
| Murine cytomegalovirus |
EC50 |
= |
5.0 |
ug.mL-1 |
Antiviral activity against mouse cytomegalovirus assessed as effect on virus-induced cytopathic effect |
CHEMBL1158236 |
| Murine cytomegalovirus |
EC50 |
= |
13.8 |
ug.mL-1 |
Antiviral activity against mouse cytomegalovirus by plaque-neutralization assay |
CHEMBL1158236 |
| Human herpesvirus 5 |
EC50 |
= |
3.4 |
ug.mL-1 |
Antiviral activity against human cytomegalovirus by plaque-neutralization assay |
CHEMBL1158236 |
| Maize chlorotic mottle virus |
EC50 |
= |
5.0 |
ug.mL-1 |
Antiviral activity against mCMV RM461 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days |
CHEMBL1150874 |
| ADMET |
IC50 |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days |
CHEMBL1150874 |
| Unchecked |
Ratio IC50/EC50 |
> |
20.0 |
|
Selectivity index, ratio of EC50 for mCMV RM461 by cytopathic effect over IC50 for human Hep2 cells |
CHEMBL1150874 |
| Human herpesvirus 3 |
EC50 |
= |
26.7 |
ug.mL-1 |
Antiviral activity against VZV 3CV-1 infected in human Hep2 cells after 3 days by plaque neutralization assay |
CHEMBL1150874 |
| ADMET |
IC50 |
= |
840.0 |
ug.mL-1 |
Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days |
CHEMBL1150874 |
| Unchecked |
Ratio IC50/EC50 |
= |
74.0 |
|
Selectivity index, ratio of EC50 for VZV 3CV-1 by plaque neutralization over IC50 for human Hep2 cells |
CHEMBL1150874 |
| Solute carrier family 22 member 1 |
Inhibition |
= |
10.5 |
% |
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy |
CHEMBL1140113 |
| ADMET |
CC50 |
= |
5860.0 |
nM |
Cytotoxicity against HSV1-tk gene overexpressing RG2TK+ cells after 72 hrs by MTT assay |
CHEMBL1140131 |
| RG2 |
CC50 |
= |
377000.0 |
nM |
Cytotoxicity against RG2 cells after 72 hrs by MTT assay |
CHEMBL1140131 |
| Human herpesvirus 5 |
EC50 |
= |
7.6 |
ug.mL-1 |
Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
4.9 |
ug.mL-1 |
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
9.1 |
ug.mL-1 |
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
1.5 |
ug.mL-1 |
Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
0.54 |
ug.mL-1 |
Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
9.4 |
ug.mL-1 |
Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
6.0 |
ug.mL-1 |
Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| Human herpesvirus 5 |
EC50 |
= |
6.2 |
ug.mL-1 |
Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1140035 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against human HEL cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days |
CHEMBL1153955 |
| Human herpesvirus 1 |
EC50 |
= |
20.0 |
nM |
Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Human herpesvirus 2 |
EC50 |
= |
200.0 |
nM |
Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Human herpesvirus 1 |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against feline CRFK cells by MTS assay |
CHEMBL1153955 |
| Feline coronavirus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Feline coronavirus in feline FRCK cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1153955 |
| Felid herpesvirus 1 |
EC50 |
= |
1200.0 |
nM |
Antiviral activity against Feline herpesvirus in feline FRCK cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1153955 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration in cell morphology by MTS assay |
CHEMBL1144203 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against CRFK cells assessed as decrease in cell viability by MTS assay |
CHEMBL1144203 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
0.51 |
ug.mL-1 |
Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity |
CHEMBL1142504 |
| Human herpesvirus 5 |
EC50 |
= |
0.8 |
ug.mL-1 |
Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity |
CHEMBL1142504 |
| HEL |
MCC |
= |
100.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as morphological alteration after 3 days |
CHEMBL1142504 |
| HEL |
CC50 |
= |
146.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as reduction of growth after 3 days |
CHEMBL1142504 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka in HEL cells assessed as inhibition of viral cytopathicity |
CHEMBL1142504 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 in HEL cells assessed as inhibition of viral cytopathicity |
CHEMBL1142504 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells by plaque reduction assay |
CHEMBL1138503 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells by neutral red uptake assay |
CHEMBL1138503 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
40.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1138503 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1200.0 |
nM |
Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay |
CHEMBL1138503 |
| Murine cytomegalovirus |
EC50 |
= |
5500.0 |
nM |
Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay |
CHEMBL1138503 |
| Hepatitis B virus |
Activity |
|
|
|
Antiviral activity against Hepatitis B virus |
CHEMBL1138503 |
| Hepatitis C virus |
Activity |
|
|
|
Antiviral activity against Hepatitis C virus |
CHEMBL1138503 |
| Human herpesvirus 5 |
EC50 |
= |
42000.0 |
nM |
Antiviral activity against cyclopropavir-resistant Human cytomegalovirus isolate 2696r with phosphotransferase UL97 mutation by plaque reduction assay |
CHEMBL1138503 |
| Human herpesvirus 5 |
EC50 |
= |
22000.0 |
nM |
Antiviral activity against Human cytomegalovirus E8 with phosphotransferase UL97 two point mutation by plaque reduction assay |
CHEMBL1138503 |
| Human herpesvirus 4 |
IC50 |
|
|
|
Antiviral activity against EBV lytic replication in GG68 cells after 72 hrs by Southern blot analysis |
CHEMBL1155120 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay |
CHEMBL1155120 |
| Human herpesvirus 3 |
IC50 |
|
|
|
Antiviral activity against VZV Webster by plaque reduction assay |
CHEMBL1155120 |
| Human herpesvirus 1 |
IC50 |
|
|
|
Antiviral activity against HSV1 KOS by plaque reduction assay |
CHEMBL1155120 |
| Human herpesvirus 5 |
IC50 |
= |
1300.0 |
nM |
Antiviral activity against HCMV Davis by plaque reduction assay |
CHEMBL1155120 |
| Human herpesvirus 5 |
Inhibition |
= |
30.0 |
% |
Antiviral activity against human cytomegalovirus |
CHEMBL1151726 |
| Monoamine oxidase A |
Activity |
|
|
|
Inhibition of bovine brain MAOA |
CHEMBL1152129 |
| Monoamine oxidase B |
Activity |
|
|
|
Inhibition of bovine brain MAOB |
CHEMBL1152129 |
| Human herpesvirus 1 |
IC50 |
|
|
|
Antiviral activity against acyclovir-sensitive HSV1 K161 isolate replication in african green monkey Vero cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 1 |
IC50 |
|
|
|
Antiviral activity against acyclovir-resistant HSV1 K143 isolate replication in african green monkey Vero cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 1 |
IC50 |
|
|
|
Antiviral activity against acyclovir-resistant HSV1 L182 isolate replication in african green monkey Vero cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 5 |
IC50 |
= |
3220.0 |
nM |
Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 5 |
IC50 |
|
|
|
Antiviral activity against ganciclovir-resistant HCMV U405 isolate replication in HFF cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 1 |
IC50 |
|
|
|
Antiviral activity against acyclovir-sensitive HSV1 L177 isolate replication in african green monkey Vero cells by plaque reduction assay |
CHEMBL1139254 |
| Human herpesvirus 5 |
IC50 |
= |
16400.0 |
nM |
Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay |
CHEMBL1139254 |
| Human adenovirus type 2 |
IC50 |
= |
35000.0 |
nM |
Antiviral activity against Human adenovirus 2 |
CHEMBL1136837 |
| Vaccinia virus |
IC50 |
= |
392000.0 |
nM |
Antiviral activity against Vaccinia virus |
CHEMBL1136837 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
2000.0 |
nM |
Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection |
CHEMBL1152768 |
| Human herpesvirus 5 |
EC50 |
= |
3600.0 |
nM |
Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection |
CHEMBL1152768 |
| HEL |
MCC |
> |
400000.0 |
nM |
Cytotoxicity against human HEL cells assessed as morphological alteration after 3 days |
CHEMBL1152768 |
| HEL |
CC50 |
= |
134000.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days |
CHEMBL1152768 |
| Human herpesvirus 5 |
EC50 |
= |
660.0 |
nM |
Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
700.0 |
nM |
Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
4300.0 |
nM |
Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
2600.0 |
nM |
Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
4000.0 |
nM |
Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
3500.0 |
nM |
Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1200.0 |
nM |
Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
690.0 |
nM |
Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1152768 |
| Human herpesvirus 5 |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
EC50 |
= |
3900.0 |
nM |
Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
EC50 |
= |
2600.0 |
nM |
Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
EC50 |
= |
6100.0 |
nM |
Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
EC50 |
= |
2700.0 |
nM |
Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
EC50 |
= |
6600.0 |
nM |
Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
EC50 |
= |
3500.0 |
nM |
Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
EC50 |
= |
8400.0 |
nM |
Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
FC |
= |
2.6 |
|
Drug resistance, ratio of EC50 for Cytomegalovirus CMV T2417 pol A809V mutant to EC50 for Cytomegalovirus CMV T2211 by plaque reduction assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
FC |
= |
5.0 |
|
Drug resistance, ratio of EC50 for Cytomegalovirus CMV pol T821I mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
FC |
= |
5.0 |
|
Drug resistance, ratio of EC50 for Cytomegalovirus CMV pol A384P mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
FC |
= |
2.0 |
|
Drug resistance, ratio of EC50 for Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
FC |
= |
2.0 |
|
Drug resistance, ratio of EC50 for Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay |
CHEMBL1137642 |
| Human herpesvirus 5 |
FC |
= |
2.0 |
|
Drug resistance, ratio of EC50 for Cytomegalovirus CMV T2817 with pol G841A UL97 C592G double mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay |
CHEMBL1137642 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against human HEL cells assessed as alteration in cell morphology |
CHEMBL1158343 |
| Human herpesvirus 1 |
EC50 |
= |
0.06 |
ug.mL-1 |
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Human herpesvirus 2 |
EC50 |
= |
0.06 |
ug.mL-1 |
Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Vaccinia virus |
EC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Vesicular stomatitis virus |
EC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Human herpesvirus 1 |
EC50 |
= |
1.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Homo sapiens |
CL |
= |
4.6 |
mL.min-1.kg-1 |
Total body clearance in human |
CHEMBL1151930 |
| Homo sapiens |
CL_renal |
= |
4.14 |
mL.min-1.kg-1 |
Renal clearance in human |
CHEMBL1151930 |
| Human herpesvirus 3 |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days |
CHEMBL1153001 |
| Human herpesvirus 3 |
EC50 |
= |
590.0 |
nM |
Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days |
CHEMBL1153001 |
| Human herpesvirus 3 |
EC50 |
= |
2500.0 |
nM |
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days |
CHEMBL1153001 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
12600.0 |
nM |
Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection |
CHEMBL1153001 |
| Human herpesvirus 5 |
EC50 |
= |
2500.0 |
nM |
Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection |
CHEMBL1153001 |
| HEL |
MCC |
> |
1575000.0 |
nM |
Cytotoxicity against human HEL cells assessed as microscopically detectable morphological alterations after 3 days |
CHEMBL1153001 |
| HEL |
CC50 |
= |
221000.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days |
CHEMBL1153001 |
| Human herpesvirus 1 |
EC50 |
= |
0.08 |
ug.mL-1 |
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Human herpesvirus 1 |
MIC50 |
= |
0.032 |
ug.mL-1 |
Antiviral activity against HSV1 KOS infected in HEL cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Human herpesvirus 2 |
MIC50 |
= |
0.0064 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 2 infected in HEL cells assessed as protection against in virus-induced cytopathogenicity |
CHEMBL1153581 |
| Vaccinia virus |
MIC50 |
= |
100.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Vesicular stomatitis virus |
MIC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against sVesicular stomatitis virus infected in HEL cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Human herpesvirus 1 |
MIC50 |
= |
2.4 |
ug.mL-1 |
Antiviral activity against acyclovir-resistant thymidine kinase-deficient HSV1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as change in cell morphology |
CHEMBL1153581 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1.4 |
ug.mL-1 |
Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL1153581 |
| Cytomegalovirus |
EC50 |
= |
1.7 |
ug.mL-1 |
Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL1153581 |
| Human herpesvirus 3 |
EC50 |
= |
1.0 |
ug.mL-1 |
Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL1153581 |
| Human herpesvirus 3 |
EC50 |
= |
15.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL1153581 |
| HEL |
CC50 |
= |
400.0 |
ug.mL-1 |
Cytotoxicity against Cytomegalovirus infected HEL cells assessed as change in cell morphology |
CHEMBL1153581 |
| HEL |
CC50 |
= |
80.0 |
ug.mL-1 |
Cytotoxicity against Cytomegalovirus infected HEL cells assessed as reduction in cell growth |
CHEMBL1153581 |
| HeLa |
CC50 |
> |
50.0 |
ug.mL-1 |
Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as change in cell morphology |
CHEMBL1153581 |
| HeLa |
CC50 |
= |
190.0 |
ug.mL-1 |
Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as reduction in cell growth |
CHEMBL1153581 |
| Human herpesvirus 2 |
EC50 |
= |
0.08 |
ug.mL-1 |
Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Human herpesvirus 1 |
EC50 |
= |
6.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology |
CHEMBL1153616 |
| Vaccinia virus |
EC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Vesicular stomatitis virus |
EC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Homo sapiens |
Vdss |
= |
1.0 |
L.kg-1 |
Volume of distribution at steady state in human |
CHEMBL1156824 |
| Homo sapiens |
Fg |
= |
1.02 |
|
Fraction escaping gut-wall elimination in human |
CHEMBL1156824 |
| Homo sapiens |
CL_renal |
= |
4.1 |
mL.min-1.kg-1 |
Renal clearance in human |
CHEMBL1156824 |
| Homo sapiens |
CL |
= |
4.6 |
mL.min-1.kg-1 |
Total clearance in human |
CHEMBL1156824 |
| ADMET |
permeability |
= |
0.7 |
10'-6 cm/s |
Permeability at pH 6.5 by PAMPA method |
CHEMBL1156784 |
| Homo sapiens |
F |
= |
7.3 |
% |
Oral bioavailability in human |
CHEMBL1156784 |
| Homo sapiens |
F_fraction |
= |
0.09 |
|
Oral bioavailability in human |
CHEMBL1156824 |
| Homo sapiens |
Fa |
= |
0.09 |
|
Fraction absorbed in human |
CHEMBL1156824 |
| Homo sapiens |
CL |
= |
0.5 |
mL.min-1.kg-1 |
Hepatic clearance in human |
CHEMBL1156824 |
| Homo sapiens |
Fh |
= |
0.98 |
|
Fraction escaping hepatic elimination in human |
CHEMBL1156824 |
| Plasma |
Fu |
= |
0.99 |
|
Fraction unbound in human plasma |
CHEMBL1156824 |
| Caco-2 |
logPapp |
= |
-6.27 |
|
Permeability across human Caco-2 cells |
CHEMBL1152590 |
| Human herpesvirus 5 |
IC50 |
= |
1300.0 |
nM |
Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay |
CHEMBL1155400 |
| Feline coronavirus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Feline coronavirus infected in cat CRFK cells assessed as protection from virus-induced cytopathogenicity by MTT assay |
CHEMBL1154855 |
| Felid herpesvirus 1 |
EC50 |
= |
2600.0 |
nM |
Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as protection from virus-induced cytopathogenicity by MTT assay |
CHEMBL1154855 |
| HEL |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method |
CHEMBL1154855 |
| HEL |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method |
CHEMBL1154855 |
| HEL |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method |
CHEMBL1154855 |
| HEL |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method |
CHEMBL1154855 |
| HEL |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method |
CHEMBL1154855 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against Feline coronavirus infected cat CRFK cells by trypan blue exclusion method |
CHEMBL1154855 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against Feline herpesvirus infected cat CRFK cells by trypan blue exclusion method |
CHEMBL1154855 |
| Human herpesvirus 1 |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay |
CHEMBL1154855 |
| Human herpesvirus 2 |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay |
CHEMBL1154855 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay |
CHEMBL1154855 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay |
CHEMBL1154855 |
| Human herpesvirus 1 |
EC50 |
= |
30.0 |
nM |
Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay |
CHEMBL1154855 |
| Unchecked |
IC50 |
= |
1300.0 |
nM |
Inhibition of HCMV DNA polymerase infected in HFF cells |
CHEMBL1157125 |
| Human herpesvirus 1 |
IC50 |
|
|
|
Antiviral activity against HSV1 KOS infected in african green monkey Vero cells assessed as reduction in plaque formation |
CHEMBL1157125 |
| Human herpesvirus 3 |
IC50 |
|
|
|
Antiviral activity against VZV Webster infected in HFF cells assessed as reduction in plaque formation |
CHEMBL1157125 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay |
CHEMBL1157125 |
| Purine nucleoside phosphorylase |
Kd |
= |
15848.93 |
nM |
Binding affinity to Mycobacterium tuberculosis purine nucleoside phosphorylase by spectrophotometric analysis |
CHEMBL1177645 |
| Macacine herpesvirus 1 |
Activity |
= |
100.0 |
% |
Antiviral activity against Macacine herpesvirus 1 infected in rabbits assessed as survival after 5 months |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Macacine herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Human herpesvirus 1 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Human herpesvirus 2 |
EC50 |
= |
19300.0 |
nM |
Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay |
CHEMBL1212758 |
| Human herpesvirus 5 |
EC50 |
= |
2700.0 |
nM |
Antiviral activity against human cytomegalovirus Davis infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
4300.0 |
nM |
Antiviral activity against human cytomegalovirus AD169 infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1730.0 |
nM |
Antiviral activity against human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 |
EC50 |
= |
2330.0 |
nM |
Antiviral activity against human cytomegalovirus RV-HG infected in NHDF after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
EC90 |
= |
10.7 |
uM |
Antiviral activity against human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 |
EC90 |
= |
18.3 |
uM |
Antiviral activity against human cytomegalovirus RV-HG infected in NHDF after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 |
EC50 |
= |
320.0 |
nM |
Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 |
EC50 |
= |
1910.0 |
nM |
Antiviral activity against human cytomegalovirus infected in NHDF after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 |
EC50 |
= |
2390.0 |
nM |
Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 |
EC50 |
= |
1650.0 |
nM |
Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 |
EC50 |
= |
2070.0 |
nM |
Antiviral activity against human cytomegalovirus infected in NHLF after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| HS27 |
CC50 |
> |
333000.0 |
nM |
Cytotoxicity against human HS27 cells infected with human cytomegalovirus after 7 days by alamar blue assay |
CHEMBL1240389 |
| NHDF |
CC50 |
> |
333000.0 |
nM |
Cytotoxicity against NHDF infected with human cytomegalovirus after 7 days by alamar blue assay |
CHEMBL1240389 |
| ADMET |
CC50 |
> |
333000.0 |
nM |
Cytotoxicity against HEL299 cells infected with human cytomegalovirus after 7 days by alamar blue assay |
CHEMBL1240389 |
| MRC5 |
CC50 |
> |
333000.0 |
nM |
Cytotoxicity against human MRC5 cells infected with human cytomegalovirus after 7 days by alamar blue assay |
CHEMBL1240389 |
| ADMET |
CC50 |
> |
333000.0 |
nM |
Cytotoxicity against HLF infected with human cytomegalovirus after 7 days by alamar blue assay |
CHEMBL1240389 |
| Unchecked |
Selectivity Index |
> |
1044.0 |
|
Selectivity index, ratio of CC50 for human HS27 cells to EC50 for human cytomegalovirus infected in human HS27 cells |
CHEMBL1240389 |
| Unchecked |
Selectivity Index |
> |
174.0 |
|
Selectivity index, ratio of CC50 for NHDF to EC50 for human cytomegalovirus infected in NHDF |
CHEMBL1240389 |
| Unchecked |
Selectivity Index |
> |
139.0 |
|
Selectivity index, ratio of CC50 for HEL299 cells to EC50 for human cytomegalovirus infected in HEL299 cells |
CHEMBL1240389 |
| Unchecked |
Selectivity Index |
> |
161.0 |
|
Selectivity index, ratio of CC50 for NHLF to EC50 for human cytomegalovirus infected in NHLF |
CHEMBL1240389 |
| Unchecked |
Selectivity Index |
> |
202.0 |
|
Selectivity index, ratio of CC50 for human MRC5 cells to EC50 for human cytomegalovirus infected in human MRC5 cells |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
990.0 |
nM |
Antiviral activity against 0.003 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
680.0 |
nM |
Antiviral activity against 0.001 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1740.0 |
nM |
Antiviral activity against 0.03 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
2210.0 |
nM |
Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
6510.0 |
nM |
Antiviral activity against 0.3 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
5260.0 |
nM |
Antiviral activity against 1 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
Activity |
|
|
|
Antiviral activity against human cytomegalovirus AD169 infected in NHDF assessed as inhibition of virus replication at 20 uM after 96 hrs by fluorescence assay |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
Activity |
|
|
|
Antiviral activity against human cytomegalovirus AD169 infected in NHDF assessed as inhibition of virus replication at 50 nM measured after 24 to 72 hrs of compound wash by fluorescence assay |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
Activity |
|
|
|
Antiviral activity against human cytomegalovirus AD169 infected in NHDF at 10 times EC50 treated after 168 hrs postinfection measured after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
Activity |
|
|
|
Antiviral activity against human cytomegalovirus AD169 infected in NHDF at 20 uM treated after 33 hrs postinfection measured after 7 days by GFP-based fluorescent reduction assay |
CHEMBL1240389 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
12000.0 |
nM |
Antiviral activity against ganciclovir-resistant human cytomegalovirus AD169 UL97 M460I infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining |
CHEMBL1240389 |
| Human herpesvirus 5 |
EC50 |
= |
5000.0 |
nM |
Antiviral activity against human cytomegalovirus isolate 472 infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining |
CHEMBL1240389 |
| Human herpesvirus 5 |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against human cytomegalovirus isolate E16415S infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining |
CHEMBL1240389 |
| Human herpesvirus 5 |
EC50 |
= |
14000.0 |
nM |
Antiviral activity against ganciclovir-resistant human cytomegalovirus isolate E17251S infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining |
CHEMBL1240389 |
| Human herpesvirus 5 |
EC50 |
= |
15000.0 |
nM |
Antiviral activity against ganciclovir-resistant human cytomegalovirus isolate 1947R infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining |
CHEMBL1240389 |
| Unchecked |
Inhibition |
|
|
% |
Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay |
CHEMBL1255231 |
| Human herpesvirus 5 strain AD169 |
Activity |
|
|
|
Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as inhibition of viral replication up to 72 hrs post infection |
CHEMBL1255448 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against 0.01 MOI human cytomegalovirus AD169 infected in human HFF assessed as virus yield reduction by yield reduction assay |
CHEMBL1255448 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as virus yield reduction by yield reduction assay |
CHEMBL1255448 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
800.0 |
nM |
Antiviral activity against 1 MOI human cytomegalovirus AD169 infected in human HFF assessed as virus yield reduction by yield reduction assay |
CHEMBL1255448 |
| Human herpesvirus 5 strain AD169 |
Inhibition |
= |
98.0 |
% |
Antiviral activity against human cytomegalovirus AD169 infected in human HFF assessed as inhibition of DNA synthesis after 72 hrs by qPCR |
CHEMBL1255448 |
| Unchecked |
Selectivity Index |
= |
289.0 |
|
Selectivity index, ratio of CC50 for human HFF to EC50 for human cytomegalovirus AD169 |
CHEMBL1255448 |
| HFF |
CC50 |
= |
550000.0 |
nM |
Cytotoxicity against human HFF by MTT assay |
CHEMBL1255448 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1900.0 |
nM |
Antiviral activity against human cytomegalovirus AD169 infected in human HFF assessed as inhibition of plaque formation by plaque reduction assay |
CHEMBL1255448 |
| HEL |
CC50 |
= |
1077000.0 |
nM |
Cytotoxicity against HEL |
CHEMBL1255569 |
| ADMET |
MCC |
|
|
|
Cytotoxicity against human HSB2 cells assessed as change in cell morphology |
CHEMBL1255569 |
| HEL |
MCC |
>= |
392000.0 |
nM |
Cytotoxicity against HEL assessed as change in cell morphology |
CHEMBL1255569 |
| Human herpesvirus 6 |
EC50 |
|
|
|
Antiviral activity against Human herpesvirus 6 infected in HEL assessed as reduction in virus-induce cytopathicity |
CHEMBL1255569 |
| Human herpesvirus 5 |
EC50 |
= |
10200.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis infected in HEL assessed as reduction in virus-induce cytopathicity |
CHEMBL1255569 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
9400.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in HEL assessed as reduction in virus-induce cytopathicity |
CHEMBL1255569 |
| Vaccinia virus |
EC50 |
|
|
|
Antiviral activity against Vaccinia virus infected in HEL assessed as reduction in virus-induce cytopathicity |
CHEMBL1255569 |
| Human herpesvirus 5 |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1110.0 |
nM |
Antiviral activity against Human cytomegalovirus T2233 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1020.0 |
nM |
Antiviral activity against Human cytomegalovirus T3099 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against Human cytomegalovirus T3135 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
960.0 |
nM |
Antiviral activity against Human cytomegalovirus T3185 harboring Frt motif upstream of UL97 gene and expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
990.0 |
nM |
Antiviral activity against Human cytomegalovirus T3261 harboring Frt motif upstream of UL97 kinase infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1090.0 |
nM |
Antiviral activity against Human cytomegalovirus T3326 harboring Frt motif upstream of UL97 kinase N68D L126Q I244V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
3020.0 |
nM |
Antiviral activity against Human cytomegalovirus T2789 expressing UL97 kinase L405P mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
2760.0 |
nM |
Antiviral activity against Human cytomegalovirus T3184 expressing UL97 kinase L405P mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
9240.0 |
nM |
Antiviral activity against Human cytomegalovirus T3346 expressing UL97 kinase M460T mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
8520.0 |
nM |
Antiviral activity against Human cytomegalovirus T2259 expressing UL97 kinase M460V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1240.0 |
nM |
Antiviral activity against Human cytomegalovirus T3257 expressing UL97 kinase V466M mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1330.0 |
nM |
Antiviral activity against Human cytomegalovirus T2924 expressing UL97 kinase H469Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1050.0 |
nM |
Antiviral activity against Human cytomegalovirus T3136 expressing UL97 kinase H469Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
770.0 |
nM |
Antiviral activity against Human cytomegalovirus T3242 expressing UL97 kinase A478V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
950.0 |
nM |
Antiviral activity against Human cytomegalovirus T3215 expressing UL97 kinase A478V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1140.0 |
nM |
Antiviral activity against Human cytomegalovirus T3240 expressing UL97 kinase N510S mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1230.0 |
nM |
Antiviral activity against Human cytomegalovirus T3216 expressing UL97 kinase A588V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
990.0 |
nM |
Antiviral activity against Human cytomegalovirus T3244 expressing UL97 kinase A588V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
3360.0 |
nM |
Antiviral activity against Human cytomegalovirus T2258 expressing UL97 kinase C592G mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against Human cytomegalovirus T3259 expressing UL97 kinase C592G mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
3310.0 |
nM |
Antiviral activity against Human cytomegalovirus T3217 expressing UL97 kinase A594E mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
2980.0 |
nM |
Antiviral activity against Human cytomegalovirus T3258 expressing UL97 kinase A594E mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
9240.0 |
nM |
Antiviral activity against Human cytomegalovirus T2255 expressing UL97 kinase A594V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
8480.0 |
nM |
Antiviral activity against Human cytomegalovirus T3252 expressing UL97 kinase A594V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1230.0 |
nM |
Antiviral activity against Human cytomegalovirus T3253 expressing UL97 kinase K599R mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
940.0 |
nM |
Antiviral activity against Human cytomegalovirus T3146 expressing UL97 kinase K599R mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1500.0 |
nM |
Antiviral activity against Human cytomegalovirus T3041 expressing UL97 kinase L600I mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
8180.0 |
nM |
Antiviral activity against Human cytomegalovirus T3331 expressing UL97 kinase C603R mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1850.0 |
nM |
Antiviral activity against Human cytomegalovirus T3327 expressing UL97 kinase C603S mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
7810.0 |
nM |
Antiviral activity against Human cytomegalovirus T3329 expressing UL97 kinase C603W mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1130.0 |
nM |
Antiviral activity against Human cytomegalovirus T3264 expressing UL97 kinase G623S mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1260.0 |
nM |
Antiviral activity against Human cytomegalovirus T3243 expressing UL97 kinase T659I mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1060.0 |
nM |
Antiviral activity against Human cytomegalovirus T3239 expressing UL97 kinase V665I mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
1220.0 |
nM |
Antiviral activity against Human cytomegalovirus T3130 expressing UL97 kinase V665I mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
2.7 |
|
Ratio of EC50 for Human cytomegalovirus T2789 expressing UL97 kinase L405P mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
2.5 |
|
Ratio of EC50 for Human cytomegalovirus T3184 expressing UL97 kinase L405P mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
9.3 |
|
Ratio of EC50 for Human cytomegalovirus T3346 expressing UL97 kinase M460T mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
8.6 |
|
Ratio of EC50 for Human cytomegalovirus T2259 expressing UL97 kinase M460V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.3 |
|
Ratio of EC50 for Human cytomegalovirus T3257 expressing UL97 kinase V466M mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.2 |
|
Ratio of EC50 for Human cytomegalovirus T2924 expressing UL97 kinase H469Y mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.1 |
|
Ratio of EC50 for Human cytomegalovirus T3136 expressing UL97 kinase H469Y mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
0.8 |
|
Ratio of EC50 for Human cytomegalovirus T3242 expressing UL97 kinase A478V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
0.9 |
|
Ratio of EC50 for Human cytomegalovirus T3215 expressing UL97 kinase A478V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.2 |
|
Ratio of EC50 for Human cytomegalovirus T3240 expressing UL97 kinase N510S mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.1 |
|
Ratio of EC50 for Human cytomegalovirus T3216 expressing UL97 kinase A588V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.0 |
|
Ratio of EC50 for Human cytomegalovirus T3244 expressing UL97 kinase A588V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
3.0 |
|
Ratio of EC50 for Human cytomegalovirus T2258 expressing UL97 kinase C592G mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
3.0 |
|
Ratio of EC50 for Human cytomegalovirus T3259 expressing UL97 kinase C592G mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
3.0 |
|
Ratio of EC50 for Human cytomegalovirus T3217 expressing UL97 kinase A594E mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
3.0 |
|
Ratio of EC50 for Human cytomegalovirus T3258 expressing UL97 kinase A594E mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
8.3 |
|
Ratio of EC50 for Human cytomegalovirus T2255 expressing UL97 kinase A594V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
8.6 |
|
Ratio of EC50 for Human cytomegalovirus T3252 expressing UL97 kinase A594V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.2 |
|
Ratio of EC50 for Human cytomegalovirus T3253 expressing UL97 kinase K599R mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
0.9 |
|
Ratio of EC50 for Human cytomegalovirus T3146 expressing UL97 kinase K599R mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.4 |
|
Ratio of EC50 for Human cytomegalovirus T3041 expressing UL97 kinase L600I mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
8.3 |
|
Ratio of EC50 for Human cytomegalovirus T3331 expressing UL97 kinase C603R mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.9 |
|
Ratio of EC50 for Human cytomegalovirus T3327 expressing UL97 kinase C603S mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
7.9 |
|
Ratio of EC50 for Human cytomegalovirus T3329 expressing UL97 kinase C603W mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.1 |
|
Ratio of EC50 for Human cytomegalovirus T3264 expressing UL97 kinase G623S mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.3 |
|
Ratio of EC50 for Human cytomegalovirus T3243 expressing UL97 kinase T659I mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.1 |
|
Ratio of EC50 for Human cytomegalovirus T3239 expressing UL97 kinase V665I mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
Ratio EC50 |
= |
1.2 |
|
Ratio of EC50 for Human cytomegalovirus T3130 expressing UL97 kinase V665I mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast |
CHEMBL1255499 |
| Human herpesvirus 5 |
EC50 |
= |
4100.0 |
nM |
Antiviral activity against Human cytomegalovirus |
CHEMBL1275262 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
0.05 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Human herpesvirus 2 strain G |
EC50 |
= |
0.07 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Felid herpesvirus 1 |
EC50 |
= |
0.8 |
ug.mL-1 |
Antiviral activity against Feline herpes virus infected in cat CRFK cells assessed as protection against virus-induced cytopathogenicity after 2 days by MTS assay |
CHEMBL1287642 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
2.0 |
ug.mL-1 |
Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| HEL |
Activity |
> |
100.0 |
ug ml-1 |
Cytotoxicity against human HEL cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days |
CHEMBL1287642 |
| Vaccinia virus |
EC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Vesicular stomatitis virus |
EC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| ADMET |
CC50 |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against cat CRFK cells by MTS assay |
CHEMBL1287642 |
| NON-PROTEIN TARGET |
EC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Feline coronavirus FIPV infected in cat CRFK cells assessed as protection against virus-induced cytopathogenicity after 2 days by MTS assay |
CHEMBL1287642 |
| Menin/Histone-lysine N-methyltransferase MLL |
Potency |
= |
10000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Prelamin-A/C |
Potency |
= |
3162.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Nuclear factor NF-kappa-B p105 subunit |
Potency |
= |
10000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway. (Class of assay: confirmatory) [Related pubchem assays: 895 ] |
CHEMBL1201862 |
| Survival motor neuron protein |
Potency |
= |
35481.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Survival motor neuron protein |
Potency |
= |
1584.9 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Endonuclease 4 |
Potency |
= |
12589.3 |
nM |
PUBCHEM_BIOASSAY: Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV. (Class of assay: confirmatory) [Related pubchem assays: 1705, 1707 ] |
CHEMBL1201862 |
| Hypoxia-inducible factor 1 alpha |
Potency |
= |
3981.1 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway. (Class of assay: confirmatory) [Related pubchem assays: 915 ] |
CHEMBL1201862 |
| Aldehyde dehydrogenase 1A1 |
Potency |
= |
39810.7 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] |
CHEMBL1201862 |
| Hypoxia-inducible factor 1 alpha |
Potency |
= |
3981.1 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway. (Class of assay: confirmatory) [Related pubchem assays: 914 ] |
CHEMBL1201862 |
| Menin/Histone-lysine N-methyltransferase MLL |
Potency |
= |
10000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Nuclear factor NF-kappa-B p105 subunit |
Potency |
= |
10000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Bloom syndrome protein |
Potency |
= |
3.2 |
nM |
PUBCHEM_BIOASSAY: qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM). (Class of assay: confirmatory) [Related pubchem assays: 593 (Fluorescein region spectral profiling screen), 594 (Rhodamine region spectral profiling screen)] |
CHEMBL1201862 |
| Bloom syndrome protein |
Potency |
= |
3.2 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM). (Class of assay: confirmatory) [Related pubchem assays: 593 (Fluorescein region spectral profiling screen), 2386 (Probe Development Summary for Inhibitors of Bloom's syndrome helicase (BLM)), 594 (Rhodamine region spectral profiling screen), 2364 (qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM))] |
CHEMBL1201862 |
| Cytochrome P450 3A4 |
Potency |
= |
25118.9 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Activators of Cytochrome P450 3A4. (Class of assay: confirmatory) [Related pubchem assays: 410 ] |
CHEMBL1201862 |
| Cytochrome P450 3A4 |
Potency |
= |
25118.9 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4. (Class of assay: confirmatory) [Related pubchem assays: 410 ] |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Fu |
= |
0.99 |
|
Fraction unbound in human after iv administration |
CHEMBL1614632 |
| ADMET |
Vdss |
= |
1.0 |
L.kg-1 |
Volume of distribution at steady state in human after iv administration |
CHEMBL1614632 |
| ADMET |
MRT |
= |
3.7 |
hr |
Mean residence time in human after iv administration |
CHEMBL1614632 |
| ADMET |
T1/2 |
= |
3.7 |
hr |
Half life in human after iv administration |
CHEMBL1614632 |
| ADMET |
CL |
= |
4.6 |
mL.min-1.kg-1 |
Clearance in human after iv administration |
CHEMBL1614632 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1900.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast assessed as inhibition of viral replication after 10 days by plaque reduction assay |
CHEMBL1629610 |
| HFF |
CC50 |
= |
550000.0 |
nM |
Cytotoxicity against human foreskin fibroblast after 5 days by MTT assay |
CHEMBL1629610 |
| Unchecked |
Ratio CC50/EC50 |
= |
289.0 |
|
Selectivity index, ratio of CC50 for Human foreskin fibroblast to EC50 for Human cytomegalovirus AD169 |
CHEMBL1629610 |
| Vaccinia virus |
EC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Human herpesvirus 2 strain G |
EC50 |
= |
0.03 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
0.03 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against human HEL cells assessed as altered cell morphology |
CHEMBL1629526 |
| Feline coronavirus |
EC50 |
= |
1.7 |
ug.mL-1 |
Antiviral activity against Feline coronavirus infected in cat CRFK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Felid herpesvirus 1 |
EC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Feline herpesvirus 1 infected in cat CRFK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| ADMET |
CC50 |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against cat CRFK cells assessed as cell viability by MTS assay |
CHEMBL1629526 |
| Vesicular stomatitis virus |
EC50 |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
58.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| HEL |
CC50 |
= |
164000.0 |
nM |
Cytotoxicity against human HEL cells after 3 days |
CHEMBL1649078 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against human HEL cells after 3 days |
CHEMBL1649078 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
80.0 |
nM |
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days |
CHEMBL1649078 |
| Human herpesvirus 2 strain G |
EC50 |
= |
50.0 |
nM |
Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days |
CHEMBL1649078 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days |
CHEMBL1649078 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days |
CHEMBL1649078 |
| Human herpesvirus 5 |
EC50 |
= |
5200.0 |
nM |
Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days |
CHEMBL1649078 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
3300.0 |
nM |
Antiviral activity against human cytomegalovirus AD169 infected in HFF after 8 to 10 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 5 |
EC50 |
= |
44000.0 |
nM |
Antiviral activity against human cytomegalovirus RC314 harboring UL97 K355M mutant gene infected in HFF after 8 to 10 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 5 |
EC50 |
= |
53000.0 |
nM |
Antiviral activity against human cytomegalovirus C8914-6 harboring UL97 I244V, L595F and UL54 L501F mutant gene infected in HFF after 8 to 10 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 5 |
EC50 |
= |
230000.0 |
nM |
Antiviral activity against human cytomegalovirus 759D100 harboring deletion mutation in UL97 gene and UL54 A987G mutant gene infected in HFF after 8 to 10 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 5 |
EC50 |
= |
15000.0 |
nM |
Antiviral activity against human cytomegalovirus 1117 harboring UL54 K513N mutant gene infected in HFF after 8 to 10 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 5 |
EC50 |
= |
7200.0 |
nM |
Antiviral activity against human cytomegalovirus VR4955 harboring UL54 T700A mutant gene infected in HFF after 8 to 10 days by plaque reduction assay |
CHEMBL1649277 |
| Human herpesvirus 5 |
EC50 |
= |
9800.0 |
nM |
Antiviral activity against human cytomegalovirus PFAB300 harboring UL54 L724V mutant gene infected in HFF after 8 to 10 days by plaque reduction assay |
CHEMBL1649277 |
| ADMET |
log10(%HIA +10) |
= |
1.134 |
|
Drug absorption in human assessed as human intestinal absorption rate |
CHEMBL1649380 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
10.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| Human herpesvirus 2 strain G |
EC50 |
= |
40.0 |
nM |
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
100.0 |
nM |
Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells after 3 days by coulter counter analysis |
CHEMBL1667805 |
| HEL |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells after 3 days by coulter counter analysis |
CHEMBL1667805 |
| Human herpesvirus 5 |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days |
CHEMBL1671855 |
| Guinea pig cytomegalovirus |
EC50 |
= |
25900.0 |
nM |
Antiviral activity against Guinea pig cytomegalovirus (strain 22122; ATCC VR-682) infected in guinea pig lung fibroblast after 6 to 7 days by plaque reduction assay |
CHEMBL1671855 |
| Human herpesvirus 5 |
EC50 |
= |
1400.0 |
nM |
Antiviral activity against Human cytomegalovirus Towne infected in human HFL after 10 to 12 days by plaque reduction assay |
CHEMBL1671855 |
| NON-PROTEIN TARGET |
EC50 |
= |
5700.0 |
nM |
Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay |
CHEMBL1671855 |
| Homo sapiens |
CL |
= |
7.49 |
L/hr |
Clearance in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by final population pharmacokinetic model |
CHEMBL1671675 |
| Homo sapiens |
Vd |
= |
31.9 |
l |
Central volume of distribution in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by final population pharmacokinetic model |
CHEMBL1671675 |
| Homo sapiens |
CL |
= |
10.2 |
L/hr |
Intercompartmental clearance between central and peripheral compartments in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by final population pharmacokinetic model |
CHEMBL1671675 |
| Homo sapiens |
Vd |
= |
32.0 |
l |
Peripheral volume of distribution in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by final population pharmacokinetic model |
CHEMBL1671675 |
| Homo sapiens |
Ka |
= |
0.895 |
/hr |
Drug absorption in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus assessed as first-order absorption rate constant at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function |
CHEMBL1671675 |
| Homo sapiens |
F |
= |
0.825 |
% |
Bioavailability in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by final population pharmacokinetic model |
CHEMBL1671675 |
| Homo sapiens |
F |
= |
0.76 |
% |
Bioavailability in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by basal population pharmacokinetic model |
CHEMBL1671675 |
| Homo sapiens |
Ka |
= |
0.971 |
/hr |
Drug absorption in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus assessed as first-order absorption rate constant at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by basal population pharmacokinetic model |
CHEMBL1671675 |
| Homo sapiens |
Vd |
= |
31.1 |
l |
Peripheral volume of distribution in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by basal population pharmacokinetic model |
CHEMBL1671675 |
| Homo sapiens |
CL |
= |
9.65 |
L/hr |
Intercompartmental clearance between central and peripheral compartments in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by basal population pharmacokinetic model |
CHEMBL1671675 |
| Homo sapiens |
Vd |
= |
32.0 |
l |
Central volume of distribution in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by basal population pharmacokinetic model |
CHEMBL1671675 |
| Homo sapiens |
CL |
= |
6.34 |
L/hr |
Clearance in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by basal population pharmacokinetic model |
CHEMBL1671675 |
| Human herpesvirus 5 |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against human cytomegalovirus infected in HELF assessed as decrease in plaque formation after 7 days by microscopy |
CHEMBL1671794 |
| ADMET |
MCC |
>= |
1575000.0 |
nM |
Cytotoxicity against HELF cells assessed as after 3 days by Coulter counting analysis |
CHEMBL1671794 |
| ADMET |
CC50 |
= |
580000.0 |
nM |
Cytotoxicity against HELF cells assessed as after 3 days by Coulter counting analysis |
CHEMBL1671794 |
| Bacillus anthracis |
IC50 |
|
|
|
Inhibition of inosine/L-alanine-induced Bacillus anthracis Sterne 34F2 spore germination pretreated for 15 mins before inosine/L-alanine challenge |
CHEMBL1687814 |
| Bacillus anthracis |
IC50 |
|
|
|
Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining after 3 hrs measured every hours for up to 7 hrs |
CHEMBL1687814 |
| J774.A1 |
Activity |
|
|
|
Cytotoxicity against mouse J774A1 cells |
CHEMBL1687814 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans |
CHEMBL1697731 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents |
CHEMBL1697731 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents |
CHEMBL1697731 |
| Hepatotoxicity |
Composite Activity - Score |
|
|
|
FDA HLAED, liver enzyme composite activity |
CHEMBL1697781 |
| Hepatotoxicity |
Composite Activity - Marginal |
= |
0.0 |
|
FDA HLAED, liver enzyme composite activity |
CHEMBL1697781 |
| Hepatotoxicity |
Composite Activity - Active |
= |
1.0 |
|
FDA HLAED, liver enzyme composite activity |
CHEMBL1697781 |
| Hepatotoxicity |
Alkaline Phosphatase Increase - Activity Score |
|
|
|
FDA HLAED, alkaline phosphatase increase |
CHEMBL1697781 |
| Hepatotoxicity |
Alkaline Phosphatase Increase - Number of Reports |
>= |
4.0 |
|
FDA HLAED, alkaline phosphatase increase |
CHEMBL1697781 |
| Hepatotoxicity |
Alkaline Phosphatase Increase - Index Value |
= |
4.2 |
|
FDA HLAED, alkaline phosphatase increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGOT Increase - Activity Score |
|
|
|
FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGOT Increase - Index Value |
= |
2.7 |
|
FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGOT Increase - Number of Reports |
>= |
4.0 |
|
FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGPT Increase - Activity Score |
|
|
|
FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGPT Increase - Index Value |
= |
2.3 |
|
FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGPT Increase - Number of Reports |
>= |
4.0 |
|
FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
LDH Increase - Activity Score |
|
|
|
FDA HLAED, lactate dehydrogenase (LDH) increase |
CHEMBL1697781 |
| Hepatotoxicity |
LDH Increase - Index Value |
= |
1.9 |
|
FDA HLAED, lactate dehydrogenase (LDH) increase |
CHEMBL1697781 |
| Hepatotoxicity |
LDH Increase - Number of Reports |
>= |
4.0 |
|
FDA HLAED, lactate dehydrogenase (LDH) increase |
CHEMBL1697781 |
| Hepatotoxicity |
GGT Increase - Activity Score |
|
|
|
FDA HLAED, gamma-glutamyl transferase (GGT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
GGT Increase - Index Value |
= |
0.8 |
|
FDA HLAED, gamma-glutamyl transferase (GGT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
GGT Increase - Number of Reports |
< |
4.0 |
|
FDA HLAED, gamma-glutamyl transferase (GGT) increase |
CHEMBL1697781 |
| Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 |
Potency |
|
22.4 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] |
CHEMBL1201862 |
| Cytochrome P450 2C9 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 2C9 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 3A4 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 2C19 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 2D6 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 1A2 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 3A4 |
AC50 |
= |
25118.86 |
nM |
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 2C19 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 1A2 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 2D6 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Caco-2 |
logPapp |
= |
-6.32 |
|
Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis |
CHEMBL1764994 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against Varicella-zoster virus Ellen infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| Human herpesvirus 3 |
EC90 |
|
|
|
Antiviral activity against Varicella-zoster virus Ellen infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| Human herpesvirus 5 strain AD169 |
EC90 |
|
|
|
Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| HFF |
CC50 |
|
|
|
Cytotoxicity against human HFF cells infected with Varicella-zoster virus Ellen assessed as viable cells by neutral red uptake assay |
CHEMBL1773001 |
| Unchecked |
Selectivity Index |
|
|
|
Selectivity index, ratio of CC50 for human HFF cells infected with Hepatitis C virus to EC50 for Varicella-zoster virus Ellen |
CHEMBL1773001 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| Vaccinia virus Copenhagen |
EC50 |
|
|
|
Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| NON-PROTEIN TARGET |
EC90 |
|
|
|
Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| Vaccinia virus Copenhagen |
EC90 |
|
|
|
Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| HFF |
CC50 |
|
|
|
Cytotoxicity against human HFF cells infected with Cowpox virus (Brighton Red) assessed as viable cells by neutral red uptake assay |
CHEMBL1773001 |
| Unchecked |
Selectivity Index |
|
|
|
Selectivity index, ratio of CC50 for human HFF cells infected with Cowpox virus (Brighton Red) to EC50 for Cowpox virus (Brighton Red) |
CHEMBL1773001 |
| Unchecked |
Selectivity Index |
> |
2500.0 |
|
Selectivity index, ratio of CC50 for human HFF cells infected with Hepatitis C virus to EC50 for Human cytomegalovirus AD169 |
CHEMBL1773001 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HFF cells infected with Human cytomegalovirus AD169 assessed as viable cells by neutral red uptake assay |
CHEMBL1773001 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
40.0 |
nM |
Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay |
CHEMBL1773001 |
| Human herpesvirus 5 |
IC50 |
= |
3000.0 |
nM |
Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days |
CHEMBL1799947 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against Varicella-zoster virus YS expressing thymidine kinase assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against Varicella-zoster virus strain OKA expressing thymidine kinase assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07/1 assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase-deficient Varicella-zoster virus YS/R assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
17.0 |
nM |
Antiviral activity against Herpes simplex virus 1 strain KOS assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 2 strain G |
EC50 |
= |
23.0 |
nM |
Antiviral activity against Herpes simplex virus 2 strain G assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
120.0 |
nM |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 strain KOS assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
5900.0 |
nM |
Antiviral activity against Human cytomegalovirus strain AD169 assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Human herpesvirus 5 |
EC50 |
= |
5100.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus Lederle assessed as reduction of virus induced cytopathicity by cell based assay |
CHEMBL1806434 |
| HEL |
MCC |
> |
394000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration of cell morphology after 3 days by microscopic analysis |
CHEMBL1806434 |
| HEL |
CC50 |
= |
543000.0 |
nM |
Cytotoxicity against human HEL cells after 3 days by coulter counter |
CHEMBL1806434 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration of normal cell morphology by microscopic analysis |
CHEMBL1806488 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis |
CHEMBL1806488 |
| Human herpesvirus 2 strain G |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis |
CHEMBL1806488 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
800.0 |
nM |
Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis |
CHEMBL1806488 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis |
CHEMBL1806488 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
15700.0 |
nM |
Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human herpesvirus 2 strain G |
EC50 |
= |
27.0 |
nM |
Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
6000.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human herpesvirus 5 |
EC50 |
= |
6540.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Felid herpesvirus 1 |
EC50 |
= |
8100.0 |
nM |
Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| HEL |
MCC |
> |
392000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration of cell morphology after 3 days by microscopy |
CHEMBL1811861 |
| HEL |
CC50 |
= |
435000.0 |
nM |
Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter |
CHEMBL1811861 |
| ADMET |
CC50 |
> |
394000.0 |
nM |
Cytotoxicity against cat CRFK cells assessed as growth inhibition after 3 days by coulter counter |
CHEMBL1811861 |
| DNA polymerase iota |
Potency |
|
39810.7 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] |
CHEMBL1201862 |
| Thioredoxin reductase 1, cytoplasmic |
Potency |
|
7079.5 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] |
CHEMBL1201862 |
| Unchecked |
Potency |
|
125.9 |
nM |
PUBCHEM_BIOASSAY: qHTS for inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249, AID540278] |
CHEMBL1201862 |
| Acetylcholinesterase |
IC50 |
|
|
|
DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) |
CHEMBL1909046 |
| Acetylcholinesterase |
Ki |
|
|
|
DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) |
CHEMBL1909046 |
| Adenosine A1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) |
CHEMBL1909046 |
| Adenosine A1 receptor |
Ki |
|
|
|
DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) |
CHEMBL1909046 |
| Adenosine A2a receptor |
IC50 |
|
|
|
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) |
CHEMBL1909046 |
| Adenosine A2a receptor |
Ki |
|
|
|
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) |
CHEMBL1909046 |
| Adenosine A3 receptor |
IC50 |
|
|
|
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) |
CHEMBL1909046 |
| Adenosine A3 receptor |
Ki |
|
|
|
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine) |
CHEMBL1909046 |
| Alpha-1a adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1a adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1b adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1b adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1d adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1d adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-2a adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) |
CHEMBL1909046 |
| Alpha-2a adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) |
CHEMBL1909046 |
| Alpha-2b adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) |
CHEMBL1909046 |
| Alpha-2b adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) |
CHEMBL1909046 |
| Alpha-2c adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) |
CHEMBL1909046 |
| Alpha-2c adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) |
CHEMBL1909046 |
| Beta-1 adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Beta-1 adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Beta-2 adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177) |
CHEMBL1909046 |
| Beta-2 adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177) |
CHEMBL1909046 |
| Beta-3 adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Beta-3 adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Norepinephrine transporter |
IC50 |
|
|
|
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) |
CHEMBL1909046 |
| Norepinephrine transporter |
Ki |
|
|
|
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) |
CHEMBL1909046 |
| Aldose reductase |
IC50 |
|
|
|
DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) |
CHEMBL1909046 |
| Aldose reductase |
Ki |
|
|
|
DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) |
CHEMBL1909046 |
| Angiotensin II type 2 (AT-2) receptor |
IC50 |
|
|
|
DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) |
CHEMBL1909046 |
| Angiotensin II type 2 (AT-2) receptor |
Ki |
|
|
|
DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin) |
CHEMBL1909046 |
| Bradykinin B2 receptor |
IC50 |
|
|
|
DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) |
CHEMBL1909046 |
| Bradykinin B2 receptor |
Ki |
|
|
|
DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) |
CHEMBL1909046 |
| Calcitonin receptor |
IC50 |
|
|
|
DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)) |
CHEMBL1909046 |
| Calcitonin receptor |
Ki |
|
|
|
DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888)) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888)) |
CHEMBL1909046 |
| Cannabinoid CB1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) |
CHEMBL1909046 |
| Cannabinoid CB1 receptor |
Ki |
|
|
|
DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) |
CHEMBL1909046 |
| Carbonic anhydrase II |
IC50 |
|
|
|
DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)) |
CHEMBL1909046 |
| Carbonic anhydrase II |
Ki |
|
|
|
DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)) |
CHEMBL1909046 |
| C-C chemokine receptor type 2 |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) |
CHEMBL1909046 |
| C-C chemokine receptor type 2 |
Ki |
|
|
|
DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) |
CHEMBL1909046 |
| C-C chemokine receptor type 4 |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) |
CHEMBL1909046 |
| C-C chemokine receptor type 4 |
Ki |
|
|
|
DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) |
CHEMBL1909046 |
| C-C chemokine receptor type 5 |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) |
CHEMBL1909046 |
| C-C chemokine receptor type 5 |
Ki |
|
|
|
DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) |
CHEMBL1909046 |
| Interleukin-8 receptor A |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CXCR1 (IL-8A) |
CHEMBL1909046 |
| Interleukin-8 receptor A |
Ki |
|
|
|
DRUGMATRIX: Chemokine CXCR1 (IL-8A) |
CHEMBL1909046 |
| Interleukin-8 receptor B |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) |
CHEMBL1909046 |
| Interleukin-8 receptor B |
Ki |
|
|
|
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) |
CHEMBL1909046 |
| Cholecystokinin A receptor |
IC50 |
|
|
|
DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) |
CHEMBL1909046 |
| Cholecystokinin A receptor |
Ki |
|
|
|
DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) |
CHEMBL1909046 |
| Cyclooxygenase-1 |
IC50 |
|
|
|
DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) |
CHEMBL1909046 |
| Cyclooxygenase-1 |
Ki |
|
|
|
DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) |
CHEMBL1909046 |
| Cyclooxygenase-2 |
IC50 |
|
|
|
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) |
CHEMBL1909046 |
| Cyclooxygenase-2 |
Ki |
|
|
|
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) |
CHEMBL1909046 |
| Cytochrome P450 1A2 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 1A2 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2A6 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2A6 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2C19 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2C19 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2C9 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2C9 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2D6 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2D6 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2E1 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2E1 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 3A4 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) |
CHEMBL1909046 |
| Cytochrome P450 3A4 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) |
CHEMBL1909046 |
| Dopamine D1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) |
CHEMBL1909046 |
| Dopamine D1 receptor |
Ki |
|
|
|
DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) |
CHEMBL1909046 |
| Dopamine D2 receptor |
IC50 |
|
|
|
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D2 receptor |
Ki |
|
|
|
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D3 receptor |
IC50 |
|
|
|
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D3 receptor |
Ki |
|
|
|
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D4 receptor |
IC50 |
|
|
|
DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D4 receptor |
Ki |
|
|
|
DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine transporter |
IC50 |
|
|
|
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) |
CHEMBL1909046 |
| Dopamine transporter |
Ki |
|
|
|
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) |
CHEMBL1909046 |
| Endothelin receptor ET-A |
IC50 |
|
|
|
DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) |
CHEMBL1909046 |
| Endothelin receptor ET-A |
Ki |
|
|
|
DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) |
CHEMBL1909046 |
| Estrogen receptor alpha |
IC50 |
|
|
|
DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) |
CHEMBL1909046 |
| Estrogen receptor alpha |
Ki |
|
|
|
DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) |
CHEMBL1909046 |
| Estrogen receptor beta |
IC50 |
|
|
|
DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) |
CHEMBL1909046 |
| Estrogen receptor beta |
Ki |
|
|
|
DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB) |
CHEMBL1909046 |
| Glucocorticoid receptor |
IC50 |
|
|
|
DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) |
CHEMBL1909046 |
| Glucocorticoid receptor |
Ki |
|
|
|
DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP) |
CHEMBL1909046 |
| Glycine receptor |
IC50 |
|
|
|
DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) |
CHEMBL1909046 |
| Glycine receptor |
Ki |
|
|
|
DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) |
CHEMBL1909046 |
| Histamine H1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) |
CHEMBL1909046 |
| Histamine H1 receptor |
Ki |
|
|
|
DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) |
CHEMBL1909046 |
| Histamine H2 receptor |
IC50 |
|
|
|
DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) |
CHEMBL1909046 |
| Histamine H2 receptor |
Ki |
|
|
|
DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) |
CHEMBL1909046 |
| HMG-CoA reductase |
IC50 |
|
|
|
DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA) |
CHEMBL1909046 |
| HMG-CoA reductase |
Ki |
|
|
|
DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan) |
CHEMBL1909046 |
| Insulin receptor |
IC50 |
|
|
|
DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin) |
CHEMBL1909046 |
| Insulin receptor |
Ki |
|
|
|
DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4) |
CHEMBL1909046 |
| Leukotriene C4 synthase |
IC50 |
|
|
|
DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) |
CHEMBL1909046 |
| Leukotriene C4 synthase |
Ki |
|
|
|
DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) |
CHEMBL1909046 |
| Cysteinyl leukotriene receptor 1 |
IC50 |
|
|
|
DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) |
CHEMBL1909046 |
| Cysteinyl leukotriene receptor 1 |
Ki |
|
|
|
DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) |
CHEMBL1909046 |
| Arachidonate 15-lipoxygenase |
IC50 |
|
|
|
DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) |
CHEMBL1909046 |
| Arachidonate 15-lipoxygenase |
Ki |
|
|
|
DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) |
CHEMBL1909046 |
| Melanocortin receptor 3 |
IC50 |
|
|
|
DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 3 |
Ki |
|
|
|
DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 4 |
IC50 |
|
|
|
DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 4 |
Ki |
|
|
|
DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 5 |
IC50 |
|
|
|
DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 5 |
Ki |
|
|
|
DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Monoamine oxidase A |
IC50 |
|
|
|
DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) |
CHEMBL1909046 |
| Monoamine oxidase A |
Ki |
|
|
|
DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M1 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M1 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M2 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M2 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M3 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M3 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M4 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M4 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M5 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M5 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Neuropeptide Y receptor type 1 |
IC50 |
|
|
|
DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) |
CHEMBL1909046 |
| Neuropeptide Y receptor type 1 |
Ki |
|
|
|
DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) |
CHEMBL1909046 |
| Neuropeptide Y receptor type 2 |
IC50 |
|
|
|
DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) |
CHEMBL1909046 |
| Neuropeptide Y receptor type 2 |
Ki |
|
|
|
DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) |
CHEMBL1909046 |
| Nitric-oxide synthase, brain |
IC50 |
|
|
|
DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) |
CHEMBL1909046 |
| Nitric-oxide synthase, brain |
Ki |
|
|
|
DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) |
CHEMBL1909046 |
| Nitric oxide synthase, inducible |
IC50 |
|
|
|
DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine) |
CHEMBL1909046 |
| Nitric oxide synthase, inducible |
Ki |
|
|
|
DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine) |
CHEMBL1909046 |
| Delta opioid receptor |
IC50 |
|
|
|
DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) |
CHEMBL1909046 |
| Delta opioid receptor |
Ki |
|
|
|
DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) |
CHEMBL1909046 |
| Kappa opioid receptor |
IC50 |
|
|
|
DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) |
CHEMBL1909046 |
| Kappa opioid receptor |
Ki |
|
|
|
DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) |
CHEMBL1909046 |
| Mu opioid receptor |
IC50 |
|
|
|
DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) |
CHEMBL1909046 |
| Mu opioid receptor |
Ki |
|
|
|
DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP) |
CHEMBL1909046 |
| Phosphodiesterase 5A |
IC50 |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) |
CHEMBL1909046 |
| Phosphodiesterase 5A |
Ki |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) |
CHEMBL1909046 |
| Platelet activating factor receptor |
IC50 |
|
|
|
DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) |
CHEMBL1909046 |
| Platelet activating factor receptor |
Ki |
|
|
|
DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) |
CHEMBL1909046 |
| HERG |
IC50 |
|
|
|
DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) |
CHEMBL1909046 |
| HERG |
Ki |
|
|
|
DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) |
CHEMBL1909046 |
| Progesterone receptor |
IC50 |
|
|
|
DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) |
CHEMBL1909046 |
| Progesterone receptor |
Ki |
|
|
|
DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) |
CHEMBL1909046 |
| Angiotensin-converting enzyme |
IC50 |
|
|
|
DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) |
CHEMBL1909046 |
| Angiotensin-converting enzyme |
Ki |
|
|
|
DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) |
CHEMBL1909046 |
| Caspase-1 |
IC50 |
|
|
|
DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) |
CHEMBL1909046 |
| Caspase-1 |
Ki |
|
|
|
DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) |
CHEMBL1909046 |
| Cathepsin G |
IC50 |
|
|
|
DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC) |
CHEMBL1909046 |
| Cathepsin G |
Ki |
|
|
|
DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC) |
CHEMBL1909046 |
| Leukocyte elastase |
IC50 |
|
|
|
DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) |
CHEMBL1909046 |
| Leukocyte elastase |
Ki |
|
|
|
DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) |
CHEMBL1909046 |
| Matrix metalloproteinase-1 |
IC50 |
|
|
|
DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) |
CHEMBL1909046 |
| Matrix metalloproteinase-1 |
Ki |
|
|
|
DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) |
CHEMBL1909046 |
| Matrix metalloproteinase 9 |
IC50 |
|
|
|
DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) |
CHEMBL1909046 |
| Matrix metalloproteinase 9 |
Ki |
|
|
|
DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) |
CHEMBL1909046 |
| Protein kinase C alpha |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone) |
CHEMBL1909046 |
| Protein kinase C alpha |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone) |
CHEMBL1909046 |
| MAP kinase ERK1 |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase ERK1 |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase ERK2 |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase ERK2 |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase p38 alpha |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase p38 alpha |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP) |
CHEMBL1909046 |
| Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP) |
CHEMBL1909046 |
| Epidermal growth factor receptor erbB1 |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Epidermal growth factor receptor erbB1 |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Tyrosine-protein kinase FYN |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Tyrosine-protein kinase FYN |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Receptor protein-tyrosine kinase erbB-2 |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Receptor protein-tyrosine kinase erbB-2 |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Tyrosine-protein kinase LCK |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Tyrosine-protein kinase LCK |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Leukocyte common antigen |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP) |
CHEMBL1909046 |
| Leukocyte common antigen |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) |
CHEMBL1909046 |
| Serotonin 1a (5-HT1a) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) |
CHEMBL1909046 |
| Serotonin 1a (5-HT1a) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) |
CHEMBL1909046 |
| Serotonin 1b (5-HT1b) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Serotonin 1b (5-HT1b) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Serotonin 2a (5-HT2a) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) |
CHEMBL1909046 |
| Serotonin 2a (5-HT2a) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) |
CHEMBL1909046 |
| Serotonin 2b (5-HT2b) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) |
CHEMBL1909046 |
| Serotonin 2b (5-HT2b) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) |
CHEMBL1909046 |
| Serotonin 2c (5-HT2c) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) |
CHEMBL1909046 |
| Serotonin 2c (5-HT2c) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630) |
CHEMBL1909046 |
| Serotonin 4 (5-HT4) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) |
CHEMBL1909046 |
| Serotonin 4 (5-HT4) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) |
CHEMBL1909046 |
| Serotonin 6 (5-HT6) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) |
CHEMBL1909046 |
| Serotonin 6 (5-HT6) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) |
CHEMBL1909046 |
| Serotonin transporter |
IC50 |
|
|
|
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) |
CHEMBL1909046 |
| Serotonin transporter |
Ki |
|
|
|
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) |
CHEMBL1909046 |
| Sigma opioid receptor |
IC50 |
|
|
|
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) |
CHEMBL1909046 |
| Sigma opioid receptor |
Ki |
|
|
|
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin) |
CHEMBL1909046 |
| Neurokinin 1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) |
CHEMBL1909046 |
| Neurokinin 1 receptor |
Ki |
|
|
|
DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) |
CHEMBL1909046 |
| Neurokinin 2 receptor |
IC50 |
|
|
|
DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) |
CHEMBL1909046 |
| Neurokinin 2 receptor |
Ki |
|
|
|
DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) |
CHEMBL1909046 |
| Androgen Receptor |
IC50 |
|
|
|
DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) |
CHEMBL1909046 |
| Androgen Receptor |
Ki |
|
|
|
DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) |
CHEMBL1909046 |
| Thromboxane-A synthase |
IC50 |
|
|
|
DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) |
CHEMBL1909046 |
| Thromboxane-A synthase |
Ki |
|
|
|
DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha) |
CHEMBL1909046 |
| Vascular endothelial growth factor receptor 1 |
IC50 |
|
|
|
DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF) |
CHEMBL1909046 |
| Vascular endothelial growth factor receptor 1 |
Ki |
|
|
|
DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF) |
CHEMBL1909046 |
| Vasoactive intestinal polypeptide receptor 1 |
IC50 |
|
|
|
DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) |
CHEMBL1909046 |
| Vasoactive intestinal polypeptide receptor 1 |
Ki |
|
|
|
DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) |
CHEMBL1909046 |
| Vasopressin V1a receptor |
IC50 |
|
|
|
DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) |
CHEMBL1909046 |
| Vasopressin V1a receptor |
Ki |
|
|
|
DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) |
CHEMBL1909046 |
| Hepatotoxicity |
LTKB_BD DILI severity score |
= |
7.0 |
|
FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI |
CHEMBL1909281 |
| Hepatotoxicity |
HepSE_bilirubinemia |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_cholecystitis |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_cholelithiasis |
= |
1.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_cirrhosis |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_elevated liver function tests |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_hepatic failure |
= |
1.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_hepatic necrosis |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_hepatitis |
= |
1.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_hepatomegaly |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_jaundice |
= |
1.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_liver disease |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_liver fatty |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_liver function tests abnormal |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_Combined Scores |
= |
4.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score |
CHEMBL1909294 |
| Human herpesvirus 1 strain KOS |
Activity |
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 2 strain G |
Activity |
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 1 strain KOS |
Activity |
|
|
|
Antiviral activity against thymidine kinase-deficient acv-resistant Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Vaccinia virus |
Activity |
|
|
|
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Vesicular stomatitis virus |
Activity |
|
|
|
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 5 strain AD169 |
Activity |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 5 |
Activity |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| NON-PROTEIN TARGET |
Activity |
|
|
|
Antiviral activity against thymidine kinase-positive Varicella Zoster virus Oka infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 3 |
Activity |
|
|
|
Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07/1 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human parainfluenza virus 3 |
Activity |
|
|
|
Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Mammalian orthoreovirus 1 |
Activity |
|
|
|
Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Sindbis virus |
Activity |
|
|
|
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human coxsackievirus B4 |
Activity |
|
|
|
Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Punta Toro virus |
Activity |
|
|
|
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Vesicular stomatitis virus |
Activity |
|
|
|
Antiviral activity against Vesicular stomatitis virus infected in human Hela cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human coxsackievirus B4 |
Activity |
|
|
|
Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Influenza A virus |
Activity |
|
|
|
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Influenza A virus |
Activity |
|
|
|
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Influenza B virus |
Activity |
|
|
|
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Felid herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against Felid herpesvirus 1 infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Feline coronavirus |
Activity |
|
|
|
Antiviral activity against Feline coronavirus infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human immunodeficiency virus 1 |
Activity |
|
|
|
Antiviral activity against Human immunodeficiency virus 1 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis |
CHEMBL1926651 |
| Human immunodeficiency virus 2 |
Activity |
|
|
|
Antiviral activity against Human immunodeficiency virus 2 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis |
CHEMBL1926651 |
| NON-PROTEIN TARGET |
IC50 |
|
|
|
Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay |
CHEMBL1926544 |
| Vaccinia virus Copenhagen |
IC50 |
|
|
|
Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay |
CHEMBL1926544 |
| Human herpesvirus 1 strain KOS |
IC50 |
|
|
|
Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay |
CHEMBL1926544 |
| Human herpesvirus 5 |
IC50 |
= |
140.0 |
nM |
Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay |
CHEMBL1926544 |
| KB |
IC50 |
|
|
|
Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis |
CHEMBL1926544 |
| HFF |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay |
CHEMBL1926544 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
10.0 |
nM |
Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity |
CHEMBL2010784 |
| Human herpesvirus 2 strain G |
EC50 |
= |
10.0 |
nM |
Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity |
CHEMBL2010784 |
| Vaccinia virus |
EC50 |
= |
100000.0 |
nM |
Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity |
CHEMBL2010784 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against ACV-resistant TK-deficient HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity |
CHEMBL2010784 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against human HEL cells assessed as changes in cell morphology by microscopy |
CHEMBL2010784 |
| Unchecked |
Ratio EC50 |
= |
100.0 |
|
Ratio of EC50 for ACV-resistant TK-deficient HSV-1 KOS to EC50 for wild type HIV-1 |
CHEMBL2010784 |
| Murine cytomegalovirus |
Activity |
= |
7.0 |
% |
Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mortality at 50 mg/kg, po qd for 5 days administered 24 hrs after viral infection (Rvb = 67%) |
CHEMBL2010769 |
| Murine cytomegalovirus |
Activity |
= |
20.0 |
% |
Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mortality at 16.7 mg/kg, po qd for 5 days administered 24 hrs after viral infection (Rvb = 67%) |
CHEMBL2010769 |
| Murine cytomegalovirus |
Activity |
= |
87.0 |
% |
Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mortality at 5.6 mg/kg, po qd for 5 days administered 24 hrs after viral infection (Rvb = 67%) |
CHEMBL2010769 |
| Murine cytomegalovirus |
Activity |
= |
20.0 |
% |
Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mortality at 50 mg/kg, po qd for 5 days administered 48 hrs after viral infection (Rvb = 100%) |
CHEMBL2010769 |
| Murine cytomegalovirus |
Activity |
= |
53.0 |
% |
Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mortality at 16.7 mg/kg, po qd for 5 days administered 48 hrs after viral infection (Rvb = 100%) |
CHEMBL2010769 |
| Murine cytomegalovirus |
Activity |
= |
93.0 |
% |
Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mortality at 5.6 mg/kg, po qd for 5 days administered 48 hrs after viral infection (Rvb = 100%) |
CHEMBL2010769 |
| Murine cytomegalovirus |
Activity |
= |
6.0 |
day |
Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mean day of death at 50 mg/kg, po qd for 5 days administered 24 hrs after viral infection (Rvb = 4.9 +/- 0.7 days) |
CHEMBL2010769 |
| Murine cytomegalovirus |
Activity |
= |
6.3 |
day |
Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mean day of death at 16.7 mg/kg, po qd for 5 days administered 24 hrs after viral infection (Rvb = 4.9 +/- 0.7 days) |
CHEMBL2010769 |
| Murine cytomegalovirus |
Activity |
= |
6.8 |
day |
Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mean day of death at 5.6 mg/kg, po qd for 5 days administered 24 hrs after viral infection (Rvb = 4.9 +/- 0.7 days) |
CHEMBL2010769 |
| Murine cytomegalovirus |
Activity |
= |
5.7 |
day |
Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mean day of death at 50 mg/kg, po qd for 5 days administered 48 hrs after viral infection (Rvb = 5.1 +/- 0.9 days) |
CHEMBL2010769 |
| Murine cytomegalovirus |
Activity |
= |
7.3 |
day |
Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mean day of death at 16.7 mg/kg, po qd for 5 days administered 48 hrs after viral infection (Rvb = 5.1 +/- 0.9 days) |
CHEMBL2010769 |
| Murine cytomegalovirus |
Activity |
= |
6.4 |
day |
Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mean day of death at 5.6 mg/kg, po qd for 5 days administered 48 hrs after viral infection (Rvb = 5.1 +/- 0.9 days) |
CHEMBL2010769 |
| Felid herpesvirus 1 |
EC50 |
= |
4100.0 |
nM |
Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect after 4 days by colorimetric formazan-based MTS assay |
CHEMBL2021854 |
| NON-PROTEIN TARGET |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against FIPV infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect after 4 days by colorimetric formazan-based MTS assay |
CHEMBL2021854 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against cat CRFK cells assessed as cell viability by colorimetric formazan-based MTS assay |
CHEMBL2021854 |
| HeLa |
CC50 |
= |
221800.0 |
nM |
Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay |
CHEMBL2021854 |
| Human herpesvirus 5 |
EC50 |
= |
1650.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days |
CHEMBL2021854 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
1650.0 |
nM |
Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days |
CHEMBL2021854 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against human HEL cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology |
CHEMBL2021854 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
100000.0 |
nM |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Human herpesvirus 2 strain G |
EC50 |
= |
30.0 |
nM |
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
20.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
7500.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity |
CHEMBL2034851 |
| Human herpesvirus 5 |
EC50 |
= |
7100.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity |
CHEMBL2034851 |
| HEL |
MCC |
> |
350000.0 |
nM |
Cytotoxicity against human HEL cells assessed as change in cell morphology by microscopic analysis |
CHEMBL2034851 |
| HEL |
CC50 |
= |
130000.0 |
nM |
Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter |
CHEMBL2034851 |
| Human herpesvirus 5 |
IC50 |
= |
2100.0 |
nM |
Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay |
CHEMBL2034823 |
| HFF |
CC50 |
> |
300000.0 |
nM |
Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining |
CHEMBL2034823 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase positive VZV YS infected in HEL cells by plaque formation assay |
CHEMBL2062419 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against thymidine kinase positive VZV OKa infected in HEL cells by plaque formation assay |
CHEMBL2062419 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase negative VZV 07/01 infected in HEL cells by plaque formation assay |
CHEMBL2062419 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase negative VZV YS/R infected in HEL cells by plaque formation assay |
CHEMBL2062419 |
| Human herpesvirus 1 |
EC50 |
= |
27.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay |
CHEMBL2062419 |
| Human herpesvirus 2 strain G |
EC50 |
= |
29.0 |
nM |
Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay |
CHEMBL2062419 |
| Human herpesvirus 1 |
EC50 |
= |
14700.0 |
nM |
Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay |
CHEMBL2062419 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
9100.0 |
nM |
Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay |
CHEMBL2062419 |
| Human herpesvirus 5 |
EC50 |
= |
5900.0 |
nM |
Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay |
CHEMBL2062419 |
| Felid herpesvirus 1 |
EC50 |
= |
1150.0 |
nM |
Antiviral activity against Feline herpesvirus infected in CRFK cells by viral CPE assay |
CHEMBL2062419 |
| Vaccinia virus |
EC50 |
>= |
93000.0 |
nM |
Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay |
CHEMBL2062419 |
| HEL |
MCC |
> |
394000.0 |
nM |
Cytotoxicity against HEL cells assessed as effect on cell morphology incubated for 3 days by microscopy |
CHEMBL2062419 |
| HEL |
CC50 |
= |
231000.0 |
nM |
Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay |
CHEMBL2062419 |
| Solute carrier family 22 member 6 |
Activity |
= |
87.1 |
% |
TP_TRANSPORTER: inhibition of PAH uptake (PAH: 5 uM, GCV: 1000 uM) in OAT1-expressing S2 cells |
CHEMBL2074052 |
| Solute carrier family 22 member 7 |
Activity |
= |
63.3 |
% |
TP_TRANSPORTER: inhibition of PGF2alpha uptake (PGF2alpha: 0.005 uM, GCV: 1000 uM) in OAT2-expressing S2 cells |
CHEMBL2074052 |
| Solute carrier family 22 member 8 |
Activity |
= |
74.3 |
% |
TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, GCV: 1000 uM) in OAT3-expressing S2 cells |
CHEMBL2074052 |
| Solute carrier family 22 member 1 |
Activity |
= |
88.3 |
% |
TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, GCV: 1000 uM) in OCT1-expressing S2 cells |
CHEMBL2074052 |
| Solute carrier family 22 member 1 |
Km |
= |
516200.0 |
nM |
TP_TRANSPORTER: uptake in OCT1-expressing S2 cells |
CHEMBL2074052 |
| Solute carrier family 22 member 6 |
Km |
= |
895500.0 |
nM |
TP_TRANSPORTER: uptake in OAT1-expressing S2 cells |
CHEMBL2074052 |
| ATP-dependent Clp protease proteolytic subunit |
Potency |
|
707.9 |
nM |
PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Geminin |
Potency |
|
3264.3 |
nM |
PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Felid herpesvirus 1 |
EC50 |
= |
1200.0 |
nM |
Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL2146385 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against CRFK cells after 3 days |
CHEMBL2146385 |
| HEL |
MCC |
> |
100000.0 |
nM |
Toxicity in HEL cells assessed as induction of cell morphology changes |
CHEMBL2203009 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
4000.0 |
nM |
Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| Human herpesvirus 2 strain G |
EC50 |
= |
13.0 |
nM |
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
15.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
6000.0 |
nM |
Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Human herpesvirus 2 strain G |
EC50 |
= |
80.0 |
nM |
Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
80.0 |
nM |
Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against Homo sapiens (human) HEL cells after 3 days by microscopic analysis |
CHEMBL3046360 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against HEL assessed as minimum concentration required to cause morphological changes |
CHEMBL3045401 |
| Human herpesvirus 5 |
EC50 |
= |
1.79 |
ug.mL-1 |
Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation |
CHEMBL3045401 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
2.68 |
ug.mL-1 |
Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation |
CHEMBL3045401 |
| HEL |
CC50 |
= |
60.5 |
ug.mL-1 |
Cytotoxicity against HEL |
CHEMBL3045401 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
12.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase-deficient, acylcovir-resistant Human herpesvirus 1 strain KOS infected in HEL cells |
CHEMBL3045159 |
| Vesicular stomatitis virus |
MIC |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected HEL cells |
CHEMBL3045159 |
| Vaccinia virus |
MIC |
> |
100.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected HEL cells |
CHEMBL3045159 |
| Human herpesvirus 2 strain G |
MIC |
= |
4.0 |
ug.mL-1 |
Antiviral activity against Human herpesvirus 2 strain G infected HEL cells |
CHEMBL3045159 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
0.48 |
ug.mL-1 |
Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells |
CHEMBL3045159 |
| HEL |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against Homo sapiens (human) HEL cells |
CHEMBL3045159 |
| Felid herpesvirus 1 |
EC50 |
= |
7300.0 |
nM |
Antiviral activity against Felid herpesvirus 1 infected cat CRFK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Feline infectious peritonitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Feline Infectious peritonitis virus infected cat CRFK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against Felis catus (cat) CRFK cells assessed as change in cellular morphology |
CHEMBL3045116 |
| Human herpesvirus 1 strain KOS |
EC50 |
>= |
20000.0 |
nM |
Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Human herpesvirus 2 strain G |
EC50 |
= |
70.0 |
nM |
Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against Homo sapiens (human) HEL cells assessed as change in cellular morphology |
CHEMBL3045116 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
90.0 |
nM |
Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Human herpesvirus 5 |
IC50 |
= |
5700.0 |
nM |
Antiviral activity against HCMV Davis |
CHEMBL2331304 |
| Human herpesvirus 5 strain AD169 |
IC50 |
= |
6300.0 |
nM |
Antiviral activity against HCMV AD169 |
CHEMBL2331304 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
2592.9 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
1013.7 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
5011.9 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
3548.1 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
1606.7 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
1299.5 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Cytomegalovirus |
EC50 |
= |
2700.0 |
nM |
Antiviral activity against Cytomegalovirus infected in HFF after 72 hrs by luciferase reporter gene assay |
CHEMBL2390864 |
| HEL |
MCC |
= |
394000.0 |
nM |
Cytotoxicity against HEL assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in cell morphology |
CHEMBL2396525 |
| HEL |
CC50 |
= |
200000.0 |
nM |
Cytotoxicity against HEL |
CHEMBL2396525 |
| Human herpesvirus 5 |
EC50 |
= |
8300.0 |
nM |
Antiviral actiivty against Human herpesvirus 5 Davis infected in HEL assessed as reduction of virus-induced plaque formation |
CHEMBL2396525 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
7000.0 |
nM |
Antiviral actiivty against Human herpesvirus 5 AD169 infected in HEL assessed as reduction of virus-induced plaque formation |
CHEMBL2396525 |
| Felid herpesvirus 1 |
EC50 |
= |
4100.0 |
nM |
Antiviral activity against feline herpesvirus infected in cat CRFK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay |
CHEMBL2417501 |
| Feline coronavirus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Feline coronavirus infected in cat CRFK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay |
CHEMBL2417501 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against cat CRFK cells |
CHEMBL2417501 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
4000.0 |
nM |
Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Human herpesvirus 2 strain G |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against human HEL cells |
CHEMBL2417501 |
| Cytomegalovirus |
EC50 |
= |
5980.0 |
nM |
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation |
CHEMBL2417501 |
| Cytomegalovirus |
EC50 |
= |
7870.0 |
nM |
Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation |
CHEMBL2417501 |
| HEL |
CC50 |
> |
350000.0 |
nM |
Cytotoxicity against human HEL cells after 3 days by Coulter counting method |
CHEMBL2417392 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
8200.0 |
nM |
Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after |
CHEMBL2417392 |
| Cytomegalovirus |
EC50 |
= |
3100.0 |
nM |
Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation |
CHEMBL2417481 |
| Human herpesvirus 2 strain G |
EC50 |
= |
900.0 |
nM |
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Felid herpesvirus 1 |
EC50 |
= |
900.0 |
nM |
Antiviral activity against Feline Herpes virus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay |
CHEMBL2417481 |
| Cytomegalovirus |
EC50 |
= |
380.0 |
nM |
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation |
CHEMBL2417481 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against human HEL cells assessed as morphological changes |
CHEMBL2417481 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Feline coronavirus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Feline coronavirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay |
CHEMBL2417481 |
| HeLa |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as morphological changes |
CHEMBL2417481 |
| ADMET |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against cat CRFK cells assessed as cell viability by MTS assay |
CHEMBL2417481 |
| Rattus norvegicus |
LD50 |
= |
80.0 |
mg.kg-1 |
Toxicity in Wistar albino rat |
CHEMBL2424645 |
| Unchecked |
Activity |
= |
60.11 |
% |
Immunomodulatory activity in human neutrophils assessed as increase in intracellular killing activity at 1000 ug/mL after 20 mins by NBT dye reduction assay relative to control |
CHEMBL2424645 |
| Unchecked |
Activity |
= |
58.23 |
% |
Immunomodulatory activity in human neutrophils assessed as increase in intracellular killing activity at 100 ug/mL after 20 mins by NBT dye reduction assay relative to control |
CHEMBL2424645 |
| Unchecked |
Activity |
= |
55.89 |
% |
Immunomodulatory activity in human neutrophils assessed as increase in intracellular killing activity at 40 ug/mL after 20 mins by NBT dye reduction assay relative to control |
CHEMBL2424645 |
| Unchecked |
Activity |
= |
53.21 |
% |
Immunomodulatory activity in human neutrophils assessed as increase in intracellular killing activity at 20 ug/mL after 20 mins by NBT dye reduction assay relative to control |
CHEMBL2424645 |
| Unchecked |
Activity |
= |
39.43 |
% |
Immunomodulatory activity in human neutrophils assessed as increase in intracellular killing activity at 10 ug/mL after 20 mins by NBT dye reduction assay relative to control |
CHEMBL2424645 |
| NON-PROTEIN TARGET |
Hepatotoxicity (moderate) |
= |
9.0 |
|
Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (moderate) |
= |
55.0 |
% |
Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (acute) |
= |
1.0 |
|
Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (acute) |
= |
0.0 |
% |
Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (cytolytic) |
= |
1.0 |
|
Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (choleostasis) |
= |
1.0 |
|
Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (severe hepatitis) |
= |
0.0 |
|
Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (chronic liver disease) |
= |
0.0 |
|
Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (cirrhosis) |
= |
0.0 |
|
Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (granulomatous hepatitis) |
= |
0.0 |
|
Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (association with vascular disease) |
= |
0.0 |
|
Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (steatosis) |
= |
0.0 |
|
Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (malignant tumour) |
= |
0.0 |
|
Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (benign tumour) |
= |
0.0 |
|
Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (animal toxicity known) |
|
|
|
Animal toxicity known. [column 'TOXIC' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (successful reintroduction) |
|
|
|
Presence of at least one case with successful reintroduction. [column 'REINT' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (comment) |
|
|
|
Comments (NB not yet translated). [column 'COMMENTAIRES' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (time to onset) |
|
|
|
Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (mechanism) |
|
|
|
Proposed mechanism(s) of liver damage. [column 'MEC' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Potency |
|
0.7 |
nM |
PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
|
595.2 |
nM |
PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Cerebroside-sulfatase |
Potency |
|
30.1 |
nM |
PubChem BioAssay. qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
|
3.8 |
nM |
PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2). (Class of assay: confirmatory) |
CHEMBL1201862 |
| DNA-(apurinic or apyrimidinic site) lyase |
Potency |
|
14125.4 |
nM |
PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
|
3.8 |
nM |
PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Trypanosoma brucei rhodesiense |
IC50 |
= |
251530.0 |
nM |
DNDI: HAT in Vitro, 72 hour |
CHEMBL3392926 |
| Trypanosoma cruzi |
IC50 |
= |
240170.0 |
nM |
DNDI: Chagas in Vitro, 96 hour |
CHEMBL3392926 |
| Leishmania donovani |
IC50 |
> |
391800.0 |
nM |
DNDI: Leish (axenic) in Vitro, 72 hour |
CHEMBL3392926 |
| Leishmania donovani |
IC50 |
> |
117540.0 |
nM |
DNDI: Leish (macro) in Vitro, 96 hour |
CHEMBL3392926 |
| Plasmodium falciparum |
IC50 |
> |
195900.0 |
nM |
DNDI: Malaria in Vitro, 72 hour |
CHEMBL3392926 |
| NON-PROTEIN TARGET |
IC50 |
= |
179440.0 |
nM |
DNDI: Cytotoxicity in Vitro, 72 hour, in rat skeletal myoblast cells |
CHEMBL3392926 |
| NON-PROTEIN TARGET |
IC50 |
> |
117540.0 |
nM |
DNDI: Cytotoxicity in Vitro, 96 hour, in mouse macrophages (infected-amastigotes) |
CHEMBL3392926 |
| ADMET |
Ratio |
= |
0.09 |
|
Ratio of unbound drug level in brain to plasma in Sprague-Dawley rat at 3 mg/kg, sc by LC-MS/MS analysis |
CHEMBL3526130 |
| ADMET |
Ratio |
= |
1.85 |
|
Ratio of unbound brain concentration to drug level in cerebrospinal fluid in Sprague-Dawley rat at 3 mg/kg, sc by LC-MS/MS analysis |
CHEMBL3526130 |
| Nucleic Acid |
Ratio |
= |
0.05 |
|
Ratio of drug level in cerebrospinal fluid to unbound plasma concentration in Sprague-Dawley rat at 3 mg/kg, sc by LC-MS/MS analysis |
CHEMBL3526130 |
| Nucleic Acid |
BPR |
= |
0.1 |
|
Ratio of drug level in brain to plasma in Sprague-Dawley rat at 3 mg/kg, sc by LC-MS/MS analysis |
CHEMBL3526130 |
| Brain |
AUC |
= |
182.0 |
ng.hr.mL-1 |
AUC(0 to infinity) in Sprague-Dawley rat brain at 3 mg/kg, sc by LC-MS/MS analysis |
CHEMBL3526130 |
| Brain |
AUC |
= |
170.0 |
ng.hr.mL-1 |
AUC(0 to 7 hrs) in Sprague-Dawley rat brain at 3 mg/kg, sc by LC-MS/MS analysis |
CHEMBL3526130 |
| Cerebrospinal fluid |
AUC |
= |
82.5 |
ng.hr.mL-1 |
AUC(0 to infinity) in Sprague-Dawley rat cerebrospinal fluid at 3 mg/kg, sc by LC-MS/MS analysis |
CHEMBL3526130 |
| Cerebrospinal fluid |
AUC |
= |
78.4 |
ng.hr.mL-1 |
AUC(0 to 7 hrs) in Sprague-Dawley rat cerebrospinal fluid at 3 mg/kg, sc by LC-MS/MS analysis |
CHEMBL3526130 |
| Plasma |
AUC |
= |
1720.0 |
ng.hr.mL-1 |
AUC(0 to infinity) in Sprague-Dawley rat plasma at 3 mg/kg, sc by LC-MS/MS analysis |
CHEMBL3526130 |
| Plasma |
AUC |
= |
1700.0 |
ng.hr.mL-1 |
AUC(0 to 7 hrs) in Sprague-Dawley rat plasma at 3 mg/kg, sc by LC-MS/MS analysis |
CHEMBL3526130 |
| Solute carrier family 22 member 7 |
FC |
= |
12.0 |
|
Drug transport in human OAT2 expressed in HEK Flp-In cells at 0.19 uM for 10 mins relative to control |
CHEMBL3526025 |
| Solute carrier family 22 member 6 |
Drug transport |
|
|
|
Drug transport in human OAT1 expressed in HEK Flp-In cells at 0.19 uM for 10 mins relative to control |
CHEMBL3526025 |
| Solute carrier family 22 member 8 |
Drug transport |
|
|
|
Drug transport in human OAT3 expressed in HEK Flp-In cells at 0.19 uM for 10 mins relative to control |
CHEMBL3526025 |
| POU domain, class 2, transcription factor 2 |
Drug transport |
|
|
|
Drug transport in human OCT2 expressed in HEK Flp-In cells at 0.19 uM for 10 mins relative to control |
CHEMBL3526025 |
| ADMET |
Drug transport |
|
|
|
Drug transport in human ENT in HEK cells in presence of 100 uM ENT inhibitor benzythioinosine |
CHEMBL3526025 |
| POU domain, class 2, transcription factor 2 |
Jmax |
= |
1838.0 |
pmol/min |
Drug transport in human OAT2 expressed in HEK Flp-In cells assessed as maximal rate of transport measured per mg of protein |
CHEMBL3526025 |
| POU domain, class 2, transcription factor 2 |
Km |
= |
264000.0 |
nM |
Drug transport in human OAT2 expressed in HEK Flp-In cells |
CHEMBL3526025 |
| POU domain, class 2, transcription factor 2 |
Ratio |
= |
7.0 |
uL/min |
Transport efficiency, ratio of maximal rate of transport to Km for drug transport in human OAT2 expressed in HEK Flp-In cells measured per mg of protein |
CHEMBL3526025 |
| Unchecked |
AC50 |
|
290.0 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
|
10000.0 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
0.2818 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
|
707.9 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
|
10000.0 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
10.0 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
10.0 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
19.95 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
0.7079 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
|
19952.6 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Cytomegalovirus |
EC50 |
= |
7100.0 |
nM |
Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL3585293 |
| Cytomegalovirus |
EC50 |
= |
6300.0 |
nM |
Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL3585293 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
500.0 |
nM |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL3585293 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
20.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL3585293 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against HEL cells assessed as alternation of cell morphology by microscopic analysis |
CHEMBL3585293 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL3585293 |
| Human herpesvirus 2 strain G |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL3585293 |
| Human herpesvirus 5 strain AD169 |
IC50 |
= |
2600.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 expressing GFP infected in HFF assessed as inhibition of viral replication after 7 days |
CHEMBL3600384 |
| Human herpesvirus 5 |
IC50 |
= |
3600.0 |
nM |
Antiviral activity against HCMV infected in HFF after 3 days by neutral red dye-based plaque reduction assay |
CHEMBL3603790 |
| HFF |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HFF |
CHEMBL3603790 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
13900.0 |
nM |
Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation |
CHEMBL3621200 |
| Human herpesvirus 5 |
EC50 |
= |
7800.0 |
nM |
Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation |
CHEMBL3621200 |
| HEL |
MCC |
> |
350000.0 |
nM |
Cytotoxicity against human cytomegalovirus infected HEL cells assessed as alteration of cell morphology incubated for 3 days by microscopy |
CHEMBL3621200 |
| HEL |
CC50 |
>= |
319000.0 |
nM |
Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method |
CHEMBL3621200 |
| HEL |
MCC |
> |
350000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration in cell morphology incubated for 3 days by microscopy |
CHEMBL3627667 |
| HEL |
CC50 |
= |
328500.0 |
nM |
Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days |
CHEMBL3627667 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
6120.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy |
CHEMBL3627667 |
| Human herpesvirus 5 |
EC50 |
= |
4720.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy |
CHEMBL3627667 |
| Human herpesvirus 2 |
EC50 |
= |
1400.0 |
nM |
Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay |
CHEMBL3632602 |
| Herpes simplex virus (type 1 / strain F) |
EC50 |
= |
900.0 |
nM |
Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay |
CHEMBL3632602 |
| Human herpesvirus 3 |
EC50 |
= |
11100.0 |
nM |
Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay |
CHEMBL3632602 |
| Human herpesvirus 5 |
EC50 |
= |
2140.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay |
CHEMBL3632602 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HEL299 cells after 3 days by MTT assay |
CHEMBL3632602 |
| No relevant target |
Solubility |
= |
4960.0 |
ug.mL-1 |
Solubility of compound in double-deionized water after 3 days by LC-MS/MS analysis |
CHEMBL3632602 |
| Cytomegalovirus |
EC50 |
= |
250.0 |
nM |
Antiviral activity against Cytomegalovirus AD169 infected in HEL cells |
CHEMBL3826905 |
| Cytomegalovirus |
EC50 |
= |
400.0 |
nM |
Antiviral activity against Cytomegalovirus Davis 07/1 infected in HEL cells |
CHEMBL3826905 |
| NON-PROTEIN TARGET |
EC50 |
= |
3100.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation |
CHEMBL3877247 |
| NON-PROTEIN TARGET |
EC50 |
= |
2100.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation |
CHEMBL3877247 |
| NON-PROTEIN TARGET |
EC50 |
= |
90.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation |
CHEMBL3877247 |
| NON-PROTEIN TARGET |
EC50 |
= |
100000.0 |
nM |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation |
CHEMBL3877247 |
| NON-PROTEIN TARGET |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation |
CHEMBL3877247 |
| NON-PROTEIN TARGET |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration of cell morphology after 3 days by microscopic method |
CHEMBL3877247 |
| Schistosoma mansoni |
ALT |
= |
48.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
41700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
319.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
96.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
180.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
24000000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
103.0 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
676.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
635.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
2.1 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1650.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
646.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
8.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
142.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
6.69 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
145.5 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
2.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
59000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
22.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
152.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
12965.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
505.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
1544.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
1.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5640000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
35.17 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
131700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
15170.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
85.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
23.37 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
374700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
62.37 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
3.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
10.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.0 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1360000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
47.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
42000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
323.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
91.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
193.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
25330000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
106.33 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
746.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
428.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
1.5 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1506.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
720.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
8.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
114.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
5.57 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
145.9 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
1.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
57700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
8.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
86.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
11979.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
137.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
1530.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
0.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5690000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
35.37 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
132300.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
13730.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
87.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
23.27 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
374700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
62.13 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
1.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
11.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.0 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1168000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
45.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
43000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
313.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
76.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
190.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
27330000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
103.67 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
796.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
222.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
2.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1570.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
239.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
9.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
123.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
6.13 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
145.57 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
2.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
59300.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
12.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
180.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
12632.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
432.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
1155.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
1.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5520000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
33.9 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
129000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
14400.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
87.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
23.43 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
380700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
61.57 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
3.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
8.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.33 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1439000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
42.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
42000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
345.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
78.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
196.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
29330000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
102.33 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
653.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
220.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
1.8 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1570.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
181.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
8.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
117.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
6.54 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
145.77 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
1.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
59000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
14.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
164.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
13318.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
365.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
1652.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
1.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5490000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
34.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
131300.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
15500.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
86.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
23.93 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
382700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
62.6 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
2.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
10.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.33 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1216670.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against virus infected HEL cells assessed as alteration in cell morphology by microscopic method |
CHEMBL3994569 |
| HEL |
CC50 |
> |
350000.0 |
nM |
Cytotoxicity against HEL cells infected with Cytomegalovirus assessed as growth inhibition |
CHEMBL3994569 |
| HEL |
MCC |
> |
350000.0 |
nM |
Cytotoxicity against HEL cells infected with Cytomegalovirus assessed as alteration in cell morphology by microscopic method |
CHEMBL3994569 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
4000.0 |
nM |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL3994569 |
| Human herpesvirus 2 strain G |
EC50 |
= |
55.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL3994569 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
32.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL3994569 |
| Cytomegalovirus |
EC50 |
= |
6500.0 |
nM |
Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL3994569 |
| Cytomegalovirus |
EC50 |
= |
14900.0 |
nM |
Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL3994569 |
| Bile salt export pump |
IC50 |
> |
135000.0 |
nM |
Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-taurocholate by topcount based membrane vesicle transport assay |
CHEMBL4011581 |
| Human immunodeficiency virus 1 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against HIV1 X4LAI.04 infected in human MT4 cells assessed as decrease in viral replication by p24gag-based luminex assay |
CHEMBL4017507 |
| MT4 |
IC50 |
> |
50000.0 |
nM |
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by cell counting method |
CHEMBL4017507 |
| CCRF-CEM |
CC50 |
> |
100000.0 |
nM |
Cytostatic activity human CEM cells assessed as reduction in cell viability after 72 hrs by cell counting method |
CHEMBL4017507 |
| Human immunodeficiency virus 1 |
EC50 |
= |
5000.0 |
nM |
Antiviral activity against HIV1 X4LAI.04 infected in human tonsillar tissues assessed as inhibition of virus-induced cytopathic effect by p24gag-based luminex assay |
CHEMBL4017507 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| Human herpesvirus 2 strain G |
EC50 |
= |
40.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
4300.0 |
nM |
Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| HEL |
MCC |
>= |
100000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration to cell morphology by microscopic analysis |
CHEMBL4017507 |
| Human herpesvirus 5 |
EC50 |
= |
7400.0 |
nM |
Antiviral activity against human cytomegalovirus AD-169 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| Human herpesvirus 5 |
EC50 |
= |
7300.0 |
nM |
Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
|
|
|
Antiviral activity against Varicella-Zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4017507 |
| HEL |
CC50 |
= |
273000.0 |
nM |
Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method |
CHEMBL4017507 |
| Bile salt export pump |
IC50 |
> |
133000.0 |
nM |
Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay |
CHEMBL4028801 |
| Canalicular multispecific organic anion transporter 1 |
IC50 |
> |
133000.0 |
nM |
Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay |
CHEMBL4028801 |
| Canalicular multispecific organic anion transporter 2 |
IC50 |
> |
133000.0 |
nM |
Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay |
CHEMBL4028801 |
| Multidrug resistance-associated protein 4 |
IC50 |
> |
133000.0 |
nM |
Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay |
CHEMBL4028801 |
| Homo sapiens |
DILI_severity_class |
= |
7.0 |
|
Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index |
CHEMBL4028802 |
| Homo sapiens |
DILI_Concern |
|
|
|
Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status |
CHEMBL4028802 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
8700.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4038313 |
| Human herpesvirus 5 |
EC50 |
= |
16500.0 |
nM |
Antiviral activity against HCMV Davis strain infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4038313 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
|
|
|
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka strain assessed as inhibition of plaque formation |
CHEMBL4038313 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of plaque formation |
CHEMBL4038313 |
| HEL |
MCC |
> |
391000.0 |
nM |
Cytotoxic activity against HEL cells assessed as alteration of cell morphology after 3 days by microscopic method |
CHEMBL4038313 |
| HEL |
CC50 |
> |
391000.0 |
nM |
Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method |
CHEMBL4038313 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
40.0 |
nM |
Antiviral activity against wild type Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4043131 |
| Human herpesvirus 2 strain G |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4043131 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
100.0 |
nM |
Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4043131 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against wild type thymidine kinase expressing Varicella-Zoster virus Oka infected in HEL cells assessed as inhibition of virus-induced plaque formation |
CHEMBL4043131 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against wild type thymidine kinase-deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of virus-induced plaque formation |
CHEMBL4043131 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
6790.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4043131 |
| Human herpesvirus 5 |
EC50 |
= |
2960.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4043131 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4043131 |
| HEL |
MCC |
> |
350000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis |
CHEMBL4043131 |
| HEL |
CC50 |
= |
308000.0 |
nM |
Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method |
CHEMBL4043131 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
20.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Human herpesvirus 2 strain G |
EC50 |
= |
20.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
800.0 |
nM |
Antiviral activity against acyclovir-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
11430.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Human herpesvirus 5 |
EC50 |
= |
2290.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis |
CHEMBL4118253 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
2600.0 |
nM |
Antiviral activity against GFP-fused Human cytomegalovirus AD169 infected in primary HFF |
CHEMBL4118267 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
2600.0 |
nM |
Antiviral activity against recombinant HCMV AD169 expressing GFP infected in human foreskin fibroblast assessed as reduction in virus-induced cytopathic effect after 7 days |
CHEMBL4145629 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
5630.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral cytopathic effect |
CHEMBL4196014 |
| Human herpesvirus 5 |
EC50 |
= |
4050.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral cytopathic effect |
CHEMBL4196014 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
|
|
|
Antiviral activity against Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation |
CHEMBL4196014 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in HEL cells assessed as reduction in viral plaque formation |
CHEMBL4196014 |
| HEL |
MCC |
>= |
350000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic method |
CHEMBL4196014 |
| HEL |
CC50 |
> |
350000.0 |
nM |
Cytostatic activity against HEL cells after 3 days by Coulter counting method |
CHEMBL4196014 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
|
|
|
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka infected in HEL cells assessed as inhibition of plaque formation measured after 5 days post infection |
CHEMBL4229353 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of plaque formation measured after 5 days post infection |
CHEMBL4229353 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
6460.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection |
CHEMBL4229353 |
| Human herpesvirus 5 |
EC50 |
= |
4830.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection |
CHEMBL4229353 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
45.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection |
CHEMBL4229353 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
3910.0 |
nM |
Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection |
CHEMBL4229353 |
| Human herpesvirus 2 strain G |
EC50 |
= |
19.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection |
CHEMBL4229353 |
| HEL |
CC50 |
> |
391000.0 |
nM |
Cytostatic activity against HEL cells after 3 days by Coulter counting method |
CHEMBL4229353 |
| HEL |
MCC |
> |
391000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days by microscopic analysis |
CHEMBL4229353 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
57.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection |
CHEMBL4251741 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
29500.0 |
nM |
Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection |
CHEMBL4251741 |
| Human herpesvirus 2 strain G |
EC50 |
= |
51.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection |
CHEMBL4251741 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
|
|
|
Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka assessed as inhibition of plaque formation measured after 5 days post-infection |
CHEMBL4251741 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 assessed as inhibition of plaque formation measured after 5 days post-infection |
CHEMBL4251741 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
7410.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection |
CHEMBL4251741 |
| Human herpesvirus 5 |
EC50 |
= |
3310.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection |
CHEMBL4251741 |
| HEL |
MCC |
> |
39200.0 |
nM |
Cytotoxicity against HEL cells assessed as morphological changes after 3 days by microscopic analysis |
CHEMBL4251741 |
| HEL |
CC50 |
> |
319000.0 |
nM |
Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method |
CHEMBL4251741 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days by microscopic method |
CHEMBL4265975 |
| Herpes simplex virus (type 1 / strain F) |
EC50 |
= |
10.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method |
CHEMBL4265975 |
| Human herpesvirus 2 strain G |
EC50 |
= |
10.0 |
nM |
Antiviral activity against Human herpesvirus 2 strain G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method |
CHEMBL4265975 |
| Herpes simplex virus (type 1 / strain F) |
EC50 |
= |
200.0 |
nM |
Antiviral activity against acyclovir-resistant TK-defecient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method |
CHEMBL4265975 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method |
CHEMBL4265975 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
2600.0 |
nM |
Antiviral activity against GFP-fused Human cytomegalovirus AD169 infected in HFF measured 7 days post infection |
CHEMBL4266063 |
| Human herpesvirus 5 |
EC50 |
= |
6520.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL4270599 |
| Human herpesvirus 5 strain AD169 |
EC50 |
= |
11750.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL4270599 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07-1 strain infected in HELF cells assessed as inhibition of virus-induced plaque formation |
CHEMBL4270599 |
| Human herpesvirus 3 strain Oka vaccine |
EC50 |
|
|
|
Antiviral activity against thymidine kinase-deficient Varicella Zoster virus Oka strain infected in HELF cells assessed as inhibition of virus-induced plaque formation |
CHEMBL4270599 |
| Unchecked |
CC50 |
|
|
|
Cytotoxicity against HELF cells after by Coulter counter method |
CHEMBL4270599 |
| Unchecked |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against HELF cells assessed as alteration of cell morphology by microscopic analysis |
CHEMBL4270599 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus Lederle infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL4270599 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
500.0 |
nM |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL4270599 |
| Human herpesvirus 2 strain G |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Human herpesvirus 2 G strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL4270599 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
30.0 |
nM |
Antiviral activity against Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL4270599 |
| SARS-CoV-2 |
Inhibition index |
= |
0.1348 |
|
Inhibition of cell viability relative to arbidol control (inhibition index > 1 indicates higher activity) measured by fluorescence (OD590nm) in Vero E6 cells infected with SARS-CoV-2 (strain BavPat1) at MOI 0.002 after 72hrs |
CHEMBL4303097 |
| SARS-CoV-2 |
Inhibition |
= |
3.23 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging |
CHEMBL4303101 |
| SARS-CoV-2 |
Hit score |
= |
0.1061 |
|
Antiviral activity against SARS-CoV-2 (USA-WA1/2020 strain) measured by imaging in HRCE cells at MOI 0.4 after 96 hrs (reported as hit score from 0-1 for on-disease vs off-disease activity: scores >0.6 considered hits) |
CHEMBL4303122 |
| Human herpesvirus 5 |
EC50 |
= |
2600000.0 |
nM |
Antiviral activity against recombinant HCMV AD169 infected in human foreskin fibroblasts measured after 7 days by GFP-based multi-round replication assay relative to control |
CHEMBL4342409 |
| Human herpesvirus 5 |
IC50 |
= |
1300.0 |
nM |
Antiviral activity against Human Cytomegalovirus |
CHEMBL4354809 |
| Human herpesvirus 5 |
EC50 |
= |
720.0 |
nM |
Antiviral activity against HCMV TB40 infected in human HFF cells assessed as reduction in plaque formation treated with compound following viral infection and incubated for 8 to 10 days by crystal violet staining based assay |
CHEMBL4354867 |
| Human herpesvirus 5 |
EC50 |
= |
29700.0 |
nM |
Antiviral activity against GCV-resistant HCMV Towne infected in human HFF cells assessed as reduction in plaque formation treated with compound following viral infection and incubated for 8 to 10 days by crystal violet staining based assay |
CHEMBL4354867 |
| Human herpesvirus 5 |
EC50 |
= |
2100.0 |
nM |
Antiviral activity against HCMV Towne infected in human HFF cells assessed as reduction in plaque formation treated with compound following viral infection and incubated for 8 to 10 days by crystal violet staining based assay |
CHEMBL4354867 |
| HFF |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs or 10 days by MTT assay |
CHEMBL4354867 |
| Human herpesvirus 1 |
EC50 |
= |
40.0 |
nM |
Antiviral activity against HSV 1 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay |
CHEMBL4354867 |
| Human herpesvirus 2 |
EC50 |
= |
580.0 |
nM |
Antiviral activity against HSV 2 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay |
CHEMBL4354867 |
| Human herpesvirus 4 |
EC50 |
= |
5200.0 |
nM |
Antiviral activity against EBV infected in human AKATA cells assessed as reduction in IgG-induced lytic virus replication measured at 48 hrs post-lytic induction by qRT-PCR analysis |
CHEMBL4354867 |
| Unchecked |
EC50 |
= |
960.0 |
nM |
Antiviral activity against Mouse Cytomegalovirus Smith (ATCC VR-1399) infected in mouse MEF cells assessed as reduction in plaque formation measured after 3 days by crystal violet staining based assay |
CHEMBL4354867 |
| Human herpesvirus 5 |
Activity |
|
|
|
Antiviral activity against pp28-luciferase expressing HCMV Towne infected in human HFF cells assessed as reduction in viral replication treated with compound at 24 hrs post viral infection at MOI of 1 PFU/cell and measured after 3 days by luciferase reporter gene assay |
CHEMBL4354867 |
| Human herpesvirus 5 |
Activity |
|
|
|
Antiviral activity against pp28-luciferase expressing HCMV Towne infected in human HFF cells assessed as reduction in viral replication treated with compound immediately after viral infection at MOI of 1 PFU/cell followed by compound washout after 6 hrs and measured after 3 days by luciferase reporter gene assay |
CHEMBL4354867 |
| Human herpesvirus 5 |
Activity |
|
|
|
Antiviral activity against HCMV Towne infected in human HFF cells assessed as reduction in viral entry into host cell by measuring nuclear localization of pp65 at 5 uM treated with compound for 24 hrs followed by viral infection at MOI of 0.01 to 1 PFU/cell measured at 2 hrs post infection by immunofluorescence microscopy |
CHEMBL4354867 |
| Human herpesvirus 5 |
Activity |
|
|
|
Antiviral activity against HCMV Towne infected in human HFF cells assessed as reduction in viral DNA replication at 5 uM treated with compound following viral infection at MOI of 0.1 PFU/cell by US17 real time PCR analysis |
CHEMBL4354867 |
| Human herpesvirus 5 |
Activity |
|
|
|
Antiviral activity against HCMV Towne infected in human HFF cells assessed as reduction in viral DNA yields in the supernatant at 5 uM treated with compound following viral infection at MOI of 0.1 PFU/cell by US17 real time PCR analysis |
CHEMBL4354867 |
| Human herpesvirus 1 |
EC50 |
= |
70.0 |
nM |
Antiviral activity against herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis |
CHEMBL4368930 |
| Human herpesvirus 2 |
EC50 |
= |
400.0 |
nM |
Antiviral activity against herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis |
CHEMBL4368930 |
| Human herpesvirus 1 |
EC50 |
= |
800.0 |
nM |
Antiviral activity against thymidine kinase deficient and aciclovir resistant herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis |
CHEMBL4368930 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells assessed as effect on cell morphology at 0.32 to 200 uM by microscopic analysis |
CHEMBL4368930 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against Varicella-zoster virus Oka harboring thymidine kinase infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL4368930 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient Varicella-zoster virus 07-1 infected in HEL cells assessed as reduction in virus plaque formation |
CHEMBL4368930 |
| Human herpesvirus 5 |
EC50 |
= |
6500.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 assessed as reduction in virus-induced cytopathogenicity by microscopic analysis |
CHEMBL4368930 |
| Human herpesvirus 5 |
EC50 |
= |
4600.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis assessed as reduction in virus-induced cytopathogenicity by microscopic analysis |
CHEMBL4368930 |
| Human herpesvirus 5 |
EC50 |
= |
2600.0 |
nM |
Antiviral activity against recombinant HCMV AD169 expressing GFP infected in human foreskin fibroblasts measured after 7 days by GFP-based multi-round replication assay |
CHEMBL4371023 |
| Plasmodium falciparum |
EC50 |
|
|
|
Antimalarial activity against ring stage Plasmodium falciparum 3D7 infected in type A-positive human erythrocytes after 72 hrs by SYBR green 1 dye-based fluorescence assay |
CHEMBL4371023 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| Human herpesvirus 1 |
EC50 |
= |
800.0 |
nM |
Antiviral activity against Herpes simplex virus 1 TK-KOS-ACV infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| Human herpesvirus 2 |
EC50 |
= |
300.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| Human herpesvirus 1 |
EC50 |
= |
70.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| Unchecked |
CC50 |
> |
350000.0 |
nM |
Cytotoxicity against human HELF cells assessed as reduction in cell viability incubated for 3 days by coulter counter method |
CHEMBL4406859 |
| Unchecked |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HELF cells assessed as minimum cytotoxic concentration by observing alteration in cell morphology incubated for 3 days by microscopic analysis |
CHEMBL4406859 |
| Cytomegalovirus |
EC50 |
= |
2300.0 |
nM |
Antiviral activity against Cytomegalovirus Davis infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by Giemsa staining based microscopic analysis |
CHEMBL4406859 |
| Cytomegalovirus |
EC50 |
= |
3150.0 |
nM |
Antiviral activity against Cytomegalovirus AD169 infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by Giemsa staining based microscopic analysis |
CHEMBL4406859 |
| Human herpesvirus 1 |
EC50 |
= |
25.0 |
nM |
Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of GFP expression after 72 hrs by GFP-based fluorescence microscopic analysis |
CHEMBL4414579 |
| Human herpesvirus 1 |
Inhibition |
|
|
% |
Inhibition of UL42 gene transcription in HSV-1 infected in African green monkey Vero cells at 10 uM by qRT-PCR analysis |
CHEMBL4414579 |
| Cytochrome P450 3A4 |
FC |
= |
1.0 |
|
Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone |
CHEMBL4477225 |
| Cytochrome P450 2D6 |
FC |
= |
1.0 |
|
Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone |
CHEMBL4477225 |
| Cytochrome P450 2C9 |
FC |
= |
1.0 |
|
Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone |
CHEMBL4477225 |
| Replicase polyprotein 1ab |
Inhibition |
= |
6.335 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| SARS-CoV-2 |
Inhibition |
= |
-0.14 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| Candida albicans |
Inhibition |
= |
0.0 |
% |
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 |
CHEMBL4513141 |
| Filobasidiella neoformans |
Inhibition |
= |
-0.42 |
% |
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) |
CHEMBL4513141 |
| Escherichia coli |
Inhibition |
= |
0.63 |
% |
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513141 |
| Klebsiella pneumoniae |
Inhibition |
= |
11.05 |
% |
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513141 |
| Pseudomonas aeruginosa |
Inhibition |
= |
9.56 |
% |
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513141 |
| Acinetobacter baumannii |
Inhibition |
= |
17.44 |
% |
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 |
CHEMBL4513141 |
| Staphylococcus aureus subsp. aureus |
Inhibition |
= |
7.88 |
% |
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) |
CHEMBL4513141 |
| Candida albicans |
MIC |
> |
20000.0 |
nM |
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 |
CHEMBL4513161 |
| Filobasidiella neoformans |
MIC |
> |
20000.0 |
nM |
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) |
CHEMBL4513161 |
| Escherichia coli |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513161 |
| Klebsiella pneumoniae |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513161 |
| Pseudomonas aeruginosa |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513161 |
| Acinetobacter baumannii |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 |
CHEMBL4513161 |
| Pseudomonas aeruginosa |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Pseudomonas aeruginosa PAO397 [PAO1 d(mexAB-oprM) d(mexCD-oprJ) d(mexEF-oprN) d(mexJKL) d(mexXY) d(opmH)] (CO-ADD:GN_211); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513161 |
| Staphylococcus aureus subsp. aureus |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) |
CHEMBL4513161 |
| Erythrocyte |
HC10 |
> |
20.0 |
uM |
Haemolysis of human Red Blood Cells (CO-ADD:HA_150); HC10, by OD(450) |
CHEMBL4513161 |
| HEK293 |
CC50 |
> |
20000.0 |
nM |
Cytotoxicity against HEK293 cells (CO-ADD:MA_007); CC50 by cell viability assay in DMEM (10% FBS) media using TC plates, by Resazurin F(560/590) |
CHEMBL4513161 |
| Cytomegalovirus |
EC50 |
= |
13000.0 |
nM |
Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days |
CHEMBL4619792 |
| Cytomegalovirus |
EC50 |
= |
4440.0 |
nM |
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days |
CHEMBL4619792 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in plaque formation measured after 5 days |
CHEMBL4619792 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation measured after 5 days |
CHEMBL4619792 |
| HEL |
MCC |
> |
394000.0 |
nM |
Cytotoxicity against human HEL cells assessed as minimum cytotoxic concentration for change in cellular morphology incubated for 3 days by microscopic analysis |
CHEMBL4619792 |
| HEL |
CC50 |
> |
394000.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method |
CHEMBL4619792 |
| SARS-CoV-2 |
Inhibition |
= |
-0.14 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
IC50 |
> |
20000.0 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| SARS-CoV-2 |
IC50 |
< |
19952.62 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| HEL |
CC50 |
= |
231220.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis |
CHEMBL4673379 |
| HEL |
MCC |
= |
350000.0 |
nM |
Cytotoxicity against human HEL cells assessed as alteration in cell morphology incubated for 3 days by microscopic analysis |
CHEMBL4673379 |
| Unchecked |
EC50 |
= |
1670.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation measured on 6 to 7 post-viral infection |
CHEMBL4673379 |
| Unchecked |
EC50 |
= |
2770.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus plaque formation measured on day 6 to 7 post-viral infection |
CHEMBL4673379 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection |
CHEMBL4673379 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection |
CHEMBL4673379 |
| Unchecked |
EC50 |
= |
2600.0 |
nM |
Antiviral activity against GFP-transfected Human cytomegalovirus AD169 infected in human HFF cells measured after 7 days by GFP fluorometry |
CHEMBL4699468 |
| HeLa |
MCC |
|
|
|
Cytotoxicity against human HeLa cells assessed as changes in cell morphology incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Vero |
MCC |
|
|
|
Cytotoxicity against African green monkey Vero cells assessed as changes in cell morphology incubated for 3 to 6 days by light microscopy |
CHEMBL4715693 |
| Unchecked |
EC50 |
= |
500.0 |
nM |
Antiviral activity against Herpes simplex virus 1 infected in human HEL cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Unchecked |
EC50 |
= |
200.0 |
nM |
Antiviral activity against Herpes simplex virus 2 infected in human HEL cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Feline coronavirus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Feline coronavirus infected in cat CRFK cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Felid herpesvirus 1 |
EC50 |
= |
7400.0 |
nM |
Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against human HEL cells assessed as changes in cell morphology incubated for 3 to 6 days by light microscopy |
CHEMBL4715693 |
| MDCK |
MCC |
|
|
|
Cytotoxicity against dog MDCK cells assessed as changes in cell morphology incubated for 3 to 6 days by light microscopy |
CHEMBL4715693 |
| Unchecked |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against cat CRFK cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay |
CHEMBL4715693 |
| MT4 |
CC50 |
|
|
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay |
CHEMBL4715693 |
| Unchecked |
EC50 |
= |
900.0 |
nM |
Antiviral activity against HCMV AD169 infected in human HFF cells assessed as reduction in virus-induced cytopathic effect incubated for 14 days by cell-titer glo assay |
CHEMBL4732039 |
| Unchecked |
EC90 |
= |
74.2 |
uM |
Antiviral activity against HCMV AD169 infected in human HFF cells assessed as reduction in virus-induced cytopathic effect incubated for 14 days by cell-titer glo assay |
CHEMBL4732039 |
| HFF |
CC50 |
> |
150000.0 |
nM |
Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 14 days by cell titer glo assay |
CHEMBL4732039 |
| Unchecked |
Ratio CC50/EC50 |
> |
175.0 |
|
Selectivity index, ratio of CC50 for human HFF cells to EC50 for antiviral activity against HCMV AD169 |
CHEMBL4732039 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against VZV infected in human HFF cells assessed as reduction in virus-induced cytopathic effect incubated for 14 days by cell-titer glo assay |
CHEMBL4732039 |
| Human herpesvirus 3 |
EC90 |
|
|
|
Antiviral activity against VZV infected in human HFF cells assessed as reduction in virus-induced cytopathic effect incubated for 14 days by cell-titer glo assay |
CHEMBL4732039 |
| Tripartite terminase subunit 3 |
Delta Tm |
= |
-0.1 |
degrees C |
Binding affinity to human cytomegalovirus pUL89 assessed as change in melting temperature at 20 uM by thermal shift assay |
CHEMBL4823278 |
| Unchecked |
EC50 |
= |
930.0 |
nM |
Antiviral activity against human cytomegalovirus expressing ADCREGFP infected in human HEL 299 cells assessed as reduction in viral replication by measuring GFP fluorescence incubated for 168 hrs by cell based assay |
CHEMBL4823278 |
| HEL 299 |
CC50 |
> |
50000.0 |
nM |
Cytotoxicity against human HEL 299 cells assessed as cell death incubated for 168 hrs by MTS-based tetrazolium reduction assay |
CHEMBL4823278 |
| ADMET |
Selectivity Index |
> |
53.0 |
|
Selectivity index, ratio of CC50 for human HEL 299 cells to EC50 for antiviral activity against human cytomegalovirus expressing ADCREGFP infected in human Hel-299 cells assessed as reduction in viral replication by measuring GFP fluorescence incubated for 168 hrs by cell based assay |
CHEMBL4823278 |
| Human herpesvirus 5 |
EC50 |
= |
19000.0 |
nM |
Antiviral activity against Human cytomegalovirus AD169 |
CHEMBL4842312 |
| Human herpesvirus 5 |
EC50 |
= |
1790.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis |
CHEMBL4842312 |
| HEL |
CC50 |
> |
300000.0 |
nM |
Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method |
CHEMBL4842312 |
| Human herpesvirus 1 |
EC50 |
< |
100.0 |
nM |
Antiviral activity against GFP-expressing HSV-1 assessed as reduction in viral growth by fluorescence assay |
CHEMBL5053525 |
| Transitional endoplasmic reticulum ATPase |
IC50 |
= |
1300.0 |
nM |
Inhibition of p97 (unknown origin) incubated for 15 mins in presence of ATP by ADP Glo assay |
CHEMBL5096176 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 1 |
EC50 |
= |
20.0 |
nM |
Antiviral activity against HSV-1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 2 |
EC50 |
= |
20.0 |
nM |
Antiviral activity against HSV-2 G strain infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 1 |
EC50 |
= |
800.0 |
nM |
Antiviral activity against thymidine kinase deficient mutant Acyclovir resistant HSV-1 KOS strain infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 5 |
EC50 |
= |
8270.0 |
nM |
Antiviral activity against Human cytomegalovirus AD-169 infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 5 |
EC50 |
= |
630.0 |
nM |
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against Varicella zoster-virus OKA strain harboring thymidine kinase infected in HEL cells assessed as reduction in plaque formation by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against thymidine kinase deficient Varicella zoster-virus O7-1 strain infected in HEL cells assessed as reduction in plaque formation by microscopic analysis |
CHEMBL5108006 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human adenovirus type 2 |
EC50 |
|
|
|
Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis |
CHEMBL5108006 |
| Human herpesvirus 5 |
EC50 |
= |
860.0 |
nM |
Antiviral activity against HCMV AD-169 infected in HFF cells assessed as reduction in viral replication measured after 14 days |
CHEMBL5120909 |
| Human herpesvirus 5 |
EC90 |
= |
74.23 |
uM |
Antiviral activity against HCMV AD-169 infected in HFF cells assessed as reduction in viral replication measured after 14 days |
CHEMBL5120909 |
| HFF |
CC50 |
> |
150000.0 |
nM |
Cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay |
CHEMBL5120909 |
| ADMET |
Ratio CC50/EC50 |
> |
175.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay to EC50 for antiviral activity against HCMV AD-169 infected in HFF cells assessed as inhibition of virus-induced cytopathic effect measured after 14 days |
CHEMBL5120909 |
| Human herpesvirus 3 |
EC50 |
|
|
|
Antiviral activity against VZV Ellen infected in HFF cells assessed as reduction in viral replication measured after 14 days |
CHEMBL5120909 |
| Human herpesvirus 3 |
EC90 |
|
|
|
Antiviral activity against VZV Ellen infected in HFF cells assessed as reduction in viral replication measured after 14 days |
CHEMBL5120909 |
| HFF |
CC50 |
|
|
|
Cytotoxicity against human HFF cells infected with VZV Ellen virus assessed as reduction in cell viability by cell titer-glo assay |
CHEMBL5120909 |
| ADMET |
Ratio CC50/EC50 |
|
|
|
Selectivity index, ratio of CC50 for cytotoxicity against human HFF cells infected with VZV Ellen virus assessed as reduction in cell viability by cell titer-glo assay to EC50 for antiviral activity against VZV Ellen infected in HFF cells assessed as inhibition of virus-induced cytopathic effect measured after 14 days |
CHEMBL5120909 |
| Cytomegalovirus |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against human cytomegalovirus expressing ADCREGFP infected in HFF cells assessed as inhibition in viral replication by measuring GFP fluorescence incubated for 168 hrs by cell based assay |
CHEMBL5154836 |
| HFF |
CC50 |
> |
50000.0 |
nM |
Cytotoxicity against HFF cells assessed as cell viability incubated for 168 hrs by MTS-based Cell Titer assay |
CHEMBL5154836 |
| ADMET |
Selectivity Index |
> |
54.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against HFF cells to EC50 for antiviral activity against human cytomegalovirus expressing ADCREGFP infected in HFF cells |
CHEMBL5154836 |
